Index
Note to the reader: This index contains entries for each of the six volumes of the Veterans and Agent Orange series released to date: Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam (I), Veterans and Agent Orange: Update 1996 (II), Veterans and Agent Orange: Update 1998 (III), Veterans and Agent Orange: Update 2000 (IV), Veterans and Agent Orange: Update 2002 (V), Veterans and Agent Orange: Update 2004 (VI). Page numbers for the discussions of topics in specific volumes follow the roman numerals denoted above. Thus, for example, the entry “Agent Blue, I: 27, 89–90, 93, 97, 100; III: 136, 137; IV: 118” first refers to material found on pages 27, 89–90, 93, 97, and 100 in Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam, then to material found on pages 136 and 137 of Veterans and Agent Orange: Update 1998 and on page 118 of Veterans and Agent Orange: Update 2000.
A
Abortions. See Spontaneous abortion
ACC. See US Army Chemical Corps
Acquired immune deficiency syndrome. See AIDS/HIV
ACS. See American Cancer Society
ACTH. See Adrenocorticotropic hormone
Acute lymphocytic leukemia (ALL). See Leukemia
Aacute Myelogenous Leukemia. See Veterans and Agent Orange: Herbicides/Dioxin Exposure and Acute Myelogenous Leukemia in the Children of Vietnam Veterans (Acute Myelogenous Leukemia)
Acute myelogenous leukemia (AML). See Leukemia
Acute myeloid leukemia (AML). See Leukemia
AD. See Alzheimer’s disease
ADA. See American Diabetes Association
Adipose tissue
TCDD distribution,
I: 130, 131, 168–169, 259, 269, 280;
IV: 42, 43, 64, 116, 117;
VI: 67–68
Adrenocorticotropic hormone (ACTH),
IV: 59
Aerial spraying,
I: 3, 24;
III: 135, 137, 139;
IV: 117, 120, 123, 150, 160, 303;
military early research,
I: 25–26;
III: 28;
IV: 150
records of,
I: 84–85, 287
See also Herbicide application methods;
Herbicides
AFHS. See Air Force Health Study
Aflatoxin,
I: 453;
IV: 267
Africa, sub-Saharan,
II: 181;
III: 282;
IV: 267;
VI: 221
Age and aging
acute lymphocytic leukemia incidence, data for selected age groups,
III: 384;
IV: 9, 378
acute myeloid leukemia incidence, data for selected age groups,
III: 384;
IV: 378
amyotrophic lateral sclerosis,
V: 524
bone/joint cancer incidence, data for selected age groups,
III: 302;
IV: 288;
V: 279
brain cancer incidence, data for selected age groups,
III: 356;
IV: 351;
V: 339, 524
breast cancer incidence in US women, data for selected age groups,
III: 324;
IV: 314;
V: 301
cancer age-specific incidence,
I: 436–438
chronic lymphocytic leukemia incidence, data for selected age groups,
III: 384;
IV: 378
chronic myeloid leukemia incidence, data for selected age groups,
III: 384;
IV: 378
diabetes prevalence, data by age,
III: 492
epidemiologic studies, control of aging effects,
II: 261–262;
III: 409;
IV: 3, 13, 23
female reproductive system cancer incidence, data by type, for selected age groups,
III: 329, 330;
IV: 321;
V: 310
gastrointestinal tract cancer incidence, data by type for selected age groups,
III: 267;
IV: 250;
V: 244
Hodgkin’s disease incidence, data for selected age groups,
III: 372;
IV: 365;
V: 355
immune system,
IV: 31, 79
kidney cancer,
V: 334
laryngeal cancer incidence, data for selected age groups,
III: 292;
IV: 277;
V: 268
latency and,
II: 261–262, 273, 275;
III: 409, 414–415, 425, 428, 430;
IV: 254, 256, 264, 265
leukemia incidence, data by type, for selected age groups,
III: 384;
IV: 378;
V: 367
liver/intrahepatic bile duct cancers incidence, data for selected age groups,
III: 282;
IV: 267;
V: 260
lung cancer incidence, data for selected age groups,
III: 296;
IV: 281;
V: 272
melanoma incidence, data for selected age groups,
III: 313;
IV: 300;
V: 288
multiple myeloma incidence, data for selected age groups,
III: 377;
V: 361
nasal/nasopharyngeal cancer incidence, data for selected age groups,
III: 289;
IV: 273;
V: 265
non-Hodgkin’s lymphoma age of onset,
I: 436
non-Hodgkin’s lymphoma incidence, data for selected age groups,
III: 362;
IV: 356;
V: 344
parkinsonism,
V: 524
prostate cancer incidence, data for selected age groups,
III: 334;
IV: 10, 327;
V: 317, 524
renal cancers incidence, data for selected age groups,
III: 352;
IV: 346
reproductive disorders,
IV: 51–52, 59, 63, 66, 71, 80, 200
research recommendations,
V: 524
soft-tissue sarcoma age of onset,
I: 436
soft-tissue sarcoma incidence, data for selected age groups,
III: 306;
IV: 292;
V: 282
TCDD half–life,
IV: 24, 28, 45
testicular cancer incidence, data for selected age groups,
III: 343;
IV: 335;
V: 325
urinary bladder cancer incidence, data for selected age groups,
III: 347;
IV: 340;
V: 328
See also Demographic data, Vietnam veterans
Agent Blue,
I: 27, 89–90, 93, 97, 100;
III: 136, 137;
IV: 118;
VI: 183–185
volume used in Operation Ranch Hand, data,
III: 136
Agent Green,
I: 27, 90, 92, 114;
III: 136, 137, 140, 146;
IV: 118;
VI: 183
volume used in Operation Ranch Hand, data,
III: 136;
IV: 123
Agent Orange,
II: 308;
III: 130, 159, 315, 344, 359, 389, 407, 444, 460, 462, 489, 491;
IV: 117–118, 150, 156;
V: 1, 12;
Air Force research activities,
II: 31–32;
III: 28–29
birth defects association,
II: 298, 300;
III: 435;
IV: 400
breast cancer association,
V: 307
cancer latency issues,
II: 260–276;
III: 407–431;
IV: 284
chemical composition,
I: 27;
II: 102;
IV: 119
chloracne association,
II: 317, 318;
III: 479;
IV: 138, 463;
V: 478
congressional hearings,
II: 27–28;
III: 25
defoliant effectiveness,
I: 90
Department of Veterans Affairs activities,
II: 29–31, 153, 156–157;
III: 27–28;
IV: 15
Environmental Protection Agency research activities,
II: 32;
III: 29–30
exposure opportunity index (EOI),
II: 290–291;
III: 146, 147, 148;
IV: 124, 405
federal government action/research,
I: 45–60;
II: 27–32;
III: 27–32;
IV: 13
health effects of, concerns,
I: 2;
II: 19–23, 26–27;
III: 19–20, 236, 237, 240, 242, 243
International Agency for Research on Cancer research activities,
III: 30
legislation,
I: 47–52;
II: 28–29;
III: 26–27;
IV: 1, 15
Orange II formulation,
I: 90;
III: 137;
IV: 119
product liability litigation,
I: 34–35
spontaneous abortion,
II: 283;
IV: 399–400, 409–412;
V: 414
suspension of use,
I: 92–93;
II: 26
TCDD as contaminant of,
I: 91, 114, 126–127;
II: 102;
III: 140;
IV: 133–135
Vietnam amount used,
I: 1, 27, 74, 90, 97–98, 106;
II: 1, 26;
III: 136;
IV: 115, 118–119
Vietnam military application,
I: 1, 3, 27, 74, 84–85, 90, 92–93, 97–107, 543–545;
II: 1, 26–27;
III: 1, 25, 136, 137, 138, 140;
IV: 125–126
Vietnam surplus disposal,
I: 93–94
Vietnam veterans’ concerns,
I: 32–34;
II: 26–27
Vietnam veterans’ increased disease risk,
II: 22–23;
III: 22–23, 272;
IV: 8–9, 12, 256, 270, 275, 279, 284, 290, 296, 305, 311, 318, 323, 332, 338, 343, 348, 353, 359, 367, 374, 381, 388
volume used in Operation Ranch Hand, data,
II: 136;
IV: 120, 123, 150
See also Herbicides;
Incineration, of Agent Orange
Agent Orange, the Deadly Fog,
I: 33
Agent Orange Act of 1991. See Public Law 102-4
Agent Orange Briefs,
I: 56;
II: 31;
III: 28
Agent Orange II. See Agent Orange
Agent Orange Registry (AOR),
I: 20, 53, 56, 729;
II: 29, 31, 153, 228;
III: 28, 344
See also Department of Veterans Affairs (DVA)
Agent Orange Review,
I: 56;
II: 31;
III: 28
Agent Orange Scientific Task Force,
I: 60–61
Agent Orange Study,
I: 19, 57, 58–59, 63–64, 276–278;
II: 102;
III: 147, 148;
IV: 124
Agent Orange Task Force,
II: 24–26;
III: 24–25, 148;
IV: 124
See also Department of Veterans Affairs (DVA)
Agent Orange Validation Study,
III: 240;
IV: 156, 159, 160, 162, 283, 304, 327, 403;
Agent Orange Victims International,
I: 34
Agent Orange Working Group,
I: 19, 46, 58, 277, 743
research methodology,
I: 728
Agent Pink,
I: 27, 90, 92, 114;
III: 136, 137, 140, 146;
IV: 118, 122–123;
VI: 183
volume used in Operation Ranch Hand, data,
III: 136;
IV: 123
Agent Purple,
I: 27, 89, 92, 114;
III: 136, 140, 146;
IV: 118, 122–123;
VI: 183
Operation Ranch Hand,
IV: 123
TCDD in,
I: 126;
IV: 122
volume used in Operation Ranch Hand, data,
III: 136
Agent White,
I: 27, 90, 92–93, 97, 115, 189;
III: 136, 137;
IV: 118–119;
V: 36, 40;
volume used in Operation Ranch Hand, data,
III: 136
Agricultural/forestry workers,
brain tumors,
I: 320, 523;
II: 136
Canadian Farmer Cohort,
II: 135–136
cancers,
I: 13, 37, 320–323, 443, 447, 454;
II: 133–137, 179
case-control studies,
I: 326–341, 486–488;
II: 118–122, 138–140;
III: 185–195, 228–232;
V: 113–114;
VI: 127–128
cohort studies,
I: 318–323;
II: 118–120, 135–137, 197–198;
III: 178–185, 224–228;
IV: 197–202;
V: 6, 109–113;
VI: 124–127
epidemiologic studies,
I: 37, 318–323;
II: 118–120, 135–137, 232–234, 238–239, 241–243;
III: 178–195, 224–232, 284–285, 335, 364–365, 379–380, 387–388;
IV: 134, 141–142, 145, 257, 260, 263, 265, 271, 285, 290, 296, 306, 312, 318, 324, 333, 338, 349, 353, 360, 368, 374, 381, 401;
V: 3, 143–153, 222–224;
VI: 124–125
female reproductive and breast cancers,
I: 510–511;
IV: 324–325
hepatobiliary cancer,
I: 454;
II: 183–184;
III: 284–285;
IV: 271
herbicide exposure assessment,
I: 265–266;
III: 154–157;
IV: 202
Hodgkin’s disease,
I: 550–553;
II: 135
Irish agricultural workers study,
II: 136–137
kidney cancer,
I: 515
leukemia,
I: 332–335, 566–568;
II: 136;
III: 387–388
malignant lymphoma in,
IV: 201
multiple myelomas,
I: 11–12, 558–561;
II: 138–139, 238–239, 241–243;
III: 379–380
non-Hodgkin’s lymphoma,
I: 9, 256–257, 530–540;
II: 138, 139, 232–234;
III: 364–365;
IV: 359–361
parkinsonism in,
V: 6
prostate cancer,
I: 11, 518, 519, 575;
II: 8–9;
III: 335;
IV: 327–329
reproductive outcomes,
I: 510–511, 598
respiratory cancer,
I: 11, 466;
II: 197–198
soft-tissue sarcomas,
I: 37, 326–328, 479–481, 486–488
sperm dysfunction,
I: 632
suicide,
I: 650
See also Forests;
Professional herbicide/pesticide applicators
Agricultural Health Study (AHS),
IV: 142;
See also Iowa
Agricultural herbicides,
I: 24, 35, 39, 174–175, 181;
II: 137–139
See also Herbicides
Agriculture. See Agricultural/forestry workers;
Agricultural herbicides;
Food crops;
Forests
Ah receptor (AhR),
I: 3, 123, 134;
II: 3–4, 51–53, 54–56, 57–62;
III: 54–58, 129;
IV: 25–26, 29–30, 42, 47, 50–58, 60, 68, 69, 70–73, 76, 80, 82, 84, 85, 86, 87, 90, 93, 94, 95, 99–100;
V: 24–25, 52–55;
VI: 55–66
animal studies and,
I: 114, 123;
II: 3–4, 51–53, 54–56, 57–62, 92–93;
III: 33, 34, 35, 54–58, 62–63, 67–69, 129;
IV: 48–49, 61–62, 64–67, 74–75;
VI: 55–57
anti-estrogenicity and,
II: 62;
III: 67–69
biological consequences of activation,
II: 57;
III: 62;
IV: 56–60, 323
blood abnormalities,
I: 125
cacodylic acid acute toxicity,
I: 188
cacodylic acid and mechanism of toxicity,
II: 50–51;
IV: 24
cacodylic acid carcinogenicity,
I: 118, 119, 187;
IV: 5, 387
cacodylic acid chronic exposure,
I: 188–189
cacodylic acid developmental toxicity,
I: 189
cacodylic acid genotoxicity,
I: 187–188
cacodylic acid mechanism of action,
I: 188–189
cacodylic acid pharmokinetics,
I: 186–187
cacodylic acid renal toxicity,
II: 50–51
cacodylic acid reproductive toxicity,
I: 189
cacodylic acid toxicity summary,
II: 50;
III: 48;
IV: 38
cacodylic acid toxicokinetics,
I: 188–189;
IV: 24, 27, 38
combinatorial interactions,
II: 57–58
DNA binding capability and transcription, activation of,
II: 56–57;
III: 58–61
free radicals and,
II: 60;
III: 64–65
growth/differentiation signaling,
III: 62–63
growth factor and,
II: 59
inconsistencies in,
II: 57–62
interactions,
VI: 58–59
ligand-independent activation,
II: 58
multiple forms of,
II: 57
nervous system and,
I: 161;
V: 470–471
protein and,
VI: 56–58
protein kinases and,
II: 60–62;
III: 65–67;
IV: 69–71
redox signaling,
III: 64–65;
IV: 67–69
signaling interactions,
II: 59–62;
III: 62–69;
IV: 60–61, 64, 71–74
structural and functional aspects of, II: 54–56;
III: 54–58;
IV: 54–56;
VI: 56–66
TCDD biologic plausibility and,
I: 3, 133–138, 452–453;
IV: 4, 25–26, 29, 42, 47–53, 322, 386
TCDD carcinogenicity and,
I: 118, 439
TCDD hepatotoxicity and,
I: 151, 152, 457;
II: 3–4
TCDD immunotoxicity and,
I: 122, 150
TCDD interactions with,
V: 24–25, 52–54, 309
TCDD reproductive toxicity and,
I: 123
TCDD teratogenicity and,
I: 159–160
transcriptional-independent responses,
II: 58–59
See also ARNT
AHS. See Agricultural Health Study
AIDS/HIV,
I: 338, 527, 541, 695;
II: 326;
IV: 144, 214, 356, 475, 476
Air Force. See US Air Force
Air Force Health Study (AFHS),
I: 62–63, 260, 272, 622;
II: 284, 293–295, 336;
III: 23, 25, 29, 239, 438–439, 495, 505, 514;
IV: 13, 232, 233, 234, 235;
V: 10, 513;
appropriation for,
I: 51
autoimmune disease in,
I: 698
basal/squamous cell skin cancer in,
III: 318, 321, 322;
IV: 309
baseline mortality studies,
II: 151
birth defects in offspring,
II: 286, 293–295;
III: 436, 438, 439;
IV: 402
bone/joint cancer in,
III: 303;
IV: 289
cancer and latency in,
III: 423, 424, 425, 427
chronic persistent peripheral neuropathy,
V: 465–466
circulatory disease in,
I: 703–705, 706;
II: 336;
III: 514, 517;
IV: 508–509
cognitive/neuropsychiatric disorders,
V: 449
data sources,
I: 385–386;
II: 150–151
diabetes mellitus in,
I: 684;
II: 330;
III: 495, 498–500, 502;
IV: 485–487
epidemiological studies,
II: 31, 32, 149, 150–152, 154–156, 293–295;
III: 28–29, 206–207, 218, 237–240, 303, 309–310, 313–314, 318, 321, 322, 339, 340, 385, 436, 438, 439, 446–447, 449, 452–453, 457–458, 481, 486, 495, 498–500, 502, 505, 506, 507, 510, 513, 514, 517;
IV: 291, 294–295, 298, 301, 305–306, 308–311, 313, 327, 329, 331, 334–336, 342, 345, 347, 350, 352, 355, 357, 362, 366, 370, 373, 376, 380, 383
exposure assessment in,
I: 279–280, 281, 386;
II: 4–5, 101, 103, 109;
III: 6, 146–147, 157–158, 162;
IV: 123–124
gastrointestinal ulcers in,
I: 691;
III: 510, 513
immune system disorders in,
I: 696
infertility in,
II: 280;
III: 446–447, 449
laryngeal cancer in,
V: 272
lipid abnormalities in,
I: 689;
II: 333;
III: 505, 506, 507;
IV: 494
liver toxicity in,
II: 332;
III: 510, 513;
IV: 502
low birthweight in,
I: 626, 627;
III: 457–458
melanoma in,
III: 313–314;
IV: 303–304
methodology,
I: 230–231, 385–386, 445, 757–762
multiple myelomas in,
I: 562;
II: 244, 245;
IV: 373
neurological disorders in,
I: 659;
IV: 441–443, 445, 454–455, 459
non-Hodgkin’s lymphoma in,
I: 541;
IV: 362
participants,
I: 722–723;
II: 150–152
perinatal death in offspring,
III: 452–453
peripheral nervous system disorders in,
I: 665;
IV: 454–455
porphyria cutanea tarda in,
I: 681–682;
II: 321–322;
III: 481
recommendations for,
I: 16–17, 722–724;
II: 23, 24;
IV: 13;
V: 524
reproductive outcomes in,
I: 601, 612–613, 632, 633, 727;
II: 293–295;
III: 436, 438, 439, 446–447, 449, 452–453, 457–458;
IV: 403
respiratory cancers in,
I: 469;
II: 201
respiratory disorders in,
I: 711–712;
III: 486
role of,
I: 53
skin cancers in,
II: 209;
IV: 303
skin disorders in,
I: 678
soft-tissue sarcoma in,
I: 492–493;
III: 309–310;
IV: 294–295
spina bifida in offspring,
II: 9, 295–296;
III: 7, 8, 9–10, 438
spontaneous abortions in,
II: 283–284
status of,
I: 53;
II: 31–32
TCDD half-life estimates,
I: 260–261;
II: 104–105;
III: 37, 50, 157–158
TCDD serum levels,
I: 273, 281, 285, 656;
II: 101, 103, 105, 109, 351, 356, 357;
III: 146, 147
update of,
V: 6
See also Operation Ranch Hand;
Ranch Hand study;
US Air Force;
Vietnam veterans
Aktiengesellschaft, Germany,
IV: 137
AL-type primary amyloidosis. See Amyloidosis
Alanine aminotransferase (ALT),
II: 331, 332;
III: 45, 509, 510;
IV: 37
Alaskan natives
Inuit,
III: 50–51
See also Race/ethnicity
Alberta, Canada,
II: 135–136, 232, 242, 246;
III: 234–235, 319–320;
IV: 149, 198, 229, 312–313;
V: 117
Alberta Cancer Registry,
III: 235
Alberta Health Care Insurance Plan,
III: 235
Alcohol consumption,
I: 507
ALL. See Leukemia
Allergies,
II: 327, 329;
III: 487–488;
IV: 469–470
See also Immune system disorders
ALS. See Amyotrophic lateral sclerosis
ALS. See Assembly of Life Sciences
Alsea, Oregon,
I: 42–43, 372–373, 598
ALT. See Alanine aminotransferase
Alzheimer’s disease (AD),
V: 6, 449, 451
American Association for the Advancement of Science,
I: 29, 92
Herbicide Assessment Commission,
I: 30–31
American Cancer Society (ACS),
I: 334;
II: 177, 181, 189, 191, 204, 205, 209, 211, 217, 223, 228, 231, 239, 245;
III: 267, 282, 289, 292, 295, 296, 302, 304, 312, 322, 324, 329, 334, 343, 347, 351, 356, 362, 371, 377, 383;
IV: 250, 267, 273, 277, 281, 287, 291, 299, 300, 314, 320, 326, 335, 339, 345, 350, 355, 364, 371, 377;
V: 244, 278, 282, 289, 309, 316, 425
Cancer Prevention Study,
II: 239;
III: 229
American College of Epidemiology,
II: 25
American Diabetes Association (ADA),
III: 492, 493, 502;
V: 485
American Industrial Hygiene Association,
II: 25
American Journal of Epidemiology,
II: 281
American Legion,
I: 60, 278–279, 399, 601–602, 626, 633;
II: 113, 157;
IV: 133, 158;
VI: 120
Vietnam veterans’ epidemiological studies,
III: 212–213, 243;
V: 126;
V: 126, 187;
VI: 140
American Public Health Association,
II: 25
American Thoracic Society
Epidemiology Standardization Questionnaire,
II: 136
d-Aminolevulinic acid synthetase,
I: 153–154
Amitrole,
I: 323
AML. See Veterans and Agent Orange: Herbicides/Dioxin Exposure and Acute Myelogenous Leukemia in the Children of Vietnam Veterans (Acute Myelogenous Leukemia)
AML. See Leukemia
Amsterdam, Netherlands,
V: 5, 228–229, 511
Amyloidosis,
IV: 2, 7, 11, 511–513;
V: 506–507;
VI: 471–473
biologic plausibility,
VI: 473
scientific literature update,
VI: 472
Amyotrophic lateral sclerosis (ALS),
V: 6, 461–465, 524;
VI: 420–422
biologic plausibility,
VI: 420–422
clinical features,
V: 461
pesticide exposure and,
V: 463–465
pesticide occupational exposure studies,
V: 462
scientific literature update,
VI: 422
Vietnam veterans’ risk,
VI: 422
Anencephaly,
IV: 404–405
Angina,
I: 708;
IV: 135
See also Circulatory disorders
Animal studies,
III: 394–396, 524;
IV: 254, 256, 269, 275, 279, 290, 293–294, 296;
V: 35–36;
2,4-D carcinogenicity,
I: 118–119, 176–178;
II: 48;
III: 47, 396;
IV: 37;
VI: 36–40
2,4-D chronic exposure,
I: 179–180;
IV: 34
2,4-D developmental toxicity,
I: 124, 180–181;
III: 46;
VI: 38–39
2,4-D disease outcomes and mechanisms of toxicity,
II: 48–49;
III: 38–39, 44–47;
IV: 30–32, 35
2,4-D genotoxicity,
I: 178–179;
IV: 28, 33;
VI: 36–40
2,4-D immunotoxicity,
I: 122–123, 181;
III: 46, 423;
IV: 36;
VI: 39
2,4-D lethality,
III: 44–45;
IV: 35
2,4-D mechanism of action,
II: 47–48;
III: 44;
IV: 33;
VI: 40–41
2,4-D mechanism of toxicity,
II: 48–49;
IV: 28, 37;
VI: 36
2,4-D neurotoxicity,
II: 48;
III: 45–46, 473;
IV: 30, 35;
VI: 37
2,4-D pharmacokinetics,
I: 175
2,4-D reproductive toxicity,
I: 124, 180, 181;
III: 46;
IV: 29, 36;
VI: 38–39
2,4-D toxicity profile update summary,
II: 46;
IV: 33
2,4-D toxicokinetics,
II: 46–47;
III: 43–44;
IV: 24, 27;
VI: 34–36
2,4,5-T acute toxicity,
I: 184
2,4,5-T carcinogenicity,
I: 118, 119, 182–184;
III: 396
2,4,5-T chronic exposure,
I: 184
2,4,5-T developmental/reproductive toxicity,
I: 124, 185;
II: 49–50
2,4,5-T genotoxicity,
I: 184
2,4,5-T immunotoxicity,
I: 123
2,4,5-T mechanism of action,
III: 47–48
2,4,5-T mechanism of toxicity,
II: 49–50;
IV: 37
2,4,5-T pharmacokinetics,
I: 182
2,4,5-T toxicity profile update summary,
II: 49;
IV: 37
2,4,5-T toxicokinetics,
II: 49;
III: 47;
IV: 37
Ah receptor,
I: 3, 123, 134;
II: 3–4, 51–53, 54–56, 57–62;
III: 54–58, 129;
IV: 4, 30, 386
amyloidosis,
IV: 512
blood abnormalities,
I: 125;
IV: 496
breast cancer,
IV: 29, 317–318
cacodylic acid acute toxicity,
I: 188
cacodylic acid carcinogenicity,
I: 118, 119, 187;
IV: 5, 387
cacodylic acid chronic exposure,
I: 188–189
cacodylic acid developmental toxicity,
I: 189
cacodylic acid genotoxicity,
I: 187–188
cacodylic acid mechanism of action,
II: 50;
III: 49–50
cacodylic acid mechanism of toxicity,
II: 50–51;
IV: 24;
VI: 41–43
cacodylic acid pharmacokinetics,
I: 186–187
cacodylic acid renal toxicity,
II: 50–51
cacodylic acid reproductive toxicity,
I: 189
cacodylic acid toxicity summary,
II: 50;
IV: 38
cacodylic acid toxicokinetics,
II: 50;
III: 48;
IV: 24, 27, 38;
VI: 41
characteristics of,
I: 111–114;
IV: 48
epidemiologic studies,
IV: 359, 361, 369, 381
evidentiary role,
I: 228;
IV: 85, 106, 385, 515–516
generalizability,
I: 112, 113, 114, 118, 122–123, 160;
IV: 26, 85, 426, 459
hepatic abnormalities,
I: 124–125, 688;
IV: 25, 57, 59–60
human health relevance of toxicology,
III: 35–36;
IV: 26, 48
male-mediated disorders,
I: 593–594
nonhuman primates,
I: 151
picloram in,
I: 118, 119, 125, 190–192;
III: 51
research recommendations,
V: 526–527
squamous cell carcinomas,
IV: 284
TCDD acute toxicity,
II: 75–76
TCDD and bladder cancer in,
IV: 342
TCDD and bone/joint cancer in,
IV: 290
TCDD and Hodgkin’s disease in,
IV: 367
TCDD and leukemia disease in,
IV: 380
TCDD and multiple myeloma in,
IV: 374
TCDD and nasal/nasopharyngeal cancer in,
IV: 275
TCDD and non-Hodgkin’s lymphoma in,
IV: 358
TCDD and prostate cancer in,
IV: 332
TCDD and soft-tissue sarcoma in,
IV: 279
TCDD carcinogenicity,
I: 3, 116, 138–142;
II: 3, 65–68;
IV: 26, 305, 311
TCDD cardiovascular toxicity,
I: 171;
II: 76;
III: 74–75
TCDD dermal toxicity,
I: 173–174;
II: 76
TCDD developmental toxicity,
I: 123–124, 156–157, 159–160;
II: 3, 71, 72–73;
III: 92–105;
IV: 58
TCDD disease outcomes,
II: 3;
III: 39–43, 71–105;
IV: 3, 23
TCDD endocrine effects,
III: 83–84
TCDD gastrointestinal toxicity,
I: 169–170;
IV: 256
TCDD hepatotoxicity,
I: 124–125, 151–156;
II: 3, 73–75;
III: 76–79
TCDD immunotoxicity,
I: 119–122, 146–151;
II: 3, 68–71;
III: 85–92;
IV: 3, 26
TCDD-induced diabetes,
IV: 488
TCDD-induced wasting syndrome,
I: 162–166;
II: 76–77;
III: 80–83;
IV: 57, 76
TCDD lethality,
III: 71–73;
IV: 76
TCDD mechanism of action,
II: 3, 54–65;
III: 51–53, 54–58, 62–63, 67–69;
IV: 3, 24
TCDD mechanism of toxicity,
II: 65–77
TCDD metabolic toxicity,
I: 166–169
TCDD neurotoxicity,
I: 160–166;
II: 3, 75;
III: 84–85;
IV: 352, 458
TCDD pharmacokinetics,
I: 127–133
TCDD renal toxicity,
II: 77;
III: 75–76;
IV: 348
TCDD reproductive toxicity,
I: 123–124, 156–159;
II: 3, 71–72;
III: 92–105;
IV: 26, 64, 323, 337, 411, 432, 434
TCDD respiratory tract toxicity,
I: 170
TCDD toxicity update summary,
II: 51–53
TCDD toxicokinetics,
II: 3, 53–54;
III: 4–5, 33;
IV: 3, 23, 41, 47
toxicity, potential health risks and contributing factors,
III: 106, 107, 108;
VI: 45–47
Anthropometry. See Body weight
AOR. See Agent Orange Registry
Aphasia,
V: 447
Apoptosis, TCDD and,
II: 3, 67
Arctic region natives,
III: 50–51;
VI: 226
Argentina,
III: 224;
VI: 125
Arkansas,
I: 373–374, 663;
III: 234;
IV: 149, 231;
V: 117;
VI: 133
Armed Forces Institute of Pathology,
I: 494
Army. See US Army
Army Chemical Corps. See US Army Chemical Corps
Army Reserve Personnel Center,
II: 152
ARNT,
II: 4, 45, 55, 56, 57, 58, 66;
III: 38, 54–58, 63;
IV: 30, 47–56, 61, 67, 69–73, 86
See also Ah receptor (AhR)
Arsenic
cacodylic acid component,
IV: 117–118;
V: 4, 21;
VI: 21
respiratory cancer and latency,
II: 268;
III: 420
Arsenic in Drinking Water,
V: 21, 38;
Aryl hydrocarbon hydroxylase,
I: 135, 153, 155–156, 170
Aryl hydrocarbon receptor. See Ah receptor
Asbestos, respiratory cancer and latency,
II: 268;
III: 420
Asia,
III: 471;
See also Southeast Asia;
individual countries
Asian Americans,
II: 188
See also Race/ethnicity
Aspartate aminotransferase (AST),
II: 331, 333;
III: 45, 509;
IV: 37
Assembly of Life Sciences (ALS),
I: 62, 63
Association of Birth Defect Children,
II: 292
AST. See Aspartate aminotransferase
Asthma,
I: 708, 711, 713;
IV: 199
See also Respiratory disorders
Astrocytomas,
V: 525
Ataxia,
I: 658
See also Motor/coordination dysfunction;
Neurobehavioral toxicity
Atlanta, Georgia,
II: 241, 296;
III: 229
CDC Birth Defects Study,
II: 9;
III: 438;
IV: 237
Atlanta Congenital Defects Program,
I: 387
Atlantic Ocean,
III: 108
Australia,
I: 61, 91, 340, 406, 418, 444, 470, 488–489, 537, 546, 614–615, 633, 702, 710;
II: 113, 132, 149, 160, 202, 293;
III: 216–217, 218, 237, 244–245;
IV: 8, 10, 144, 150, 159, 210, 304;
VI: 128
Air Force veterans,
III: 244
Army veterans,
III: 244, 245;
IV: 159;
VI: 141
Australian National Service Vietnam veterans,
III: 273, 286
Bureau of Statistics Health Interview Survey, 1989-1990,
III: 245, 485, 511, 517
Department of Defense,
III: 244, 245
Department of Veterans Affairs,
III: 244, 245
Electoral Commission rolls,
III: 245
Health Insurance Medicare,
III: 245
herbicide use by forces,
III: 137–138
lung cancer mortality in Vietnam veterans,
III: 424
National Death Index,
III: 245
Navy veterans,
III: 244
Victorian Cancer Registry,
III: 232;
IV: 144;
VI: 128
Vietnam veterans epidemiologic studies,
III: 9, 273, 285–286, 290, 294, 295, 298, 299, 303, 310, 311, 314, 315, 327, 329, 339, 340, 343, 346, 349, 353, 355, 359, 365, 380, 389, 469, 486, 489, 500, 506, 512–513, 517;
IV: 244–247, 255, 259, 262, 264, 266, 272, 276, 280, 283, 287, 295, 298–299, 305–308, 310, 313, 319, 323–326, 332, 334–335, 337, 339, 345, 350, 355, 362–363, 371, 376, 380, 383, 404–405;
V: 127–128, 191–193, 324, 420
See also Tasmania
Austria,
IV: 138–139, 189, 467–468, 500
Autoimmune disease,
I: 697–699;
IV: 475–481
See also Immune system disorders;
Systemic autoimmune disease;
Systemic lupus erythematosus
Autoimmunity,
I: 693, 697–699;
II: 7, 21, 327, 329;
III: 487–488;
IV: 476–477
See also Immune system disorders
Axonal nerve damage,
VI: 428
B
B cell function,
I: 147, 148
Baltic Sea,
II: 329;
III: 108, 236, 272, 285, 358, 484, 515
Baltimore, Maryland,
V: 5, 400
Baltimore-Washington Infant Study,
V: 400
Basal/squamous cell skin cancer
biologic plausibility,
III: 322;
IV: 311;
V: 300;
VI: 264–265
epidemiologic studies,
III: 317–322, 323;
V: 296, 297–298, 299;
VI: 261–265
herbicide environmental exposure and,
III: 323;
IV: 229, 309;
V: 297–298, 299
herbicide occupational exposure and,
III: 321, 323;
IV: 309;
V: 296, 297, 298–299
herbicides association with,
III: 317–322, 323;
V: 295–300
incidence,
III: 319–320
morbidity studies,
V: 297–298
mortality studies,
III: 319, 321;
V: 296
scientific literature update,
III: 319–320;
IV: 309;
V: 296, 298–299;
VI: 261
Vietnam veterans and,
III: 323;
V: 298;
VI: 265
See also Melanomas;
Skin cancer
BASF,
I: 312–313, 444, 530, 550, 558;
II: 130–131, 238, 318–319, 325, 330–331, 332–333, 334, 336;
III: 153, 154, 174, 221–222, 269–270, 273, 297, 349, 484, 495, 506, 511;
IV: 112, 188–189, 257, 260, 271, 285, 290, 301, 333, 343–344, 368, 382;
V: 108, 135–136;
VI: 123, 425
Aktiengesellschaft,
III: 221;
IV: 137
Dioxin Investigation Programme,
II: 131
Occupational Safety and Employee Protection Department,
II: 131
Basic helix-loop-helix (BHLH),
II: 54, 55, 56;
IV: 49
Bayer,
III: 154;
IV: 112
Beck’s Depression Inventory,
I: 650, 651
Belgium,
Benefits. See Compensation, veterans
BHLH. See Basic helix-loop-helix
Bias
in an investigation,
V: 22;
VI: 23
methodological. See Methodological bias
publication,
VI: 30–31
Binghamton, New York,
III: 234;
IV: 149;
V: 117
Biochemical warfare,
I: 29, 45
Biologic plausibility,
II: 88, 92;
III: 2, 124, 128;
IV: 2–3, 16, 20–22, 26, 29, 106–107, 249, 385–388;
V: 4, 378–381, 516–518;
Ah receptor-TCDD interaction,
I: 3, 133–137, 439, 452–453;
III: 129;
IV: 48, 86
altered sperm parameters,
I: 634;
III: 451
amyloidosis,
V: 505;
VI: 473
amyotrophic lateral sclerosis,
VI: 420–422
animal studies,
I: 228;
II: 176;
III: 460–462, 474–475;
IV: 431–435
basal/squamous cell skin cancer,
III: 322;
V: 300;
VI: 264–265
birth defects,
II: 298;
III: 444;
IV: 403;
V: 404;
VI: 365
bladder cancer,
III: 351;
IV: 342–343;
V: 333;
VI: 291
bone/joint cancer,
I: 474;
III: 304;
IV: 290;
V: 282;
VI: 245
brain tumors,
I: 525;
III: 362;
IV: 352;
V: 343;
VI: 302
breast cancer,
II: 217;
III: 327, 329;
IV: 317–318;
V: 309;
VI: 269–270
carcinogenicity,
I: 116–118, 119, 146, 176–178, 182–184, 187, 190–191, 439, 451;
II: 176;
III: 394–397;
IV: 385–387
childhood cancer,
I: 630;
II: 300;
IV: 426;
VI: 389
chloracne,
I: 678;
II: 320–321;
III: 480;
IV: 466;
V: 479;
VI: 438
circulatory disorders,
I: 708;
III: 518;
IV: 510;
V: 505–506;
VI: 471
diabetes mellitus,
I: 692;
II: 335;
III: 502–503;
IV: 488;
V: 492;
VI: 456
endometrial cancer,
IV: 322
endometriosis,
VI: 478
evidentiary role of,
I: 111, 114, 223–224, 240–241, 434;
II: 88, 92, 176;
III: 23, 106–107;
V: 23–24
female reproductive system cancers,
I: 512;
III: 334;
IV: 323;
V: 316
fetal/neonatal/infant death,
I: 624;
III: 453
gastrointestinal disorders,
III: 513–514;
V: 502;
VI: 466
gastrointestinal tract cancers,
III: 281–282;
IV: 256;
V: 246;
VI: 221
genitourinary tract cancers,
I: 521–522
genotoxicity,
I: 178–179, 184, 187–188, 191
hepatobiliary cancer,
I: 453, 457;
III: 286, 288;
IV: 270;
V: 263–264;
VI: 225–226
Hodgkin’s disease,
I: 557;
III: 377;
IV: 367;
V: 361;
VI: 319
hormonal effects,
VI: 394–397
hyperlipidemia,
I: 692
immune system disorders,
VI: 447–448
immunotoxicity,
I: 122, 146–151, 181, 192, 699;
III: 491
infertility,
I: 634;
II: 282;
III: 451;
VI: 372
kidney cancer,
V: 338
laryngeal cancer,
III: 295;
IV: 279;
V: 271–272;
VI: 234
leukemia,
I: 571;
III: 390;
IV: 380–381;
V: 372, 376;
lipid and lipoprotein disorders,
VI: 459–463
liver disorders,
I: 691–692;
II: 335;
III: 513–514;
IV: 270
low birthweight outcomes,
I: 628;
III: 458;
V: 425;
VI: 382–383
lung cancer,
III: 302;
IV: 284;
V: 278
male-mediated reproductive outcomes,
I: 593–595;
III: 451;
IV: 413, 416–417, 426
melanoma,
III: 317;
IV: 305;
V: 295;
VI: 260
motor/coordination dysfunction,
I: 661;
III: 475;
IV: 448
multiple myeloma,
I: 12, 563;
III: 383;
IV: 374;
V: 366;
VI: 325
nasal/nasopharyngeal cancer,
I: 460;
III: 292;
IV: 275;
V: 268;
VI: 230
neurobehavioral disorders,
II: 314;
III: 474–475;
VI: 409
neuropsychological disorders,
I: 658;
IV: 457–459;
VI: 429–430
non-Hodgkin’s lymphoma,
I: 549;
III: 366;
IV: 358–359;
V: 355;
VI: 312
parkinsonism,
VI: 419–420
perinatal death,
III: 453, 458;
IV: 413;
V: 422;
VI: 379
peripheral nervous system disorders,
I: 666;
V: 470–472;
VI: 428
porphyria cutanea tarda,
I: 679, 682;
II: 323;
III: 482;
IV: 468;
V: 480
prostate cancer,
III: 343;
IV: 331–332;
V: 323–324;
VI: 282–283
renal cancers,
III: 356;
IV: 348
renal toxicity,
I: 179–180
reproductive outcomes,
I: 123–124, 180–181, 185, 189, 192, 605, 618, 628;
II: 300–301;
III: 458, 460–462;
IV: 411;
VI: 394–397
respiratory cancers,
I: 472
respiratory disorders,
I: 713;
III: 486;
V: 482;
VI: 443
sex ratio,
VI: 393–394
skin cancer,
I: 503;
IV: 305, 311;
VI: 260
soft-tissue sarcoma,
I: 500;
III: 311;
IV: 296;
V: 287;
VI: 251
spontaneous abortion,
V: 420;
VI: 378
squamous cell carcinomas,
IV: 284
testicular cancer,
III: 347;
IV: 337;
V: 327
thyroid homeostasis,
VI: 481
See also TCDD biologic plausibility
Biological samples,
I: 20–21, 729–730
Biomarkers
chloracne as,
I: 4, 10, 172–173, 262, 401, 672–674;
II: 318;
V: 478
exposure assessment and,
I: 259–262, 280–284;
II: 101–104;
sperm parameters as,
I: 631
III: 146–147;
IV: 111, 123, 448, 479
research recommendations,
I: 17, 725;
II: 25
Bionetics Research Laboratory,
I: 30
Birth defects
biologic plausibility,
III: 444;
IV: 403;
V: 404;
VI: 365
definition of,
I: 605–606;
II: 286;
III: 435;
IV: 400;
V: 393–394
epidemiologic studies,
II: 140, 286–296;
III: 436, 437–438, 443;
IV: 247, 403;
V: 404;
VI: 355–365
epidemiology,
I: 606;
II: 286;
III: 435–436
evaluation of epidemiologic data,
I: 615–618;
IV: 144–145, 403
herbicide association first reports,
I: 1
herbicide association in,
I: 13–14, 618;
II: 7, 11, 20, 286–296;
III: 436–444;
IV 400–405;
V: 393–405
herbicide environmental exposure studies,
I: 608–609;
II: 140, 287–288, 297;
III: 437;
V: 394, 400–402;
VI: 363
herbicide occupational exposure studies,
I: 607–608;
II: 286–287, 297;
III: 437;
IV: 197;
V: 394–395;
VI: 362
Ranch Hand participants’ children and,
II: 293–296;
III: 436, 438, 439;
IV: 18;
V: 16;
VI: 15
risk factors of,
I: 606–607;
II: 298;
III: 444;
V: 405
scientific literature update,
III: 437, 439–443;
IV: 401–402;
V: 394–403, 433–437;
VI: 362–365
Seveso, Italy, study,
II: 287;
III: 436
summary,
II: 295–296;
IV: 400–401
TCDD association with,
V: 5, 434, 439–441
TCDD biologic plausibility in,
I: 618;
II: 298;
III: 460–461
Vietnam veterans’ children and,
I: 609–615, 618;
II: 288–296, 297, 298;
III: 435, 436, 437–438;
IV: 403;
V: 396–398;
VI: 364
See also Cleft lip/palate;
Neural tube defects;
Reproductive disorders;
Spina bifida;
Teratogenicity
Birth Defects Study,
II: 9, 290–291, 296;
III: 147, 436, 438, 439;
IV: 405, 429
See also Centers for Disease Control and Prevention (CDC)
Births. See Birth defects;
Low birthweight;
Perinatal death;
Preterm delivery (PTD)
Bladder cancer and disorders
Birthweight. See Low birthweight
biologic plausibility,
III: 351;
IV: 342–343;
V: 333;
VI: 291
epidemiologic studies,
I: 515–517;
II: 225–227;
III: 347–351;
IV: 19, 339–347, 385, 387;
V: 5, 17, 330–332, 333;
VI: 286–292
epidemiology,
II: 223;
III: 347
herbicide association in,
I: 12, 521, 576;
II: 7, 12, 21, 225–227, 250;
III: 3, 10, 21, 132, 347–351;
IV: 19, 31, 40;
V: 17, 21, 328–333;
VI: 16–17
herbicide environmental exposure and,
III: 349, 350–351;
IV: 341;
V: 329, 331–332
herbicide occupational exposure and,
III: 348, 350;
IV: 340–341;
V: 329, 330
histopathology,
I: 513
incidence,
I: 513
incidence, data by age/gender/race, for selected age groups,
III: 347;
IV: 340;
V: 328;
VI: 287
risk factors,
I: 513–514;
V: 333
scientific literature update,
II: 226–227;
III: 348–349;
IV: 340;
V: 329, 332;
VI: 291
TCDD association with,
IV: 19, 24;
V: 5
Vietnam veterans’ risk,
I: 513, 517, 522;
II: 223, 226;
III: 349, 351;
V: 333;
VI: 292
See also Genitourinary cancers
Body mass index (BMI),
II: 281;
III: 499, 502
Body weight, loss of and TCDD,
II: 3
Boehringer-Ingelheim,
I: 313;
III: 153–154;
IV: 111–112;
V: 220;
VI: 172
Bone development effects,
VI: 68–69
Bone/joint cancer
biologic plausibility,
III: 304;
V: 282;
VI: 245
children and,
I: 628
chondrosarcomas of the skull,
III: 2, 10, 266, 304
epidemiologic studies,
III: 303–305;
V: 280–282;
VI: 242–245
epidemiology,
I: 472–473;
II: 204;
III: 302
herbicide association in,
I: 13, 473–474, 577;
II: 6, 11, 20, 204–205, 249–250;
III: 7, 10, 303–305;
V: 278–282
herbicide environmental exposure and,
III: 303, 305;
IV: 289;
V: 280
herbicide occupational exposure and,
III: 303, 305;
IV: 288;
V: 280
incidence of, data by gender/race, for selected age groups,
III: 302;
IV: 288;
VI: 242
scientific literature update,
II: 204–205;
III: 303;
IV: 288;
V: 279, 281;
VI: 242–244
Vietnam veterans’ risk,
I: 473, 474;
II: 204;
IV: 290;
V: 282;
VI: 245
Vietnam veterans’ studies,
III: 303, 305;
IV: 289;
V: 281
Boston Hospital for Women,
II: 291–292
Brain tumors,
I: 339;
IV: 350
2,4-D exposure and,
I: 119, 176–177
agricultural workers and,
I: 320;
II: 136
biologic plausibility,
III: 362;
IV: 352;
V: 343;
VI: 302
clinical features,
I: 522
epidemiologic studies,
II: 136, 229–230;
III: 356–361;
IV: 198;
V: 340–343;
VI: 296–302
epidemiology,
I: 522–523;
II: 228–229;
III: 356
herbicide association in,
I: 12, 525, 576;
II: 7, 12, 21, 229–230, 250;
III: 8, 12, 21, 356–362;
IV: 19;
V: 17, 338–343
herbicide environmental exposure and,
III: 358, 361;
IV: 351;
V: 341–342;
VI: 301
herbicide occupational exposure and,
III: 357–358, 360;
IV: 351;
V: 340–341;
VI: 301
incidence, data by gender/race, for selected age groups,
III: 356;
IV: 351;
V: 339;
VI: 297
research recommendations,
V: 524
scientific literature update,
II: 229–230;
III: 357–359;
IV: 351;
V: 339, 342;
VI: 301–302
TCDD association with,
IV: 19
Vietnam veterans’ risk,
I: 525;
II: 228–229, 230;
IV: 353;
V: 343;
VI: 302
Vietnam veterans’ studies,
III: 358–359, 361;
IV: 352;
V: 342;
VI: 301–302
Breast cancer
agricultural workers and,
I: 510;
IV: 140
biologic plausibility,
II: 217;
III: 327, 329;
IV: 318;
V: 309;
VI: 269–270
epidemiologic studies,
II: 214–216, 217;
III: 324–328;
IV: 318–320;
V: 302–304, 308;
VI: 265–270
epidemiology,
I: 505, 506–507;
II: 213–214;
III: 322, 324;
IV: 144
herbicide association in,
I: 13;
II: 6, 11, 12, 20, 89, 213–217, 249–250;
III: 7, 10, 324–329;
IV: 24, 29, 38, 73;
V: 300–309
herbicide environmental exposure studies,
I: 511, 512;
III: 328;
IV: 315;
V: 302–303, 304–307
herbicide occupational exposure studies,
II: 214–216;
III: 324–326, 328;
IV: 315;
V: 301, 302, 304
histopathology,
I: 505–506
incidence in US women, data by race, for selected age groups,
III: 324;
IV: 314;
V: 301;
VI: 265
risk, estimated,
II: 218;
V: 300–301
risk factors,
I: 507;
V: 309
scientific literature update,
III: 326–327;
IV: 315;
V: 301, 304–307;
VI: 266
TCDD association with,
V: 5, 65–66, 306–307;
VI: 81
Vietnam veterans’ risk,
I: 213, 216–217, 505, 511;
III: 329;
IV: 318;
V: 309;
VI: 270
Vietnam veterans’ studies,
III: 326, 328;
IV: 316;
V: 304
See also Reproductive system cancers, women
Breast milk,
British Columbia, Canada,
III: 10, 227–228, 338, 439–440, 447–448, 449, 452, 453, 457;
IV: 419
Cancer Incidence File,
III: 227
Death File,
III: 227
Division of Vital Statistics,
III: 452, 457
Health Surveillance Registry,
III: 227, 439
Bronchitis,
I: 708, 711, 713
See also Respiratory disorders
Bronchus cancer. See Lung cancer
Brown, Jesse,
II: 24;
III: 24, 25
Bureau of Census,
III: 231
Bureau of Labor Statistics,
I: 79, 80
Burkitt lymphoma,
V: 430
n-Butyl esters,
I: 27;
IV: 117–119
C
Ca Mau peninsula,
I: 100, 104
Cacodylic acid,
I: 88–89;
II: 4;
III: 5, 19, 32, 135, 136, 137, 218;
IV: 22, 117–118, 133;
V: 1, 3, 4;
VI: 1, 3, 11, 20–21, 41–43, 118–119, 201, 276, 436
acute toxicity,
I: 188
animal studies,
I: 185–189;
II: 50–51;
III: 34, 38, 48, 49–50, 396;
IV: 5;
VI: 41–43
carcinogenicity,
I: 118, 119, 187;
II: 40;
III: 396;
V: 39
chemical properties/structure,
I: 111, 114, 186;
II: 38;
III: 32;
V: 21
chronic exposure,
I: 188–189
and circulatory disorders,
V: 503
developmental toxicity,
I: 124, 189
dimethylarsenic radical formation and,
II: 4
disease outcomes,
III: 34, 50;
IV: 25, 31
domestic use,
I: 185–186
genotoxicity,
I: 119, 187–188
kidney toxicity,
I: 125;
II: 42
mechanism of action,
II: 50;
III: 38, 49–50;
VI: 41–43
mechanisms of toxicity,
II: 50–51
metabolism,
I: 115, 116
Operation Ranch Hand, use in,
IV: 117
pharmacokinetics,
I: 186–187
renal toxicity,
II: 50–51
reproductive toxicity,
I: 124, 189;
II: 42;
IV: 403
toxicity update summary,
II: 50;
IV: 23, 33, 38;
V: 38–40, 78;
toxicokinetics,
II: 50;
III: 32–33, 48;
IV: 24, 27–29;
V: 38–39;
VI: 41
Vietnam formulations,
I: 186
volume used in Operation Ranch Hand, data,
III: 136
Calcium, homeostasis of and 2,4,5-T,
II: 4
California,
I: 341;
III: 232;
VI: 129
See also Irvine, California
Camp Drum, New York,
I: 25–26, 89
Canada,
I: 11, 319–320, 323, 374–375, 443, 467–468, 537–539, 620, 650;
II: 8, 132, 135–136, 140, 219–220, 243, 248;
III: 226, 232, 303, 309, 335, 344, 348, 353;
IV: 141, 199, 209, 257, 296, 333, 353, 360, 374, 381;
V: 352;
Census of Agriculture, 1971,
II: 135
Census of Population, 1971,
II: 135
Central Farm Register, 1971,
II: 135
Central Farm Register, 1981,
II: 135
Mortality Data Base,
II: 135;
III: 227
Mortality Study of Canadian Male Farm Operators,
II: 135–136;
III: 224;
IV: 140, 198–200
Saskatchewan Cancer Foundation,
II: 139
Saskatchewan Hospital Services Plan,
II: 139
Statistics Canada,
III: 227
See also Alberta, Canada;
British Columbia, Canada;
Manitoba, Canada;
New Brunswick, Canada;
Ontario, Canada;
Saskatchewan, Canada
Cancer
age-specific incidence,
I: 436–438;
IV: 250, 267, 273, 277, 281, 288, 292, 300, 314, 321, 327, 335, 346, 351, 356, 365, 372, 378
agriculture workers and,
I: 320–323, 443;
II: 136, 137–138
biologic plausibility,
I: 116–118, 119, 434;
II: 176;
III: 394–397;
IV: 249, 256, 270, 275, 279, 284, 290, 296, 305, 311, 318, 322, 323, 331, 332, 337, 342, 343, 348, 352, 358, 359, 367, 374, 380, 381, 385;
VI: 339–341
children and,
I: 14, 594–595, 628–631;
IV: 345, 399, 400, 417–429;
V: 425–432
clinical features,
I: 433–436
epidemiologic studies,
I: 45, 317, 320–323, 325–326, 367, 383–384, 391–393, 443–445;
II: 133–138, 147–148;
IV: 182, 251–255, 268–269, 274–275, 277–278, 282–283, 288–289, 292–295, 302–304, 309–310, 315–316, 321–323, 327–329, 336–337, 340–342, 346–347, 351–352, 356–358, 365–367, 372–373, 379–380;
V: 5, 242–393;
epidemiology,
I: 433, 435–438, 442, 525;
II: 175;
III: 265–266
herbicide association, insufficient evidence for determining,
I: 13–14, 577–578;
II: 249–250;
III: 393;
IV: 268, 270, 274, 279, 286, 302, 305, 311, 314, 318, 321, 323, 336, 337, 338, 340, 342, 346, 348, 374, 378, 380, 384;
VI: 338
herbicide association, limited/suggestive evidence of,
I: 10–12, 574–576;
II: 247–249;
III: 393;
IV: 256, 278, 279, 283, 331, 373, 384, 385;
VI: 338
herbicide association, no evidence of,
I: 12–13, 576–577;
II: 250;
III: 393–394;
IV: 254, 256, 269, 289, 317;
VI: 338–339
herbicide association, sufficient evidence of,
I: 8–10, 572–574;
II: 175, 176, 247;
III: 390, 392;
IV: 295, 358, 367, 384;
VI: 337–338
herbicide environmental exposure epidemiologic studies,
I: 444, 469;
II: 147–148;
IV: 254, 269, 274, 278, 282, 289, 293, 302, 309, 315, 321, 329, 336, 341, 347, 351, 357, 366, 372, 379
herbicide exposure measures,
II: 175, 176;
III: 265–266
herbicide occupational exposure studies,
I: 443–444;
II: 133, 134;
IV: 251, 268, 274, 282, 288, 292, 302, 309, 315, 321, 327, 336, 340, 346, 351, 356, 365, 372, 379
herbicide/pesticide applicators and,
I: 320–321, 323, 325–326, 443, 447, 466–468, 488, 491;
II: 137–138;
IV: 276
herbicides, categories of association in,
I: 572
mortality studies,
I: 442–445;
II: 133, 134, 136, 137, 263;
III: 410–411, 421, 422, 423, 424, 426, 427, 429;
IV: 251–254, 268–270, 277, 282, 288, 289, 292, 293, 294, 299, 302, 303, 305, 327, 329, 330, 331, 332, 336, 341, 346, 347, 351, 352, 356, 357, 358, 365, 366, 367, 372, 373, 379, 380
multistage model,
I: 142–143, 434, 439
P450 induction to,
I: 144–145, 170
phenoxy herbicide association in,
I: 483;
III: 422, 423, 429
research priorities,
I: 19, 727
research recommendations,
I: 19, 727
risk assessment,
I: 442–443, 578;
II: 251, 276;
III: 430–431
site groupings for ICD-9 cancer codes,
III: 537–539
TCDD animal studies,
I: 138–142;
II: 176;
III: 394, 396;
IV: 306, 311, 317
TCDD genotoxicity,
I: 143–144
TCDD in initiation/promotion,
I: 116, 142–143, 434, 439
TCDD in P450 induction to,
I: 144–145
Vietnam civilians,
II: 148
Vietnam veterans, expected incidence,
I: 439–440, 442, 452, 460–461, 473, 475, 501, 505, 513, 522, 526, 564;
II: 176–177;
III: 266–267
Vietnam veterans’ risk,
I: 391–393, 401, 402–403, 405, 436–438, 444–445, 578;
II: 251, 276;
III: 397, 430–431;
IV: 256, 270, 275, 279, 284, 290, 296, 305, 311, 318, 323, 332, 338, 343, 348, 353, 359, 367, 374, 381, 388;
VI: 341
See also Carcinogen(s);
Latency effects in cancer studies;
specific cancer sites;
specific cancers;
specific tumors
Carcinogen(s)
2,4-D as,
I: 118–119, 176–178;
II: 40, 48;
III: 47, 396;
IV: 5;
V: 37
2,4,5-T as,
I: 118, 119, 182–184;
II: 40;
III: 396
cacodylic acid as,
I: 118, 119, 187;
II: 40;
III: 396;
IV: 29, 31
herbicides as,
I: 3, 40;
II: 273, 275;
III: 426, 428, 430;
IV: 10, 17, 267, 270, 341, 345, 511;
VI: 340
mechanism of action,
I: 434;
V: 61–62;
VI: 36–40
picloram as,
I: 118, 119, 190–191;
II: 40;
III: 396
TCDD as,
I: 3, 116–118, 434, 439;
II: 3, 39–40, 65–68;
III: 394, 396;
IV: 3, 82–83, 134, 256, 274–275, 279, 284, 290, 296, 305, 311, 318, 330, 332, 337, 342, 348, 352, 358, 367, 374, 380, 385–387, 477;
V: 61–63, 75–76;
VI: 76–78
See also Cancer
Cardiovascular system disorders
cardiomegaly,
I: 703
cardiovascular disease,
V: 6;
VI: 69–70
circulatory disorders,
I: 699–709;
IV: 182;
V: 502–506
developmental, in infants,
V: 5
herbicide association in,
V: 21
lipid abnormalities in,
I: 688
TCDD in,
I: 171;
II: 76;
III: 74–75;
IV: 23–26, 135, 156–157;
IV: 76, 135, 156–157;
V: 70
See also Circulatory disorders;
Myocardial infarction
CART. See Classification and regression tree method
CAS. See Chemical Abstract Service
Case-control studies
agriculture/forestry workers,
I: 326–341;
II: 138–140;
III: 185–195, 228–232;
V: 153–166;
VI: 127–128
evidentiary role of,
I: 234–235, 727;
II: 94–95, 178, 179, 180, 188;
III: 130;
IV: 105, 108
herbicide environmental exposure,
II: 144–146, 148–149, 184, 186, 190, 193, 241;
III: 201–204;
IV: 227–231, 322
herbicide exposure assessment for,
I: 256–257, 727;
IV: 9, 137, 144–146, 207–221, 336, 369, 401, 418–420, 428, 444–445, 447
herbicide occupational exposure,
II: 122–127, 138–140, 183, 184, 186, 188, 190, 193, 200, 222, 240;
III: 173, 175, 185–196;
IV: 133, 136, 187, 192, 207–221, 328
paper/pulp workers,
II: 126–127, 200;
IV: 147, 221–223
Vietnam veterans,
II: 155–157, 159–160, 187, 223;
III: 208–217;
IV: 124, 236–245, 247, 420, 423–425, 427
Causality
statistical association vs.,
I: 7, 227, 239, 246;
II: 5, 19, 97, 247;
III: 6, 20, 132–133, 390;
IV: 6;
V: 22–23;
VI: 7
CDC. See Centers for Disease Control and Prevention
CDDs. See Chlorinated dibenzo-p-dioxins
Cell-mediated immunity (CMI)
TCDD and,
II: 69–70
Cell proliferation
TCDD and,
II: 3, 67;
IV: 23, 60, 61, 63, 79, 82
Cell stress responses,
VI: 40
Cellular retinoic acid binding protein, type II (CRABP-II),
II: 73
Census Bureau. See Bureau of Census
Centers for Disease Control and Prevention (CDC),
I: 19, 40–41, 51;
II: 9;
III: 363, 517;
IV: 115, 123, 133;
Agent Orange action/research,
I: 57–62, 63–64;
II: 28;
III: 25;
IV: 125–126
Agent Orange Study,
I: 276–278;
II: 102;
IV: 124
birth defects research,
I: 387–389, 609–612;
II: 289;
IV: 124;
V: 418
epidemiological studies,
II: 113, 155–156;
III: 26, 207–209, 218, 240;
IV: 156–157, 208, 235, 236, 237;
V: 123, 182–183;
VI: 138–139
exposure opportunity index,
I: 274–276, 611–612;
II: 290–291;
III: 147–148
neural tube defects in children, studies by,
IV: 18;
V: 16;
VI: 15
research methodology,
I: 728
TCDD half-life investigation,
II: 104–105
validation study,
I: 59, 260–261, 281–284, 285, 387, 742–743;
II: 103, 104;
III: 240
See also Birth Defects Study;
Cerebrospinal Malformation (CSM) Study;
General Birth Defects Study (GBDS);
Selected Cancers Study;
Vietnam Experience Study (VES)
Central nervous system (CNS). See Cognitive/neuropsychiatric disorders;
Motor/coordination dysfunction;
Neurobehavioral toxicity;
Neurologic disorders
Cerebrospinal Malformation (CSM) Study,
I: 610;
II: 289–290
Cerebrovascular disease,
I: 702
stroke,
I: 658, 659, 660
Cervical cancers,
I: 13, 505, 509, 510, 512;
II: 6;
III: 329, 330, 332;
IV: 320–321, 324, 385;
V: 5, 310, 311;
VI: 272
Chance,
VI: 23
Chapaevsk, Russia,
V: 5–6, 117–118, 228, 245, 269, 279, 292, 294, 299, 305, 314, 316, 322, 329, 332–333, 337, 368, 371, 402, 416–417, 436, 504–505;
Chemical Abstract Service (CAS),
VI: 21
Chemical production. See Chemicals and chemical industry;
Herbicides;
Industrial accidents;
Production workers
Chemicals and chemical industry
Agent Orange product liability litigation,
I: 34–35
hexachlorophene production,
I: 40;
II: 128;
IV: 134–135, 138, 148
production workers exposure studies,
I: 303–318;
II: 114–118, 128–135, 171–175, 182–183, 191, 193–197, 206–207, 232, 237–238, 273–274, 275;
III: 170–178, 218, 219–224, 284, 363–364, 378–379, 386–387, 420, 423, 426, 429;
IV: 133–140, 194–197, 252, 257, 258, 260, 262, 263, 265, 266, 271, 276, 280, 285, 286, 293, 296, 297, 301, 306, 307, 318, 319, 325, 327, 333, 334, 338, 343, 344, 348, 349, 353, 354, 360, 368, 374, 381, 382;
V: 3
TCDD contamination in production,
I: 91, 126
See also Herbicides;
Industrial accidents
Chemoreception
characteristics of,
I: 133–134
dioxin-responsive enhancers in,
I: 135–136
estrogen-mediated,
I: 145
TCDD dose-response linearity,
I: 137–138
TCDD hepatotoxicity and,
I: 154–155
TCDD-induced wasting syndrome and,
I: 164
See also Ah receptor
Child mortality studies,
II: 147
See also Deaths;
Mortality studies
Childhood cancer. See Children, cancer in;
Neuroblastoma
Children
spina bifida in Vietnam veterans offspring,
II: 9–10, 296, 298, 309;
III: 7, 8, 9–10, 21, 24–25, 437–438
See also Child mortality studies;
Children, cancer in
Children, cancer in,
I: 14, 594–595, 628–631;
II: 7, 11, 20;
IV: 399–400, 417–420, 422, 425–426, 427, 428, 432;
V: 425–432
biologic plausibility,
VI: 389
epidemiologic studies,
II: 299;
V: 427–429, 432;
VI: 383–389
epidemiology,
II: 298;
IV: 422–425
herbicide association in,
II: 299–300;
V: 425–432
scientific literature update,
II: 299–300;
IV: 418–422;
V: 429–431;
VI: 384
Seveso, Italy, study,
II: 299;
IV: 428
Vietnam veterans’ offspring,
II: 299;
IV: 426, 429;
V: 431;
VI: 389
See also Wilm’s tumor
China,
I: 458;
II: 188, 320;
III: 159, 289;
IV: 273;
See also Shanghai, China
Chloracne,
I: 39
animal studies,
I: 173–174;
III: 480
biological plausibility,
II: 320–321;
III: 480;
IV: 466;
V: 479;
VI: 438
chemical production workers and,
I: 308, 310, 316;
IV: 464, 466
clinical features,
I: 672–673;
V: 477–478
diet and,
I: 174;
IV: 463–464
epidemiologic studies,
I: 674–678;
II: 318–320;
III: 479–480;
IV: 135–136, 138–139, 147, 152, 186, 189, 194, 233;
V: 478–479;
epidemiology,
II: 317–318;
III: 478–479
herbicide association in,
I: 10, 678;
II: 5, 6, 20, 318–321;
III: 6, 7, 20, 24, 479–480;
IV: 185, 463–464;
V: 14;
VI: 13
scientific literature update,
II: 318–320;
III: 480;
IV: 465;
V: 478;
VI: 437–438
Seveso, Italy, accident and,
I: 366–367;
IV: 464
skin cancer and,
I: 502
TCDD biomarker for,
I: 4, 10, 28, 172–173, 262, 401, 672–674;
II: 3, 318;
V: 478
Vietnam veterans and,
II: 317, 318, 321;
III: 479, 480;
IV: 233, 465–466;
V: 479;
VI: 438
Vietnam veterans compensation for,
I: 50, 51, 55, 56;
II: 24, 28–29, 30, 31
Vietnam veterans’ risk,
VI: 438
See also Skin sensitivity
Chlordane,
I: 91
Chlorinated dibenzo-p-dioxins (CDDs),
II: 63–64, 65
4-Chloro-2-methylphenoxyacetic acid (MCPA),
II: 113, 133, 188, 193, 195–196, 207;
III: 218, 225;
IV: 133, 197, 258, 259, 260, 262, 264, 265, 267, 276, 280, 286–287, 290, 291, 297, 299, 312, 334, 335, 338, 339, 344–345, 349, 350, 354, 355, 401
2-[4-Chloro-2-methylphenoxy]propanoic acid (MCPP),
II: 133, 195–196
Chlorodibenzodioxins,
I: 28
Chlorophenols,
I: 9;
III: 150, 151, 154, 218, 222, 223, 422, 423, 429;
IV: 16;
V: 3, 104
Chondrosarcomas of the skull. See Bone/joint cancer
Chronic lymphocytic leukemia (CLL),
III: 384–385;
IV: 208, 211, 377, 417, 422;
V: 7, 366–367, 372–376;
See also Leukemia
Chronic myeloid leukemia (CML). See Leukemia
Chronic obstructive pulmonary disease (COPD),
II: 129;
IV: 184, 470, 472, 474, 475;
VI: 441
See also Respiratory disorders
Chronic persistent peripheral neuropathy,
V: 6, 465–469;
VI: 6
scientific literature update,
V: 466–467
TCDD and,
V: 465–469
Circulatory disorders
biologic plausibility,
III: 518;
IV: 510;
V: 505–506;
VI: 471
definition,
II: 335, 337;
III: 514;
IV: 505
epidemiologic studies,
I: 700–707;
II: 335–337;
III: 514–518;
IV: 506–509;
V: 6;
VI: 467–471
epidemiology,
III: 514
herbicide association in,
I: 14, 708;
II: 7, 11, 21, 335–337;
III: 3, 8, 514–518;
VI: 467–469
morbidity studies,
II: 336
mortality studies,
II: 335
research methodology,
I: 699–700;
II: 335
scientific literature update,
II: 336–337;
III: 515–518;
IV: 506–509;
V: 503–504;
VI: 467–469
Vietnam veterans and,
II: 336;
III: 514;
IV: 510;
V: 506;
See also Angina;
Cardiovascular system disorders;
Depressive disorders;
Hypertension;
Myocardial infarction
Cirrhosis,
VI: 465
Classification and regression tree (CART) method,
V: 414–415
Cleanup efforts. See Hazardous materials disposal and cleanup
Cleft lip/palate,
I: 373–374, 375, 611, 612;
IV: 402, 433
See also Birth defects
Clinton, William J.,
III: 24
CLL. See Chronic lymphocytic leukemia;
Leukemia
CMGCs. See Congenital morphogenetic conditions
CMI. See Cell-mediated immunity
CML. See Chronic myeloid leukemia;
Leukemia
CNS. See Cognitive/neuropsychiatric disorders;
Motor/coordination dysfunction
Coast Guard. See US Coast Guard
Cognitive/neuropsychiatric disorders
covariants in,
V: 449
epidemiologic studies,
II: 148, 307–308;
III: 468–469;
V: 449–451;
VI: 406–410
herbicide association in,
I: 657–658;
II: 7, 11, 20, 307–309;
III: 468–469;
IV: 441–443;
V: 449–451;
VI: 6
herbicide environmental exposure studies,
I: 651–653;
II: 148
herbicide occupational exposure studies,
I: 649–651;
V: 6
scientific literature update,
II: 307–308;
III: 469;
IV: 441–442;
V: 449–451;
VI: 407–409
Vietnam veterans’ risk,
I: 653–656;
II: 308;
V: 449–451
See also Encephalopathy;
Neurasthenia;
Neurobehavioral toxicity;
Neurologic disorders;
Posttraumatic stress disorder (PTSD)
Cohort studies
agriculture/forestry workers,
I: 318–323;
II: 118–122, 135–138;
III: 178–182, 224–226;
IV: 140–142, 197–206;
VI: 124–127
definition,
I: 229
herbicide environmental exposure,
II: 141–147, 190, 218;
III: 197–201;
IV: 224–237
herbicide exposure assessment for,
I: 254–256;
II: 105–107, 178, 179, 180
herbicide occupational exposure,
II: 107–108, 114–122, 130–133, 182–183, 186, 190, 192, 193, 218, 222, 240;
III: 170–185, 196;
IV: 134–140, 182–206, 222–230;
VI: 169–174
methodology,
I: 229–232
Ranch Hand cohort,
II: 109, 150–152, 154–156, 201;
IV: 13, 18, 150–156
Vietnam veterans,
II: 149–160, 187, 218;
III: 206–217;
IV: 232–247
Vietnamese civilians cohort,
II: 108–109
Colon cancer
agricultural workers and,
I: 328–329
epidemiologic studies,
III: 276–278;
IV: 250–252, 255–256, 262, 385;
V: 250–253;
VI: 210–213
herbicide association in,
I: 12–13, 576–577;
II: 7, 12;
III: 8, 21;
V: 17
See also Gastrointestinal (GI) tract cancers
Colorado,
III: 47
Colorectal cancer,
I: 446
Vietnam veterans’ risk,
I: 447, 450, 451, 452;
IV: 256
See also Gastrointestinal (GI) tract cancers
Committee on the Assessment of Wartime Exposure to Herbicides in Vietnam,
V: 525;
VI: 493
Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides,
II: 17, 18, 19, 22, 23, 264–266;
III: 17, 18, 19, 23, 412;
IV: 15;
V: 2–3, 12–13;
epidemiologic studies of Vietnam Veterans, recommendations,
II: 24–25
Compensation, veterans,
I: 227
congressional legislation,
I: 47, 50–51;
II: 28–29;
III: 26–27
Department of Veterans Affairs,
I: 55–56;
II: 24, 30–31;
III: 28
product liability litigation,
I: 34–35
Con Thieu province, Vietnam,
I: 96;
III: 139;
IV: 121
Concentration difficulties,
V: 447
Confidence intervals,
I: 244;
V: 17;
VI: 23
Confounding distortion of measures of association,
V: 22;
Congenital anomalies/malformations. See Birth defects
Congenital morphogenetic conditions (CMGCs),
V: 402–403
Congress. See Congressional hearings;
Legislation;
US Congress
Congressional hearings
Agent Orange and,
II: 27–28;
III: 25
Connecticut, tumor registry,
III: 235, 388
COPD. See Chronic obstructive pulmonary disease
Corticosterone, TCDD and,
I: 168, 171–172
Cox Proportional Hazard,
III: 499, 502
CRABP-II. See Cellular retinoic acid binding protein, type II
Cretinism. See Thyroid homeostasis
Crohn’s disease,
VI: 444
Cryptorchidism,
V: 324
CSM. See Cerebrospinal Malformation Study
Cyclophosphamide,
V: 40
Cynomolgus monkeys,
V: 60
Cytochrome P450. See P450
Cytogenetics
non-Hodgkin’s lymphoma studies,
III: 365–366
Cytoplasmic inclusions,
V: 464
Czech Republic,
I: 317, 649, 675, 688;
IV: 139;
V: 6, 449–450;
VI: 408
See also Prague, Czech Republic
D
2,4-D. See 2,4-Dichlorophenoxyacetic acid
2,4-DB. See 2,4-Dichlorophenoxybutyric acid
Data sources
Agent Orange Registry,
I: 20, 53, 56, 729;
II: 153
agricultural/forestry worker studies,
I: 265–266, 318–341;
IV: 140–142
animal studies,
I: 111–114, 228
biological stored samples as,
I: 20–21, 729–730
Cancerlit,
IV: 253
case reports,
I: 235–236
Centers for Disease Control studies,
I: 387–391;
II: 113, 155–156;
III: 207–209, 218, 240;
IV: 133, 156–157
chemical production workers,
I: 303–318;
IV: 134–140
computerized data bases,
I: 735–736;
II: 24–25, 31
Department of Veterans Affairs epidemiologic studies,
I: 393–399;
II: 152, 153;
III: 209–212, 218, 240–243;
IV: 151, 157–158
epidemiologic controlled studies,
I: 228–237;
II: 150–153
epidemiologic studies as,
I: 737–738
herbicide environmental exposure studies,
I: 267–269, 372–375, 383–384;
IV: 147–150
herbicide exposure reconstruction model,
I: 725–726
herbicide non-military exposures,
I: 4–5, 222–223, 241–242
herbicide/pesticide applicators,
I: 266–267, 323–326;
IV: 142–143
HERBS tapes,
I: 20, 62, 85, 96–98, 273–279, 287, 291, 602, 725;
III: 146, 148;
IV: 123, 125
International Register of Workers Exposed to Phenoxy Herbicides and Their Contaminants,
I: 313–314;
IV: 137
mandated efforts,
I: 20–21
Medline,
IV: 252
organization of,
I: 737
paper/pulp mill workers,
I: 341, 364;
IV: 114, 134
presentations/reports to committee,
I: 739–756;
II: 343–348;
III: 533–536
randomized controlled trials,
I: 227–228
reproductive outcomes,
I: 593–595
research future recommendations,
I: 287–289, 291, 722–725, 729–730;
IV: 13
review of,
I: 244–245
self-reports,
I: 270–271
state government,
I: 60
state-sponsored Vietnam veteran studies,
I: 400–405, 495–496;
III: 213–215, 243–244
TCDD production workers,
I: 264–265;
IV: 134–140
Toxline,
IV: 252
troop location,
I: 273–279, 287;
IV: 121
Vietnam casualties,
I: 82–83
Vietnam military herbicide use,
I: 84–85
Vietnam veteran demographics,
I: 79, 80–84
Vietnam veteran exposure assessment use,
I: 270–287
Vietnam veteran reproductive outcomes,
I: 601
Vietnamese civilian health outcomes,
I: 371–372
women veterans,
I: 83–84;
II: 152–153
See also Death certificates;
Epidemiologic studies;
Military records;
Questionnaires
DBCP. See Dibromochloropropane
DDT,
I: 87, 91;
IV: 141
Death certificates,
I: 236–237;
II: 128, 136, 137–138, 151;
III: 470;
IV: 112
See also Data sources
Deaths
2,4-D lethality,
III: 44–45;
IV: 35
Australian Vietnam veterans lung cancer deaths,
III: 424
female reproductive system cancer deaths, by cancer site,
III: 329
Finland male herbicide applicators respiratory cancer mortality,
II: 271
Germany herbicide/chemical production workers cancer mortality,
III: 423, 429
non-Hodgkin’s lymphoma mortality,
III: 429;
IV: 355
prostate cancer mortality,
III: 426, 427;
IV: 326;
V: 319–321
respiratory cancer mortality,
III: 421, 422, 423;
IV: 273
Seveso, Italy, male cancer mortality,
II: 271, 275;
III: 422, 427;
IV: 282
TCDD lethality,
III: 71–73;
V: 69–70;
VI: 67
See also Child mortality studies;
Death certificates;
Mortality studies;
Perinatal death
Defense Manpower Data Center (DMDC),
II: 24–25
Defoliants
Agent Orange as,
I: 90;
IV: 38
military applications,
I: 25, 26;
III: 135, 137;
IV: 117
Vietnam herbicide mission maps,
I: 99–100
Vietnam tactical role of,
I: 85
See also Herbicides
Dekonta Company,
II: 329
Demilitarized Zone (DMZ),
IV: 120
Demographic data, Vietnam veterans,
I: 79, 80–84
DEN. See Diethylnitrosamine
Denmark,
I: 317, 443, 444, 454, 463, 477, 480, 509, 510, 537, 553, 565, 567;
II: 131–134, 139–140, 183, 194–195, 207, 209–210, 212, 215, 232, 238;
III: 223, 224, 307, 313, 318, 325, 330–331;
IV: 199–200, 209, 252, 406, 408;
Cancer Registry,
III: 232;
VI: 128
Central Population Register,
II: 133, 139, 224;
III: 352
Danish National Institute for Social Research,
II: 140
National Cancer Register,
II: 133, 139, 215, 224;
III: 325, 352;
IV: 144
Deoxyribonucleic acid (DNA),
II: 45, 48, 50, 51, 54, 55, 56, 57–58, 60, 61, 64, 74, 75;
III: 34, 35, 39, 42, 43, 48, 49, 53, 54, 56, 57, 58–61, 65, 67, 69, 75, 77, 83, 90, 91, 98, 99, 103, 104, 109;
IV: 29, 33, 40, 47, 48, 49, 53, 60, 64, 67, 68, 69, 70, 73, 75, 77, 85, 458;
V: 4;
VI: 166
Department of Agriculture, US (USDA),
I: 35, 39, 443;
II: 178, 219, 224, 229, 238–239, 248;
III: 230, 335, 352;
IV: 212, 213, 257, 259, 262, 264, 267, 301, 345, 350, 355, 364, 371, 376, 383
Agricultural Census,
IV: 149
extension agents,
IV: 144
Department of Air Force, US
Vietnam herbicide use by military, response,
II: 31–32;
III: 28–29
Department of Defense, US (DoD),
I: 17, 27, 29, 31, 78;
II: 24;
III: 138, 139, 140;
IV: 119, 121
Environmental Services Group,
III: 148
herbicide spray mission records,
I: 84–85
herbicide use precautions,
I: 95;
IV: 121
military records,
I: 78, 724–725
See also Defense Manpower Data Center (DMDC)
Department of Veterans Affairs, US (DVA),
I: 2, 8, 17, 18, 20, 50–51, 284;
II: 2, 5, 8, 11, 13, 17, 18, 19, 26, 27, 89, 153, 176, 181, 187, 218, 249, 260, 278, 305, 312;
III: 1, 2, 3, 6, 11, 12, 17, 18, 20, 24, 25, 26, 125, 132, 266, 303, 304, 390, 407, 434, 468, 478, 519;
IV: 1, 2, 6, 15, 16, 18, 123, 133, 151, 158, 284, 463;
V: 2, 12–13, 20;
Agent Orange controversy and,
I: 33, 53–54;
II: 29–31;
III: 28–29;
V: 1
Agent Orange Coordinator,
II: 31
Death Beneficiary Identification and Record Location System (BIRLS),
II: 151, 152, 153;
III: 238, 241, 242;
IV: 151, 157;
VI: 136
health care in,
I: 54;
II: 28;
III: 27
military records,
I: 78–79, 724–725;
II: 151, 152, 153
mortality studies,
II: 101, 152–153, 156–157;
III: 146;
IV: 151, 157–158
outreach activities,
I: 56;
II: 31;
III: 28
Patient Treatment File (PTF),
III: 242
recommendations for,
I: 724–725, 726–730;
II: 24–25
research efforts,
I: 54–55;
II: 29–30;
III: 27–28
veterans’ advocacy groups and,
I: 61;
VI: 20
Vietnam veteran compensation and benefits,
II: 24, 30–31;
III: 28
Vietnam veteran epidemiologic studies,
I: 50, 393–399, 445, 469–470, 493–495, 543–547, 562;
II: 101, 113, 156–157, 201–202;
III: 209–212, 218, 240–243;
V: 123–126, 183–187
women veterans epidemiological studies,
II: 152–153;
IV: 399
See also Agent Orange Registry (AOR);
Agent Orange Task Force;
Environmental Agents Service (EAS);
Environmental Epidemiology Service (EES)
Depressive disorders,
I: 650, 651
See also Cognitive/neuropsychiatric disorders;
Neurobehavioral toxicity
Dermal toxicity
TCDD and,
II: 76;
III: 73–74;
IV: 76
Desiccant herbicides,
I: 88–89;
III: 136
See also Herbicides
Detroit, Michigan,
II: 241;
III: 229
Developmental disorders,
VI: 38–39
2,4-D in,
I: 180–181;
II: 42;
III: 46
2,4,5-T in,
I: 185;
II: 42, 49–50
cacodylic acid in,
I: 189;
II: 42
neurological,
I: 660
picloram in,
I: 192;
II: 42
TCDD in,
I: 123–124, 149, 156–157, 159–160, 185;
II: 3, 41–42, 71, 72–73;
III: 92–105;
V: 67–69, 72–73;
VI: 83–87
See also Low birthweight;
Reproductive disorders
Diabetes mellitus,
I: 683–685, 691, 692, 698;
II: 7;
IV: 481;
V: 6
biologic plausibility,
III: 502–503;
IV: 488;
V: 492;
VI: 456
diagnostic criteria,
III: 493, 494
epidemiologic concerns,
III: 494
epidemiologic studies,
II: 330–331;
III: 494–502;
IV: 182, 232;
V: 492;
VI: 448–456
epidemiology,
II: 330;
III: 491–492, 493
herbicide environmental exposure and,
III: 497;
IV: 484–485;
V: 489, 491;
herbicide exposure and,
II: 332–333;
III: 2, 11–12, 125, 494–503;
IV: 152;
V: 485–492
herbicide occupational exposure and,
III: 496;
IV: 483–484;
V: 487–491;
VI: 450
pathogenetic diversity of,
III: 494
peripheral neuropathy and, relationship,
III: 471–472;
V: 468–469;
VI: 6
prevalence, data by age/race/gender,
III: 492
scientific literature update,
II: 330–331;
III: 496, 497;
IV: 483;
V: 487;
VI: 450–455
TCDD and,
V: 490
type 2 (adult-onset),
IV: 1, 8, 16–18, 21, 150–151, 182–183;
V: 485
Vietnam veterans and,
II: 330;
III: 2, 11–12, 495, 497, 498, 500, 502;
IV: 154–156, 485–487;
V: 492;
Diamond Shamrock Corporation,
I: 34, 35
Diazinon,
I: 91
Dibenzofurans,
I: 126;
IV: 41, 64, 138
Dibromochloropropane (DBCP),
II: 279
4-(2,4-Dichlorophenoxy) butyric acid,
V: 33
2,4-Dichlorophenoxyacetic acid (2,4-D),
II: 4, 18;
III: 5, 19, 135, 136, 137;
IV: 4–5, 110–111, 122, 133;
V: 1, 3, 12;
VI: 1, 3, 20, 34–41, 118–119, 201, 276, 436
acute toxicity,
I: 179
Agent Orange and,
I: 27
Agent White and,
I: 90
altered sperm parameters,
I: 632
animal studies,
I: 174–181;
II: 46–49;
III: 34, 36–37, 38–39, 43–47, 396, 462, 475;
VI: 34–41
carcinogenicity,
I: 118–119, 176–178, 439;
II: 40, 48;
III: 47, 396;
VI: 36–40
cell stress responses,
V: 34;
VI: 40–41
chemical properties,
I: 114, 175;
II: 38;
III: 32
chemical structure,
I: 111, 114
chronic exposure,
I: 179–180
development of,
I: 24, 26, 35
developmental toxicity,
I: 124, 180–181;
II: 42;
III: 46;
VI: 38–39
disease outcomes,
III: 34, 38–39, 44–47;
V: 34–37
domestic use,
I: 174–175, 177–178
energy metabolism,
V: 33–34;
VI: 40
formulations,
I: 175
genotoxicity,
I: 119, 178–179;
V: 33;
VI: 36–40
half-life of,
II: 4
immunotoxicity,
I: 122, 181;
II: 41;
III: 46, 524;
VI: 39
infertility and,
II: 280–282
ingestion of,
I: 653
kidney toxicity,
I: 125;
II: 42
lethality,
III: 44–45
liver toxicity,
I: 125;
II: 42;
III: 524
mechanism of action,
II: 47–48;
III: 44;
V: 33–34;
VI: 40–41
mechanisms of toxicity,
II: 48–49;
VI: 36
metabolism,
I: 115, 116
military field tests,
I: 26
mitochondrial function,
V: 33–34;
VI: 40
neurobehavioral disorders and,
II: 305;
III: 475
neuropsychiatric outcomes and,
I: 649, 650, 653
neurotoxicity,
II: 48;
III: 45–46;
V: 471;
VI: 37
non-Hodgkin’s lymphoma and,
I: 256–257, 574
occupational exposure,
I: 36, 37, 310–311, 321;
III: 218, 224, 225, 226;
IV: 117
peripheral neuropathy and,
II: 312;
III: 473
pharmacokinetics,
I: 175
plasma concentrations and,
V: 32
porphyria cutanea tarda and,
II: 322
reproductive toxicity,
I: 124, 180–181, 597–598;
II: 41, 280–282;
III: 46, 460, 461–462;
VI: 38–39
role of,
I: 88
teratogenic potential,
I: 30, 92
therapeutic application,
I: 659
thyroid hormones,
V: 34;
VI: 40
toxicity profiles,
V: 76–77;
VI: 88
toxicokinetics,
II: 46–47;
III: 32–33, 36–37, 43–44;
IV: 27–28;
V: 31–32;
VI: 34–36
toxicologic properties,
IV: 22–25, 27–31, 33–37;
VI: 33–34
volume used in Operation Ranch Hand, data,
III: 136;
IV: 117–119
See also Herbicides
2,4-Dichlorophenoxybutyric acid (2,4-DB)
differences with 2,4-Dichlorophenoxyacetic acid (2,4-D),
IV: 5
Diet
breast cancer and,
I: 507
cancer risk and,
I: 442
chloracne and,
I: 174
gastrointestinal cancers and,
I: 446
TCDD interactions,
II: 64
Diethylnitrosamine (DEN)
TCDD and,
II: 67;
IV: 71
Digestive disorders. See Metabolic and digestive disorders
Dimethylarsenic radical
bladder hyperplasia and tumors associated with,
IV: 31, 40
cacodylic acid and formation of,
II: 4
Dimethylarsinous acid (DMA),
V: 39;
VI: 21
See also Cacodylic acid
Dinoxol,
I: 91;
III: 137;
IV: 119
Dioxin. See 2,3,7,8-Tetrachlorodibenzo-p-dioxin;
Dioxin congeners;
Dioxin-responsive enhancers;
Dioxin toxic equivalent factors (TEQ factors)
Dioxin congeners,
II: 105–107;
III: 158–159
Dioxin Registry,
I: 36–37
Dioxin-responsive enhancers,
I: 135–136
Dioxin toxic equivalent factors (TEQ factors),
II: 106, 107;
III: 99, 106, 107, 108, 158, 159;
IV: 139;
Diquat,
I: 91;
III: 137;
IV: 119
Disease-exposure associations,
V: 28
Diseases and disorders. See Health outcomes of herbicide exposure;
Military health care;
Vietnam veterans;
specific cancer sites;
specific cancers;
specific diseases and disorders
DMA. See Cacodylic acid;
Dimethylarsenic radical;
Dimethylarsinous acid;
Pentavalent dimethylarsinic acid
DMDC. See Defense Manpower Data Center
DMZ. See Demilitarized zone
DNA. See Deoxyribonucleic acid
DoD. See Department of Defense, US
Domestic herbicide use
2,4-D,
I: 174–175
2,4,5-T,
I: 181–182
agricultural use,
I: 24, 35, 39, 174–175, 181
pet cancers and,
I: 119, 177–178
picloram,
I: 189
TCDD contamination in,
I: 91
See also Agricultural/forestry workers
Dopaminergic system,
I: 163–164, 165
Doppler measurement,
VI: 467
Dormagen, Germany,
III: 154;
IV: 112
Dose-response relationship
2,4-D pharmacokinetics,
I: 175
animal fetal mortality,
I: 159
animal studies,
I: 111–114, 118
evidentiary role of,
I: 239–230, 252;
V: 18;
VI: 17
research recommendations,
I: 19, 727;
VI: 406
TCDD-chloracne,
I: 673;
II: 318
TCDD dermal application,
I: 128–129
TCDD-exposed workers and,
I: 445
TCDD-immune system processes,
I: 696
TCDD immunotoxicity,
I: 122
TCDD threshold,
I: 137–138
TCDD tissue distribution,
I: 130
Doubs, France,
IV: 116;
V: 227–228;
VI: 179–180
Dow Chemical Company,
I: 34, 35, 307–312, 461–462, 529, 558, 598, 607, 620, 674;
II: 115–116, 130, 178, 191, 193, 207, 232, 238, 286;
III: 152–153, 172–174, 220–221, 270–271, 357–358, 387, 484, 511, 516;
IV: 136, 186–188;
V: 5, 6, 107–108, 132–135, 221–222, 245–246, 298, 318, 325, 329, 334, 338, 339, 351, 356, 419, 462;
VI: 5, 122–124, 171–173, 235, 310
Drosophila melanogaster
genotoxicity in,
V: 38
DVA. See Department of Veterans Affairs, US
Dystonia,
I: 658
See also Motor/coordination dysfunction
E
EAS. See Environmental Agents Service
East Germany. See German Democratic Republic
EES. See Environmental Epidemiology Service
EGF. See Epidermal growth factor
EGFR. See Epidermal growth factor receptor
Electrical transformers,
I: 364–365, 444, 626, 675
Electrophoretic mobility shift gene (EMSA)
TCDD and,
II: 66
Emphysema,
I: 708, 713
See also Respiratory disorders
EMSA. See Electrophoretic mobility shift gene
Encephalopathy,
I: 649
See also Cognitive/neuropsychiatric disorders
End points
molecular and cellular,
V: 26
nonfunctional,
V: 484
toxic,
V: 55–69;
Endocrine system,
I: 150–151;
IV: 156
TCDD toxicity,
III: 83–84;
IV: 77, 331;
V: 66–67, 73–74;
VI: 82–83
Endometrial cancer,
IV: 320–324, 385
Endometriosis,
V: 508–510
biological plausibility,
V: 509–510;
VI: 478
clinical features,
V: 508
epidemiologic studies,
V: 509;
VI: 473–478
herbicide association in,
V: 508–510
scientific literature review,
V: 508–509;
VI: 474–477
TCDD and,
V: 508
Vietnam veterans and,
V: 510;
VI: 478
Energy metabolism,
VI: 40
England. See United Kingdom
Environmental Agents Service (EAS),
II: 31;
III: 28
See also Department of Veterans Affairs, US (DVA)
Environmental Epidemiology Service (EES),
II: 29
See also Department of Veterans Affairs, US (DVA)
Environmental herbicide exposure
accidental exposures,
I: 364–365, 368–370;
II: 141–143, 144, 148;
IV: 114–116
acute and subacute transient peripheral neuropathy and,
II: 312–313
agricultural areas exposure,
I: 372–375
Alsea, Oregon,
I: 39, 42–43, 372–373, 598;
II: 149
assessment strategies,
I: 262–263, 267–270;
III: 144–145, 156–157
basal/squamous cell skin cancer and,
III: 323;
V: 297–298, 299
birth defects and,
I: 608–609;
II: 140, 287–288;
III: 437;
V: 394, 400–402;
VI: 363
birthweight, low, and,
III: 459
bladder cancer and,
I: 516–517;
III: 349, 350–351;
V: 329, 331–332
bone/joint cancer and,
III: 303, 305;
V: 280
brain tumors and,
I: 523;
III: 358, 361;
V: 341–342;
VI: 301
breast cancer and,
III: 328;
V: 302–303, 304–307
breast cancer estimated risk,
II: 218;
V: 300–301
cancer risk factor,
I: 442
cancer studies,
I: 442, 444, 454–455, 469;
II: 147–148, 179–180, 184
chloracne and,
I: 676–677
circulatory disorders and,
I: 701–702;
VI: 468
colon cancer and,
V: 251–252
diabetes and,
III: 497;
V: 489, 491;
VI: 450
epidemiologic studies,
I: 3, 301, 365–384, 469;
II: 3, 6–7, 140–149;
III: 197–205, 218, 232–236, 271–272, 275, 277, 279–281, 283, 285, 287–288, 290, 291, 297–298, 301, 303, 305, 309, 316, 323, 328, 333, 336, 338, 342, 344, 345, 349, 350–351, 353, 354, 358, 361, 365, 369, 373, 375, 380, 382, 388–389, 392, 437, 454, 455, 456, 459, 467, 497, 520;
IV: 147–150, 224–231, 254;
V: 226–229;
evidentiary role of research on,
I: 4–5, 222–223, 241–242
female reproductive system cancers and,
I: 511;
III: 333;
V: 311, 312, 313, 314
gastrointestinal/digestive disorders and,
V: 245
gastrointestinal tract tumors and,
II: 179–180;
III: 271–272, 275, 277, 279–281;
IV: 254;
V: 245;
VI: 219–220
hepatobiliary cancers and,
I: 454–455;
II: 184, 185, 186;
III: 283, 285, 287–288;
V: 262–263, 269
Hodgkin’s disease and,
II: 236;
III: 373, 375;
V: 358–359, 366;
VI: 318
immune modulation and,
I: 693–694
immune system disorder and,
VI: 445–446
infant death and,
III: 456
infertility and,
VI: 366–371
laryngeal cancer and,
V: 270–271;
VI: 233
leukemia and,
I: 568–570;
III: 388–389, 392;
IV: 379;
V: 368, 370–371;
VI: 332
lipid/lipoprotein disorders and,
III: 520;
IV: 493;
VI: 458
low birthweight,
VI: 381–382
lung cancer and,
III: 297–298, 301;
IV: 282–283;
V: 275–276;
VI: 240
melanoma and,
III: 316;
IV: 302–303;
V: 291–292;
VI: 256
motor/coordination dysfunction and,
I: 658–659
multiple myeloma and,
I: 562;
II: 243;
III: 380, 382;
V: 364–365;
VI: 324
nasal/nasopharyngeal cancer,
II: 189;
III: 290, 291;
IV: 274–275;
V: 266;
VI: 229
neonatal death and,
I: 621;
III: 455
neural tube defects,
II: 297;
III: 437;
IV: 18
neurobehavioral disorders association
studies,
II: 306;
III: 467
neuroblastoma,
V: 429–431
neuropsychiatric outcomes and,
I: 651–653;
II: 148
non-Hodgkin’s lymphoma and,
I: 540–541;
II: 234;
III: 365, 369;
IV: 17;
V: 347–348, 351–354;
VI: 310–311
ovarian cancer and,
III: 333;
IV: 321–322
pancreatic cancer and,
V: 258
peripheral nervous system disorders and,
I: 663–665
porphyria cutanea tarda and,
I: 680–681
preterm birth and,
III: 459
prostate cancer and,
II: 221, 222;
III: 336, 338, 342;
IV: 329;
V: 320–321, 322;
VI: 281
rectal cancer and,
V: 255–256
renal cancers and,
III: 353, 354;
IV: 347
respiratory cancers and,
I: 469;
II: 190, 193, 200–201
skin cancers and,
VI: 256
soft-tissue sarcomas and,
I: 491–492;
II: 207–208;
III: 319;
IV: 116;
V: 285–286;
VI: 246–250
spontaneous abortion and,
I: 598–599;
V: 414–417
stillbirth and,
I: 620;
III: 454
stomach cancer and,
V: 248–249
testicular cancer and,
III: 344, 345;
V: 327
thyroid homeostasis and,
VI: 480
uterine cancer and,
III: 333
Vietnam exposure studies,
III: 156–157
Washington residents,
II: 149
See also Herbicide exposure assessment;
Herbicides;
Seveso, Italy;
Times Beach, Missouri
Environmental Protection Agency (EPA),
I: 39, 59–60, 93;
V: 27;
VI: 132
Alsea, Oregon,
I: 42–43
directives,
IV: 117
Science Advisory Board (SAB),
II: 32;
III: 29
TCDD cancer potency estimate,
I: 138
Times Beach, Missouri,
I: 41;
III: 234;
IV: 148
Vietnam military use of herbicides, response,
II: 32;
III: 29–30, 136
Enzyme induction
liver,
I: 155–156
lung,
I: 170
porphyria,
I: 153–154
TCDD and,
II: 3, 66–67
EPA. See Environmental Protection Agency
Epidemiologic studies
acute and subacute transient peripheral neuropathy,
II: 312–314
aging effects control,
II: 261–262;
III: 409
agricultural/forestry workers,
I: 318–323, 326–341;
II: 118–120, 135–137, 183, 197–198, 232–234, 238–239, 241–243;
III: 178–195, 224–232, 335, 364–365, 379–380, 387–388;
IV: 134, 140, 144–145, 197–206;
VI: 124–128
Air Force personnel involved in herbicide spraying,
II: 31–32;
III: 28–29;
IV: 232–235
altered sperm parameters,
I: 632;
III: 445–449, 450
amyloidosis,
IV: 512;
V: 507
autoimmunity,
I: 697–698;
II: 7;
III: 488–491
basal/squamous cell skin cancer,
III: 317–322, 323;
V: 296, 297–298, 299;
VI: 261–265
birth defects,
I: 607–618;
II: 7, 140, 286–296;
III: 436, 437–438, 443;
IV: 400–405;
V: 404;
VI: 355–365
bladder cancer,
I: 515–517;
II: 7, 225–227;
III: 7, 10, 347–351;
IV: 340–342;
V: 330–332, 333;
VI: 286–292
bone/joint cancer,
I: 472–473;
II: 6, 204–205;
III: 7, 10, 303–305;
IV: 288–289;
V: 280–282;
VI: 242–245
brain tumors,
I: 523;
II: 7, 136, 229–230;
III: 8, 12, 356–361;
IV: 351–352;
V: 340–343;
VI: 296–302
breast cancer,
II: 6, 176, 213–217, 218;
III: 7, 10, 324–328;
IV: 315–316;
V: 302–304, 308;
VI: 265–270
cancer,
I: 45, 59, 317, 320–323, 367, 383–384, 391–393, 401, 402–403, 435–445, 574;
II: 133–138, 147–148, 175, 176;
III: 265–266;
cancer latency issues,
II: 260–276;
III: 407–431
case-control studies,
I: 326–341;
II: 94–95, 118–127, 138–140, 144–146, 148–149, 155, 157, 159–160, 183–184, 186–187, 188, 190, 193, 200, 222–223, 240–241;
III: 173, 175, 185–195, 201–204, 208–217, 228–232;
IV: 143–146, 207–220, 227–231, 236–245, 247;
VI: 127–128
cervical cancer,
III: 332
Chapevsk, Russia,
VI: 180
chemical industry production workers,
I: 303–318;
II: 114–118, 128–135, 191, 193–197, 206–207, 232, 237–238;
III: 170–178, 218, 219–224, 363–364, 378–379, 386–387;
IV: 134–140, 182–197
childhood cancer,
I: 628–630;
II: 7, 299–300;
VI: 383–389
chloracne,
I: 674–678;
II: 5, 6, 318–320;
III: 6, 7, 479–480;
chronic persistent peripheral neuropathy,
II: 310–311
circulatory disorders,
I: 700–707;
II: 7, 335–337;
III: 8, 514–518;
IV: 510;
V: 505;
VI: 467–471
cleft lip/palate,
I: 373–374, 375
cofounders, possible,
V: 527
cognitive/neuropsychiatric disorders,
II: 7, 307–308;
III: 468–469;
V: 449–451;
VI: 406–410
cohort studies,
I: 229–232;
II: 105–109, 135–138, 141–147, 154–160, 178, 179, 180, 182–183, 186, 187, 190, 192–193, 204, 218, 222, 240;
III: 170–185, 196, 197–200, 206–208, 217;
IV: 140–143, 182–206, 222–230, 232–247;
V: 25–26;
VI: 124–127
colon cancer,
I: 12, 328–329, 576–577;
II: 7;
III: 8, 276–278
congressionally mandated,
I: 50;
II: 5
controlled observational,
I: 228
cost of,
I: 727
cross-sectional studies,
IV: 187, 188, 196, 197, 199, 204, 226, 228, 229, 238, 242
cytogenetic studies,
III: 365–366
developmental studies,
IV: 196, 227, 229, 231, 242;
diabetes mellitus,
I: 684–685;
II: 7, 330–331;
III: 494–502;
IV: 482, 488–492;
V: 492;
VI: 448–456
Doubs, France,
VI: 179–180
ecological design studies,
IV: 231
endometriosis,
VI: 473–478
environmental exposure,
evaluation of,
I: 300–301, 591–592, 737–738;
II: 5, 93–94;
III: 129–130;
VI: 2
evidentiary role of,
I: 224–225, 228–237, 300, 305;
II: 175, 176;
III: 265, 266;
IV: 104–105
female reproductive system/breast cancers,
I: 508–511;
II: 6, 211–213;
III: 7, 10, 330–334;
V: 311–316;
VI: 265–275
gastrointestinal tract cancers,
I: 446–447;
II: 7, 177–181;
III: 8, 12, 268–281;
V: 246;
VI: 203–221
gastrointestinal ulcers,
I: 691;
II: 334;
III: 510–513;
IV: 505;
V: 502
hepatic enzyme disorders,
I: 686–688
hepatobiliary cancers,
I: 453–455;
II: 6, 176, 181–187;
III: 7, 10, 282–288;
V: 261–263;
VI: 221–226
herbicide environmental exposures,
I: 365–384;
II: 140–149, 189, 190, 193, 200–201, 207–208, 218, 221, 222, 234, 236, 241, 243, 287–288, 297, 306, 312–313;
III: 197–205, 218, 232–236, 275, 277, 279–281, 283, 285, 287–288, 290, 291, 297–298, 301, 303, 305, 309, 316, 323, 328, 333, 336, 338, 342, 344, 345, 349, 350–351, 353, 354, 358, 361, 365, 369, 373, 375, 380, 382, 388–389, 392, 437, 454, 455, 456, 459, 467, 497, 520;
IV: 147–149, 224–231, 255, 269, 274–275, 278, 282–283, 289, 293, 294, 302–303, 315–316, 321–322, 329, 336, 341, 347, 351–352, 357, 366, 372–373, 379;
V: 2–3
herbicide exposure assessment for,
I: 251–259;
II: 99–109;
III: 142–146;
VI: 165–169
herbicide exposure indices development,
II: 107–109
herbicide exposure levels,
II: 175
herbicide exposure reconstruction model and,
I: 725, 726–728
herbicide occupational exposure studies,
II: 107–108, 112, 113–140, 188–189, 190, 191–199, 206–207, 214–216, 218, 219–220, 222, 232–234, 235–236, 237–243, 286–287, 297, 306, 312;
III: 170–196, 218, 219–232, 274–280, 282–283, 284, 287, 290, 291, 293–294, 296–297, 300–301, 303, 305, 308–309, 312, 316, 317, 321, 323, 324–326, 328, 332–333, 335–336, 337, 338, 341, 344, 345, 348, 350, 353, 354, 360, 363–365, 367–369, 372–373, 374–375, 378–380, 381–382, 386–388, 391–392, 437, 450, 454, 455, 456, 459, 467, 483–485, 489, 491, 496, 510–512, 515–516, 520;
IV: 134–143, 182–223, 251–254, 268–269, 274, 277–278, 282, 288–289, 292–293, 302, 321, 327–329, 336, 340–341, 346, 351, 356, 365–366, 372, 379
herbicide/pesticide applicators,
I: 323–326;
II: 31–32, 120–122, 137–138, 198–200;
III: 182–185, 226–228;
IV: 202–206
Hodgkin’s disease,
I: 9, 329, 331, 335–336, 341, 384, 391, 393, 549–556, 574;
II: 5,
6, 138, 235–236;
III: 6, 7, 372–376;
V: 357–360;
VI: 313–319
immune modulation,
I: 693–696
immune system disorders,
II: 7, 327–329;
III: 488–491;
IV: 480–481;
V: 484–485;
VI: 443–448
infant death,
III: 456
infertility,
I: 632–633;
II: 7, 280–282;
III: 445–449, 450;
VI: 365–372
kidney cancer,
I: 515;
II: 7, 139–140, 224–225;
III: 352–355;
VI: 292–296
laryngeal cancer,
II: 202–203;
III: 293–295;
V: 270–271;
VI: 230–234
latency (cancer) issues,
II: 260–276;
III: 407–431
leukemia,
I: 13, 332–333, 334–335, 564–571, 577–578;
II: 7, 136, 245–247;
III: 7, 10, 385–390, 391–392;
IV: 379–380;
V: 369–372;
VI: 325–337
limitations,
I: 4, 223;
VI: 23
lipid abnormalities,
I: 688–690;
II: 7, 333–334;
III: 504–506, 520–521;
IV: 493, 495;
VI: 457–463
liver cancer,
I: 13, 329, 391, 393
liver toxicity,
II: 332–333;
III: 510–513;
IV: 499;
VI: 463–466
low birthweight,
I: 626–627;
II: 7;
III: 456–457, 459;
V: 425;
VI: 379–383
lung cancer,
III: 296–298, 300–301;
IV: 282–283;
V: 274–277;
VI: 234–241
melanoma,
III: 313–317;
V: 288–294;
VI: 251–261
meta-analysis,
I: 225, 237–238, 242–243, 244
metabolic and digestive disorders,
II: 7, 330–337;
VI: 463–466
molecular and cellular end points,
V: 26
motor/coordination dysfunction,
I: 658–661;
II: 7, 309–310;
III: 469–470;
VI: 410–422
multiple myeloma,
I: 11–12, 331, 334, 335, 336, 341, 557–563, 576;
II: 6, 138–139, 176, 237–244;
III: 7, 8, 9, 377–383;
V: 363–366;
VI: 319–325
nasal/nasopharyngeal cancer,
I: 459;
II: 6, 176, 187–189;
III: 7, 10, 290–291;
V: 267;
VI: 226–230
neonatal death,
III: 455
neural tube defects numbers,
II: 297
neurobehavioral disorders,
II: 305–308, 309–311, 312–314;
III: 457;
VI: 406–410
neurological disorders,
I: 365–366, 642–648;
II: 141;
neuropsychiatric disorders,
I: 649–657;
II: 7, 148;
III: 468–469
non-Hodgkin’s lymphoma,
I: 9, 328, 329, 330, 331, 333–334, 335–338, 383, 384, 391–393, 401, 528–548, 573–574;
II: 5, 6, 134–135, 136, 138, 139, 231–234;
III: 6, 7, 362–371, 428–430;
IV: 356–358;
V: 345–355;
VI: 303–312
NRC Commission on Life Sciences,
I: 63
occupational exposures,
VI: 496–539
ovarian cancer,
III: 333
pancreatic cancer,
III: 280–281
paper/pulp workers,
II: 126–127, 200, 243;
III: 196, 232;
IV: 134, 252;
VI: 128–129
parkinsonism,
VI: 410–420
perinatal death,
I: 620–624;
II: 7, 285–286;
III: 451–453, 454, 455, 456;
V: 421–422;
VI: 378–379
peripheral nervous system disorders,
I: 662–666;
II: 6, 7, 310–311, 312–314;
III: 7, 8, 470–471, 473;
VI: 423–429
porphyria cutanea tarda,
I: 680–682;
II: 5, 6, 129, 321–323;
III: 7, 8, 481–482;
V: 480;
VI: 439–440
proportionate mortality studies,
I: 232–233
prostate cancer,
I: 11, 518–519, 575–576;
II: 6, 176, 219–223;
III: 7, 8, 9, 335–342, 426–428;
IV: 327–329;
V: 319–323;
VI: 275–283
Quail Run, Missouri,
VI: 132
Ranch Hand cohort,
II: 31, 32, 109, 150–152, 154–156, 201, 209, 280, 283–284, 286, 293–295, 321–322, 330, 332, 336;
III: 28–29, 218, 206–207, 237–240, 309–310, 313–314, 318, 321, 322, 339, 340, 385, 436, 438, 439, 446–447, 449, 452–453, 457–458, 481, 486, 495, 498, 502;
IV: 13, 232–235;
VI: 5–6
rare diseases in,
I: 231, 499
recommendations,
I: 15–20, 721–725, 731;
II: 24–25;
III: 23;
V: 523–527;
VI: 10
rectal cancer,
III: 278–279
renal cancer,
VI: 292–296
reproductive outcomes,
I: 41–42, 311–312, 321, 364–365, 368, 370, 371–375, 387–388, 389–390, 591–592;
II: 280–282, 283–284, 285, 286–296;
III: 436, 437–438, 443, 445–449, 450, 451–453, 454, 455, 456–457, 459;
IV: 401–402, 406–407, 410–411;
VI: 354–403
resolution in,
I: 242–243;
IV: 513
resolving power of,
V: 23
respiratory cancers,
I: 10–11, 364, 461–472, 575;
II: 6, 176, 189–203;
III: 7, 8, 9, 418, 420–426;
IV: 273, 278, 282, 284
respiratory disease,
I: 709–713;
II: 7, 324–326;
III: 483–486;
IV: 475;
VI: 440–443
Seveso, Italy, population studies,
I: 44–45, 365–368, 444, 454–455, 469, 491–492, 503, 511, 517, 523, 540, 568–570, 571, 598–599;
II: 141–143, 148, 200–201, 206, 207–208, 209, 210, 211–212, 213, 216, 221, 225, 226–227, 228, 230, 234, 236, 243, 245, 246, 287, 299–300, 312–313;
III: 197–200, 218, 232–233, 283, 285, 290, 296, 297–298, 299, 303, 307, 309, 314, 318, 324–326, 327, 330, 331, 332, 336, 338, 344, 348, 349, 352, 353, 356, 358, 363, 365, 372, 373, 380, 385, 386, 388–389, 390, 408, 414, 420, 422, 427, 436, 449, 495, 505;
IV: 114–115, 464, 468, 472–475, 484, 487, 491, 501, 507, 509;
skin cancer,
I: 502–503;
II: 7, 209–211;
III: 8, 10, 312–313;
IV: 302–303;
VI: 251–265
soft-tissue sarcoma,
I: 8, 311, 326–328, 329–330, 335–336, 337, 339–340, 384, 391, 393, 395–396, 401, 403, 476, 477–500, 572–573, 574;
II: 5, 6, 132, 134–135, 205–208;
III: 6, 7, 306–311;
IV: 116, 292–296;
V: 284–287;
VI: 245–251
sperm abnormal parameters,
II: 7;
III: 445–449, 450
spina bifida,
II: 6;
III: 7, 8, 9–10, 437–438;
IV: 404–405
spontaneous abortion,
I: 42, 336–337, 372–373, 405–406, 596–605;
II: 7, 283–284;
IV: 410–411;
V: 420;
VI: 372–378
state-sponsored,
I: 399–405, 495–496, 546;
II: 153, 158–159, 161, 202, 292;
III: 213–215, 243–244
stillbirth,
III: 454
stomach cancer,
III: 274–275;
IV: 251–255
strength of evidence in assessment of,
I: 238–241
tables of,
VI: 495–568
TCDD biomarkers,
I: 259–262;
II: 101–105, 318
testicular cancer,
I: 405, 519;
II: 7, 153, 227–228;
III: 7, 10, 343–346;
IV: 336;
V: 325–327;
VI: 283–286
thyroid homeostasis,
VI: 478–481
Times Beach, Missouri,
I: 368–370;
II: 144;
III: 200–201, 218, 234, 283;
IV: 115–116, 133, 148;
uroporphyrins,
VI: 7
usefulness of,
IV: 103–108
uterine cancer,
III: 333;
IV: 321–324
Vietnam environmental herbicide exposure,
II: 144–145;
III: 201–202, 218, 234, 283;
Vietnam veterans in,
I: 50, 57–59, 62–63, 384–418;
II: 149–161, 189, 190, 201–202, 204, 205, 208, 209, 212, 213, 216, 217, 218, 221, 223, 224, 226, 227, 228, 229, 230, 231, 234, 235, 236, 244, 245, 246, 278, 283, 285, 286, 288–296, 299, 300–301, 305, 306, 308, 309, 310, 311, 313, 314, 317, 318, 321–322, 323, 330, 332, 333, 336;
III: 206–217, 236–245, 275, 277–278, 279, 281, 283, 285–286, 288, 290, 291, 294–295, 298, 301, 303, 305, 309–310, 312, 316, 317, 323, 326, 328, 333, 336, 338, 339, 340, 342, 343–344, 345–346, 349, 351, 353, 355, 358–359, 361, 363, 365, 370–371, 372, 373, 376, 380, 382, 385, 386, 389, 392, 435, 436, 437–438, 445, 446, 450, 454, 456, 457, 459, 467, 468, 469, 470, 473, 475, 479, 480, 481, 482, 485–486, 489, 491, 495, 497, 498, 500, 502, 505–506, 512–513, 516–518, 523;
IV: 150–160, 232–247, 255, 269, 275, 278, 282–283, 289, 294–295, 303–304, 309–310, 316, 322–323, 329, 336–337, 342, 347, 352, 357–358, 366–367, 373, 380;
VI: 551–568
Vietnamese in,
I: 370–372, 599–601;
II: 108–109, 144–145, 148, 287–288;
III: 217, 245, 283;
IV: 116–117, 227–228
Epidemiology,
acute lymphocytic leukemia,
III: 383
acute myeloid leukemia,
III: 383–384
birth defects,
I: 606;
II: 286;
III: 435–436
bladder cancer,
II: 223;
III: 347
bone/joint cancer,
I: 472–473;
II: 204;
III: 302
brain tumors,
I: 522–523;
II: 228–229;
III: 356
breast cancer,
I: 505, 506–507;
II: 213–214;
III: 322, 324
cancer,
I: 433, 435–438, 442, 525;
II: 175;
III: 265–266;
VI: 5
children, cancer in,
II: 298
chloracne,
II: 317–318;
III: 478–479
chronic lymphocytic leukemia,
III: 384–385
chronic myeloid leukemia,
III: 385
circulatory disorders,
III: 514
diabetes mellitus,
II: 330;
III: 491–492, 493
female reproductive system cancers,
I: 505, 506–508;
II: 211;
III: 329–330
gastrointestinal tract cancers,
I: 445–447;
II: 177;
III: 267–268
gastrointestinal ulcers,
II: 334;
III: 508–509
hepatobiliary cancers,
I: 452–455;
II: 181–182;
III: 282
Hodgkin’s disease,
I: 526, 527–528;
II: 231;
III: 371–372
immune system disorders,
II: 326–327;
III: 487–488
infertility,
II: 279;
III: 444–445
kidney cancer,
I: 513, 514;
II: 223;
III: 351–352;
V: 335–338
laryngeal cancer,
III: 292
leukemia,
I: 564;
II: 245;
III: 383–385
lipid abnormalities,
II: 333;
III: 503–504
liver disorders,
II: 331–332;
III: 509–510
low birthweight,
I: 625–626;
III: 454, 455, 456
lung cancer,
III: 295–296
malignant lymphomas,
II: 231;
IV: 137
multiple myeloma,
I: 526, 528;
II: 236–237;
III: 377
nasal/nasopharyngeal cancer,
I: 458–459;
II: 187–188;
III: 288–289
neurobehavioral toxicity,
II: 304–305, 307;
III: 466
non-Hodgkin’s lymphoma,
I: 526, 527;
II: 231;
III: 362
porphyria cutanea tarda (PCT),
II: 321;
III: 480–481;
IV: 10
prostate cancer,
I: 513, 514–515;
II: 217, 219;
III: 334
respiratory cancers,
I: 460–461;
II: 189–191
respiratory disorders,
III: 482–483
skin cancer,
I: 501–502;
II: 209;
III: 312, 313
soft-tissue sarcoma,
I: 475;
II: 205;
III: 304, 306;
IV: 116
spontaneous abortion,
II: 282–283
stillbirth/neonatal deaths/infant death,
III: 451
testicular cancer,
I: 515;
II: 223–224;
III: 343
See also Epidemiologic studies
Epidermal growth factor (EGF),
I: 145, 154;
II: 59, 73–74;
III: 77, 97;
IV: 51, 64, 66
Epidermal growth factor receptor (EGFR),
II: 67;
III: 78, 80, 97;
IV: 64, 67, 70
Epigenetic events. See Apoptosis;
Cell proliferation;
Enzyme induction;
Intracellular communication
Epstein-Barr virus,
I: 528;
II: 188;
V: 344, 352;
VI: 226
Erbon®,
I: 309;
II: 128;
III: 219;
IV: 134;
V: 105
EROD. See Ethoxyresorufin O-deethylase
Error in design, conduct, or analysis of an investigation,
V: 22
Erythrocyte sedimentation,
I: 696
Escherichia coli,
VI: 30
Esophageal cancer,
VI: 209
Estrogen
hepatic binding,
I: 154
receptor mediated responses,
I: 145
receptor signaling,
III: 65–67
transduction pathway, TCDD interaction,
II: 4;
VI: 58
Ethoxyresorufin O-deethylase (EROD),
I: 153, 155;
II: 52, 59, 60, 62, 63, 64, 65, 67, 69, 74;
III: 40, 42, 51, 52, 53, 68, 69, 71, 72, 74, 75, 77, 91, 96;
IV: 386
Europe,
III: 108, 308, 471
European registry,
II: 197
Evidence of herbicide association. See Herbicide association, insufficient evidence for determining;
Herbicide association, limited/suggestive evidence;
Herbicide association, limited/suggestive negative evidence;
Herbicide association, sufficient evidence
Executive Order 11850,
II: 27;
III: 25
Experimental studies
evaluation of,
II: 92–93
Exposure assessment. See Herbicide exposure assessment;
Herbicide exposure reconstruction model
Exposure reconstruction model. See Herbicide exposure reconstruction model
F
Farmers. See Agricultural/forestry workers
Fecundity Ratio (FR),
IV: 406
Federal government in herbicide management/research,
I: 45–60;
II: 27–32;
III: 25–30;
IV: 13
Federal Register,
II: 30;
III: 28
Federation of American Scientists,
I: 29
Female reproductive system cancers. See Reproductive system cancers, women
Fertility. See Infertility
Fetotoxicity
cacodylic acid,
V: 39
Fibrosarcoma. See Soft-tissue sarcoma (STS)
Finland,
I: 324, 364, 383–384, 443, 444, 467, 492, 541, 561;
II: 134, 137, 140, 179, 183, 188–189, 198, 207, 220, 222, 226, 229–230, 233, 235, 243, 246, 269, 271;
III: 226, 232, 234, 348, 372, 422, 472;
IV: 142, 146, 149, 344, 353, 359, 361, 362, 368–369, 374–375, 381, 415;
V: 117;
Finnish Cancer Registry,
II: 137
Finnish Register of Congenital Malformations,
II: 140
Social Insurance Institution,
II: 137
Florida,
I: 324, 467;
II: 199;
III: 226;
IV: 142, 258, 260, 263, 266, 286, 297, 327–328, 330, 333–334, 336, 338, 344, 349, 354
Follicle-stimulating hormone (FSH),
II: 279, 280, 282;
III: 41, 68, 72–73, 444, 445;
IV: 399–400, 405, 408;
V: 405
Food crops,
I: 89
Agent Orange in destruction of,
I: 62, 90
as military target,
I: 27, 31, 87, 97, 98–100, 106
Ford, Gerald,
II: 27;
III: 25
Foreign veterans,
II: 113, 160, 202, 293;
III: 9, 216–217, 218, 244–245, 273, 285–286, 290, 294, 295, 298, 299, 303, 310, 311, 314, 315, 327, 329, 339, 340, 343, 346, 349, 353, 355, 359, 365, 380, 389, 413, 423, 424, 469, 485, 486, 489, 500, 506, 512–513, 517
Forest Service, US,
I: 42;
IV: 410
Forestry workers. See Agricultural/forestry workers
Forests
2,4,5-T spraying,
I: 42–43
defoliant early field tests in,
I: 26
Vietnam forests,
I: 31–32, 62, 90, 104;
III: 137
See also Agricultural/forestry workers;
Lumber industry;
Mangrove forests
Fort Detrick, Maryland,
I: 25
FR. See Fecundity Ratio
France,
IV: 116;
V: 227–228;
Free radicals,
II: 4
TCDD and,
II: 60
Frierfjord, Norway,
III: 236;
IV: 117, 149
FSH. See Follicle-stimulating hormone
Fungicides,
I: 91
G
Gamma-glutamyltransferase (GGT),
II: 331–332;
III: 509, 510;
IV: 499, 503;
V: 499–501
Gamma rays
respiratory cancer and latency,
II: 268;
III: 418
Gardner’s syndrome,
V: 283;
VI: 246
Gastrointestinal (GI) disorders,
III: 508–514;
IV: 498–505;
V: 498–502;
VI: 463–466
biologic plausibility,
VI: 221
cacodylic acid in,
I: 188
science literature update,
VI: 465
TCDD in,
I: 169–170;
IV: 19, 135, 156;
V: 60
Vietnam veterans’ risk,
VI: 466
See also Gastrointestinal (GI) tract cancers;
Ulcers, gastrointestinal
Gastrointestinal (GI) tract cancers
biologic plausibility,
I: 451;
III: 281–282;
IV: 256;
V: 502;
VI: 221
colon cancer, epidemiologic studies,
VI: 210–213
epidemiologic studies,
III: 268–273, 274–281;
IV: 251–255;
V: 243–259;
VI: 203–221
epidemiology,
I: 445–447;
II: 177;
III: 267–268
esophageal cancer, epidemiologic studies,
VI: 209
herbicide association in,
I: 12, 447–451, 576–577;
II: 7, 12, 21, 177–180, 250;
III: 8, 12, 21, 268–282;
V: 17
herbicide environmental exposure and,
II: 179–180;
III: 271–272, 275, 277–278, 279, 280–281;
IV: 254;
V: 501
herbicide occupational exposure and,
II: 178–179;
III: 268–271, 274–275, 276–277, 278–279, 280;
IV: 251;
V: 500–501
incidence, data by type/gender/race/selected
age group,
III: 267;
IV: 250
pancreatic cancer, epidemiologic studies,
III: 280–281;
IV: 250–254, 256, 385–386;
V: 257–259;
rectal cancer, epidemiologic studies,
III: 278–279;
IV: 250–251, 255–256, 262n, 264n, 385;
V: 254–256;
VI: 214–216
scientific literature update,
II: 178–180;
III: 268–273;
IV: 251–255;
V: 245;
VI: 219–220
stomach cancer, epidemiologic studies,
VI: 205–208
Vietnam veterans and,
I: 446, 452;
II: 177, 180, 181;
III: 272–273, 275, 277–278, 279, 281;
IV: 255;
V: 502;
VI: 221
See also Colon cancer;
Colorectal cancer;
Gastrointestinal (GI) disorders
GBDS. See General Birth Defects Study
Gender
acute lymphocytic leukemia incidence, data by gender,
III: 384;
VI: 326
acute myeloid leukemia incidence, data by gender,
III: 384;
VI: 326
bladder cancer incidence, data by gender,
III: 347;
IV: 339;
V: 328;
VI: 287
bone/joint cancer incidence, data by gender,
III: 302;
IV: 387;
V: 279;
VI: 242
brain cancer incidence, data by gender,
III: 356;
V: 339;
VI: 297
cancer studies and,
II: 180, 181, 183, 190, 191, 204–205, 234, 242, 243, 246;
IV: 199, 249
chronic lymphocytic leukemia incidence, data by gender,
III: 384;
VI: 326
chronic myeloid leukemia incidence, data by gender,
III: 384;
VI: 326
diabetes prevalence, data by gender,
III: 492
female reproductive system cancer incidence, data by type, for selected age groups,
III: 329, 330;
IV: 321;
V: 310;
VI: 261
gastrointestinal tract cancer incidence, data by type and gender,
III: 267;
IV: 145–146;
V: 244;
VI: 204
Hodgkin’s disease incidence, data by gender,
III: 372;
IV: 356;
V: 355;
VI: 313
kidney cancer,
V: 334
laryngeal cancer incidence, data by gender,
III: 292;
IV: 277;
V: 268;
VI: 231
leukemia incidence, data by type and gender,
III: 384;
IV: 378;
V: 367;
VI: 326
liver/intrahepatic bile duct cancers incidence, data by gender,
III: 282;
IV: 267;
V: 260;
VI: 222
lung cancer incidence, data by gender,
III: 296;
IV: 281;
V: 272;
VI: 235
melanoma incidence, data by gender,
III: 313;
IV: 300;
V: 288;
VI: 252
multiple myeloma incidence, data by gender,
III: 377;
V: 361;
VI: 320
nasal/nasopharyngeal cancer incidence, data by gender,
III: 289;
IV: 273;
V: 265;
VI: 227
non-Hodgkin’s lymphoma incidence, data by gender,
III: 362;
IV: 356;
V: 344;
VI: 303
renal cancers incidence, data by gender,
III: 352;
VI: 292
Seveso, Italy, in,
IV: 148
soft-tissue sarcoma incidence, data by
gender,
III: 306;
IV: 292;
V: 282;
VI: 245
See also Demographic data, Vietnam veterans;
Women veterans
General Accounting Office,
I: 52–53, 96;
III: 139, 140;
IV: 121
General Birth Defects Study (GBDS),
I: 610, 626;
II: 289, 290;
III: 438, 439
See also Centers for Disease Control and Prevention (CDC)
General Services Administration,
I: 77
Genetic alteration
2,4-D in,
I: 119, 178–179
2,4,5-T in,
I: 119, 184
cacodylic acid in,
I: 119, 187–188
cancer mechanism,
I: 433–434
picloram in,
I: 191
reproductive outcomes, male-mediated,
I: 593–594
TCDD in,
I: 118, 142, 143–144, 439;
V: 52–53
Genetic factors
Ah receptor-mediated events and,
I: 134;
VI: 60–66
cancer risk and,
I: 10;
IV: 249, 273, 300, 364, 386;
V: 264
porphyria cutanea tarda and,
I: 10, 679
Genetics. See Cytogenetics;
Genetic alteration;
Genetic factors
Geneva Protocol,
I: 45;
II: 27;
III: 25
Genitourinary cancers,
II: 223–224
See also Bladder cancer and disorders;
Kidney cancer;
Prostate cancer;
Testicular cancer
Genotoxicity,
V: 38;
VI: 36–40
Geographic information system (GIS),
VI: 190–191
Georgia. See Atlanta, Georgia
German Democratic Republic,
III: 226;
VI: 126
Germany,
I: 312–313, 326, 443, 477, 508–509, 530, 565, 675–676;
II: 105, 108, 130–131, 149, 308, 319–320, 322, 323, 328, 331, 333;
III: 221, 222, 223, 224, 232, 234, 235, 240, 269, 284, 308, 326, 332, 337, 357, 364, 365, 379, 386, 422, 423, 429, 470, 481, 483, 490, 506, 510–511, 515;
IV: 137, 149, 156, 191, 195, 208, 420;
V: 117;
German Cancer Research Center,
III: 495, 506
herbicide exposure assessment,
III: 153–154, 158, 159–160;
IV: 124, 257, 260, 263, 265, 271, 280, 285, 297, 301, 319, 333, 349, 353, 359, 368, 374, 381
See also Aktiengesellschaft, Germany;
Dormagen, Germany;
Hamburg, Germany;
Ludwigshafen, Germany;
Uerdingen, Germany
GGT. See Gamma-glutamyltransferase
GI. See Gastrointestinal (GI) disorders;
Gastrointestinal (GI) tract cancers
GIS. See Geographic information system
Givaudan Company,
I: 43
Glioblastomas,
V: 11, 525
Glucocorticoid receptor,
I: 154
Golgi apparatus,
Grave’s disease. See Thyroid homeostasis
Great Britain. See United Kingdom
Ground/perimeter spraying,
I: 20, 24, 74, 85, 90, 91, 94–96, 100, 272, 286, 287, 288–289;
III: 138–140;
See also Herbicide application methods;
Herbicides
Growth factors
epidermal,
I: 145, 154;
II: 59
TCDD induction of,
I: 136–137;
II: 4, 59;
III: 62–63;
IV: 66
transforming,
I: 145;
II: 59
tumor necrosis,
II: 59
Guillain-Barre syndrome,
II: 10, 312
H
Half-life studies,
VI: 51–54
Halogenated aromatic hydrocarbons,
I: 125, 126, 151;
IV: 41, 58, 68, 77
hepatic enzyme induction and,
I: 155
Halsted Reitan (HR) neuropsychologic test battery,
V: 450
Hamburg, Germany,
II: 195, 214–215, 329;
III: 153, 223, 324–325, 515;
IV: 191
Hamburg Boehringer Company,
IV: 138
Hancock County, Ohio,
III: 229;
IV: 213
Hanoi, Vietnam,
II: 148
Hawaii,
I: 60, 400, 603;
II: 292;
III: 243;
V: 6
Hazardous materials disposal and cleanup
Agent Orange surplus disposal,
I: 93–94
Nitro, West Virginia, accident efforts,
I: 38;
IV: 136
Seveso, Italy,
I: 43–44, 367–368
See also Incineration, of Agent Orange
HBV. See Hepatitis B virus
HC. See Hydrocortisone
HD. See Hodgkin’s disease
HDLP. See High-density lipoprotein receptors
Headaches,
I: 650, 660;
V: 447
Health and Human Services, US, Department of,
I: 57–59
Health care. See Military health care
Health outcomes of herbicide exposure
2,4-D outcomes,
II: 48–49;
III: 34, 38–39, 44–47
2,4,5-T outcomes,
II: 49;
III: 48;
IV: 185
cacodylic acid outcomes,
II: 50–51;
III: 34, 50
categories of evidence for assessing,
I: 227–237
categories of herbicide association in,
I: 5–8, 221, 223–225, 246–247;
II: 4–14, 19–22, 97;
III: 6–15, 19–22, 132, 390, 392–394;
IV: 6–12;
V: 7
choice of,
VI: 20
disease outcomes of,
II: 37;
III: 33–35, 38–43, 44–47, 48, 50, 71–105;
IV: 22, 27, 110
early herbicide research,
I: 29–32, 35–36;
II: 19–23;
III: 19–23
early TCDD research,
I: 28–29
evaluating exposure reconstruction model and,
I: 289–290;
IV: 85
evidence inadequate/insufficient for determining herbicide association in,
I:
13–14, 19, 247, 457, 460, 473–474, 512, 521, 571, 577–578, 605, 618, 624, 627, 630, 634, 657, 666, 691, 699, 708, 713, 727;
II: 6–7, 11–12, 20–21, 22, 97, 181–187, 249–250, 282, 284, 285–286, 298, 300, 325, 329, 334–335, 337;
III: 7–8, 10–12, 21, 132, 133, 292, 304, 316, 322, 327, 332, 334, 346, 349, 351, 355, 390, 393, 444, 449, 453, 458, 459, 473–474, 486, 491, 503, 507, 513, 518, 522;
IV: 11;
V: 8–9, 15, 16–17, 377–378, 515–516;
evidence limited/suggestive of herbicide association in,
I: 10–12, 19, 247, 472, 519–521, 563, 574–576, 727;
II: 6, 8–10, 20, 22, 97, 247–249, 298, 300, 323;
III: 7, 8–10, 20–21, 133, 295, 299, 340, 342, 383, 393, 444, 458, 474, 482, 519;
IV: 6, 7–11, 384;
V: 8, 14, 15, 16, 377, 515;
evidence of no association of herbicides in,
I: 12–13, 224, 247, 447–451, 503, 521, 525, 576–577;
II: 7, 12–13, 21–22, 97, 177–181, 250–251;
III: 8, 12, 21–22, 133, 359, 393–394, 522;
IV: 7, 11, 384–385;
V: 9, 15, 17, 378, 516;
evidence sufficient for herbicide association in,
I: 8–10, 246–247, 500, 548, 556–557, 572–574, 678, 682;
II: 5, 6, 8, 19, 20, 21, 97, 247, 320;
III: 6, 7, 8, 20, 132–133, 311, 366, 373, 374, 390, 392, 480, 519;
IV: 8, 384;
V: 8, 14, 15, 377, 514–515;
research priorities,
I: 19, 726–727
research update,
II: 37
statistical association of herbicide exposure,
II: 88, 90–91;
III: 1–2, 6, 124, 126–127;
IV: 6–12;
V: 22–23
TCDD outcomes,
III: 34–35, 71–105;
IV: 20
toxicity potential health risks, estimation of,
III: 105–108;
IV: 20
Vietnam veterans’ increased risk of disease,
II: 14, 22–23, 88, 91, 218, 223, 251, 276, 283, 298, 300–301, 321, 323;
III: 12–13, 14–15, 22–23, 124, 127–128, 329, 334, 343, 397, 430–431, 444, 462, 475–476, 491, 503, 507–508, 525;
IV: 12, 403, 407, 411, 413, 417–418, 421–422, 424, 426, 431, 435, 459, 468, 475;
VI: 17–18
See also Epidemiologic studies;
specific cancer sites;
specific cancers;
specific diseases and disorders
Healthy worker effect,
I: 230
Hearing loss,
I: 659–660
Heart disease,
VI: 7
Heart neoplasms. See Soft-tissue sarcoma (STS)
Heat shock protein (HSP90),
IV: 30
Helicobacter pylori,
II: 334;
III: 268, 362, 509;
IV: 145;
V: 344;
Helicopters
herbicide delivery use,
I: 26, 86, 87, 93, 94;
III: 135, 137, 138;
IV: 117
Hematopoietic cancers,
IV: 198
Hepatic phosphoenol pyruvate carboxy kinase (PEPCK),
II: 63, 75–76, 77;
III: 71, 72, 82
Hepatitis B infection,
I: 453
Hepatitis B virus (HBV),
II: 182, 183
Hepatitis C infection,
I: 453
Hepatitis C virus,
II: 182
Hepatobiliary cancers
biologic plausibility,
III: 286, 288;
V: 263–264;
VI: 225–226
epidemiologic studies,
III: 282–288;
IV: 268–269;
V: 259–264;
VI: 221–226
epidemiology,
I: 452–455;
II: 181–182;
III: 282
herbicide association and,
I: 13, 577;
II: 2, 6, 11, 12, 20, 89, 182–187, 249–250;
III: 7, 10, 282–288;
V: 259–264
herbicide environmental exposure and,
II: 184;
III: 283, 285, 287–288;
IV: 269;
V: 262–263
herbicide occupational exposure and,
II: 182–184;
III: 282–283, 284, 287;
IV: 268–269;
V: 261
incidence, data by gender/race, for selected age groups,
III: 282;
IV: 267;
VI: 222
risk estimates,
II: 186–187;
V: 164;
VI: 226
scientific literature update,
III: 284–286;
IV: 268;
V: 260–263;
VI: 222
TCDD and,
IV: 77;
V: 264
Vietnam veterans and,
II: 181, 185, 187;
III: 283, 285–286, 288;
IV: 269;
V: 264
See also Liver cancer
Hepatocellular carcinoma,
II: 148;
IV: 149
Hepatomegaly,
V: 6, 517
Hepatotoxicity
TCDD and,
II: 3, 73–75;
III: 76–79;
IV: 23, 71, 77;
V: 58–60, 71;
VI: 70–72
Herbicide application methods
military early research,
I: 25–26
Operation Ranch Hand use,
I: 85–87;
III: 135, 136, 137, 138, 139
Vietnam use,
I: 1, 3, 24, 27, 74, 85–87, 94–96;
III: 135–142;
V: 229–232
See also Aerial spraying;
Ground/perimeter spraying;
Herbicides;
Professional herbicide/pesticide applicators
Herbicide association, insufficient evidence for determining
altered sperm parameters and,
I: 14, 634;
II: 7, 20;
III: 449, 458;
IV: 7;
amyloidosis,
IV: 7;
V: 507;
basal/squamous cell skin cancer and,
III: 322, 393;
IV: 311;
V: 299–300
basis for finding of,
I: 13, 247, 577;
II: 6–7, 11–12, 20–21, 22, 97, 249–250;
III: 7–8, 10–12, 21, 133, 393
birth defects and,
I: 14, 605;
II: 7, 20, 298, 300;
III: 444, 458;
IV: 7;
V: 404;
bladder cancer and,
III: 7, 10, 132, 349, 351, 393;
IV: 7, 19;
V: 333;
bone/joint cancer and,
I: 13, 473–474, 577;
II: 6, 20, 205;
III: 7, 10, 304, 393;
IV: 7;
V: 281–282;
breast cancer and,
II: 217;
III: 7, 10, 327, 393;
IV: 7;
V: 308;
chronic persistent peripheral neuropathy,
II: 311, 314;
IV: 7;
circulatory disorders and,
I: 14, 708;
II: 7, 21, 337;
III: 518, 522;
IV: 7;
V: 505;
cognitive/neuropsychiatric disorders and,
I: 14, 657–658;
II: 7, 20, 308–309, 314;
III: 473–474;
IV: 441;
diabetes mellitus and,
I: 14, 691;
II: 7, 21, 335;
III: 503, 522;
V: 492;
female reproductive system/breast cancers and,
I: 13, 14, 512, 577;
II: 6, 20, 213;
III: 7, 10, 332, 334, 393;
IV: 7;
V: 316;
gastrointestinal tract ulcers and,
I: 14, 691;
II: 335;
III: 513, 522;
V: 502;
genitourinary tract cancers and,
I: 13, 521, 577
hepatic enzyme abnormalities and,
I: 14, 691
hepatobiliary cancers and,
I: 13, 577;
II: 6, 20, 187;
III: 7, 10, 286, 393;
IV: 7;
V: 263;
immune system disorders and,
I: 14, 699;
II: 7, 21, 329;
III: 491, 522;
IV: 7;
V: 484–485;
infertility and,
I: 14, 634;
II: 7, 282, 300;
III: 449, 458;
IV: 7
leukemia and,
I: 13, 571, 577–578;
II: 7, 20, 247;
III: 7, 10, 390, 393;
IV: 7, 198;
V: 372;
lipid abnormalities and,
I: 14, 691;
II: 7, 21, 335;
III: 507, 522
liver cancer and,
I: 13, 457, 577
liver toxicity and,
II: 335;
III: 513, 522
low birthweight and,
I: 14, 627;
II: 7, 20;
III: 458;
IV: 7;
melanoma and,
III: 316;
V: 294
metabolic and digestive disorders and,
II: 334–335;
IV: 7;
motor/coordination dysfunction and,
I: 14, 661;
II: 7, 21, 310, 314;
III: 474;
IV: 7;
nasal/nasopharyngeal cancer and,
I: 13, 460, 577;
II: 6, 20, 189;
III: 7, 10, 292, 393;
IV: 7;
V: 267;
neonatal/infant deaths and stillbirths,
IV: 7
neurobehavioral disorders,
II: 314;
III: 473–474;
neuropsychiatric outcomes and,
I: 14, 657, 666;
II: 7, 20, 308–309, 314;
III: 473–474;
IV: 7;
perinatal death and,
I: 14, 624;
II: 7, 20, 285–286, 300;
III: 453, 458;
V: 421–422;
peripheral nervous system disorders and,
I: 14, 666;
II: 21;
III: 474;
renal cancer and,
I: 13, 521, 577;
II: 7, 20, 225;
III: 7, 10, 355, 393;
IV: 7;
research recommendations,
I: 19, 727
respiratory disorders and,
I: 14, 713;
II: 7, 21, 325;
III: 486, 522;
IV: 7;
V: 482;
skin cancers,
II: 210–211;
III: 8, 10, 21, 393;
IV: 7, 19;
spontaneous abortions and,
I: 14, 605;
II: 7, 20, 284, 300;
IV: 7;
testicular cancer and,
I: 13, 521, 577;
II: 7, 20, 228;
III: 7, 10, 346, 393;
IV: 7;
V: 325, 327;
Vietnam veterans’ children, cancer in,
I: 14, 630;
II: 7, 20, 300;
IV: 7;
V: 430–431
Herbicide association, limited/suggestive evidence
acute and subacute transient peripheral neuropathy,
II: 314;
III: 7, 8, 21, 474;
IV: 6, 18–19;
VI: 15
acute myelogenous leukemia (AML),
IV: 7;
V: 372
basis for finding of,
I: 10–12, 247, 574–575;
II: 6, 8–10, 20, 22, 97, 247–249;
III: 7, 8–10, 20–21, 133, 393
birth defects,
IV: 6, 18–19;
V: 405
cancer,
I: 10–12, 519–521, 574–576;
II: 247–249;
III: 393
diabetes, type 2,
IV: 6;
laryngeal cancer,
III: 295, 393;
V: 268–272
lung cancer,
III: 299, 393;
V: 278
multiple myeloma,
I: 10, 11–12, 563, 574, 576;
II: 6, 20, 244;
III: 7, 8, 9, 20, 383, 393;
IV: 6, 18–19;
V: 365;
VI: 15
neurobehavioral disorders,
II: 314
peripheral neuropathy,
II: 6;
VI: 15
porphyria cutanea tarda,
II: 6, 323;
III: 7, 8, 20, 482, 519;
IV: 6, 18–19;
V: 480;
VI: 15
prostate cancer,
I: 11, 519–521, 575–576;
II: 6, 20, 223;
III: 7, 8, 9, 20, 340, 342, 393;
IV: 6, 10, 18–19;
V: 316;
VI: 15
research recommendations,
I: 19, 727
respiratory cancers,
I: 10–11, 472, 574, 575;
II: 6, 20, 203;
III: 7, 8, 9, 20;
IV: 6, 18–19;
VI: 15
spina bifida,
II: 6, 298, 300;
III: 7, 8, 9–10, 21, 444, 458;
IV: 7, 18–19;
Herbicide association, limited/suggestive negative evidence
basis for finding of,
I: 12–13, 224, 247, 576–577;
II: 7, 12–13, 21, 97, 250;
III: 8, 12, 21–22, 133, 393–394, 522;
IV: 7, 19–20
brain tumors,
I: 12, 525, 576;
II: 7, 21, 230;
III: 8, 12, 21, 359, 394;
IV: 7;
V: 343
gastrointestinal tract cancers,
I: 12–13, 447–451, 576–577;
II: 7, 21, 177–181;
III: 8, 12, 21, 268, 273, 282, 394;
IV: 7, 19
skin cancer,
I: 12, 503, 576;
III: 21
urinary bladder cancer,
I: 12, 521, 576;
II: 7, 21, 227;
III: 21;
V: 333
Herbicide association, sufficient evidence
basis for finding of,
I: 8–10, 246–247, 572;
II: 5, 6, 8, 19, 20, 21, 97, 247;
III: 6, 7, 8, 20, 132–133, 390, 392;
IV: 6, 17–18
cancer and,
I: 8–10, 572–574;
II: 247;
III: 390, 392;
IV: 6, 17–18
chloracne and,
I: 10, 678;
II: 5, 6, 20, 320;
III: 6, 7, 20, 480, 519;
IV: 6, 17–18;
V: 479;
VI: 13
Hodgkin’s disease and,
I: 8, 9–10, 556–557, 573–574;
II: 5, 6, 20, 236;
III: 6, 7, 20, 373, 374, 390;
IV: 6, 17–18;
V: 360;
VI: 13
non-Hodgkin’s lymphoma and,
I: 8–9, 10, 548, 573–574;
II: 5, 6, 20, 234;
III: 6, 7, 20, 366, 390;
IV: 6, 17–18;
V: 354–355;
VI: 13
porphyria cutanea tarda and,
I: 10, 682;
II: 5, 6, 20;
III: 20;
IV: 6, 17–18;
V: 479;
VI: 13
soft-tissue sarcoma and,
I: 8, 9–10, 500;
II: 5, 6, 20, 208;
III: 6, 7, 20, 311, 390;
IV: 6, 17–18;
V: 287;
VI: 13
Herbicide exposure assessment,
agricultural/forestry workers studies,
III: 154–155;
IV: 111–113
biomarkers for,
I: 17, 259–262, 280–284;
II: 101–104;
IV: 111
cancer studies use,
I: 436–439
case-control studies use,
I: 256–257;
IV: 124
Centers for Disease Control Agent Orange Study,
I: 58;
II: 102;
IV: 124–125
Centers for Disease Control exposure opportunity index,
I: 274–276, 611–612;
III: 147–148;
IV: 124–125
Centers for Disease Control validation study,
I: 59, 260–261, 281–284, 387;
II: 103, 104;
IV: 125–126
Centers for Disease Control Vietnam Experience Study,
II: 101;
III: 240;
IV: 123
cohort studies use,
I: 254–256;
II: 107–109
cumulative exposure,
III: 144
current estimates,
I: 284–287
data sources (existing) limitations,
I: 14–15, 290–291
definition of, methodological issues,
II: 4–5;
III: 5–6;
IV: 16, 20;
V: 4, 215–216
Department of Veterans Affairs mortality studies,
II: 101;
IV: 123;
IV: 151, 157–158
difficulties in,
I: 14–15, 222, 247–248, 284, 286–287;
VI: 28–29
dioxin congeners, recent literature,
II: 106–107;
III: 158–159
environmental studies use,
I: 262–263, 267–270;
III: 156–157;
IV: 111, 114–116
epidemiologic studies evaluation and,
II: 99–101;
III: 142–146;
VI: 165–169
evidentiary role of,
I: 4, 15, 250–253;
exposure-dose relationship,
I: 252–253
ground spraying,
I: 288–289;
III: 138–140
historic exposure reconstruction,
I: 17–18, 19–20, 254, 255–256, 725–726, 728;
III: 143
indices development,
II: 107–109;
III: 161–162
individual differences,
I: 261, 286
industrial exposure,
VI: 177–181
job exposure matrix,
I: 259–262
literature update,
II: 104–109;
III: 157–162
methodological issues,
II: 4–5;
III: 5–6
misclassification bias in,
I: 17, 257–259, 724
non-military settings and,
I: 4–5, 15, 222–223, 241–242
occupational studies use,
I: 262–267, 269–270;
II: 107–108;
III: 150–156;
V: 217–225;
VI: 169–177
paper/pulp mill workers,
I: 266–267;
III: 155–156;
IV: 114, 134
process perspective,
I: 252–253
Ranch Hand study use,
I: 386;
II: 109;
III: 145–147
research recommendations,
I: 16–18, 287–290, 291, 721–722, 724–725
risk assessment use,
I: 14–15, 247–248, 250, 578;
III: 14–15
sawmill workers,
IV: 10, 114, 156, 227–228, 338, 439–440, 447–448, 449, 452, 453, 457
self-reports,
I: 270–271;
IV: 113
serum TCDD in,
I: 19, 20–21, 261, 282–285, 289, 290, 725, 742–743;
III: 159–161;
IV: 135, 400
Seveso, Italy, accident,
I: 267–268, 285, 598–599;
III: 156;
IV: 400
state-sponsored studies,
I: 400, 401–402, 403–404
Stellmans’ study,
I: 278–279, 284
strategies for,
I: 253–254;
III: 144–145
TCDD exposure levels for epidemiological studies,
II: 105–106;
III: 159–161
TCDD half-life investigation,
II: 104–105;
III: 157–158;
IV: 112, 115–116, 125–126
Times Beach, Missouri, case,
I: 268, 368–369
Vietnam military records in,
I: 271–280;
IV: 125
Vietnam service as element of,
I: 271, 284–287;
II: 101–104;
III: 146–150
Vietnam spray data,
I: 273–279
Vietnam troop movement data in,
I: 95–96, 273–279, 287
Vietnamese population,
I: 108–109, 269, 731;
III: 156–157;
IV: 148–149
workshop on,
I: 746–747
See also Environmental herbicide exposure;
Herbicide exposure reconstruction model;
Herbicides;
Occupational herbicide exposure
Herbicide exposure reconstruction model
data sources,
I: 725–726
epidemiologic research and,
I: 726–728
evaluation of,
I: 18, 289–290, 726;
II: 25
recommendations,
I: 15–16, 17–20, 287–290, 291, 721–722, 725–728;
II: 25
Request for Proposals (RFP),
II: 25–26;
IV: 5
See also Herbicide exposure assessment;
Herbicides
Herbicide/pesticide applicators. See Professional herbicide/pesticide applicators
Herbicides
action of,
I: 88
acute and subacute transient peripheral neuropathy and,
II: 2, 312–313;
III: 7, 8, 473;
IV: 441, 457
agricultural role of,
I: 24, 35, 39, 174–175, 181
Air Force research activities,
II: 31–32;
III: 28–29
basal/squamous cell skin cancer association,
III: 317–322, 323;
IV: 311;
V: 295–300
biologic plausibility,
II: 88, 92, 176, 217, 282, 298, 300;
III: 2, 23, 124, 128, 281–282, 286, 288, 292, 295, 302, 304, 311, 317, 322, 327, 329, 334, 343, 347, 351, 356, 362, 366, 377, 383, 390, 444, 451, 453, 458, 460–462, 467, 480, 482, 486, 491, 502–503, 507, 513–514, 518, 522–525;
IV: 22, 26, 29, 48, 85, 86, 249,
256, 270, 275, 279, 284, 290, 296, 306, 311, 318, 322, 323, 331, 332, 337, 342, 343, 348, 352, 358, 359, 367, 374, 380–381, 385;
V: 25
birth defects association,
II: 286–298;
III: 436–444;
IV: 403
bladder cancer association,
II: 225–227;
III: 7, 10, 132, 347–351;
IV: 342;
V: 328–333
bone/joint cancer association,
II: 204–205;
III: 7, 10, 303–305;
IV: 289;
V: 278–282
brain tumors association,
II: 229–230;
III: 8, 12, 356–362;
IV: 352
breast cancer association,
II: 213–217;
III: 7, 10, 324–329;
IV: 318;
V: 300–309
cancer latency issues,
II: 2, 13–14, 175, 260–276;
III: 3, 12–14, 407–431;
IV: 289
cancer risk and development,
II: 13–14, 175;
III: 12–14, 265–266
carcinogenicity,
I: 118–119;
II: 175;
III: 265–266;
IV: 256, 270, 275, 279, 284, 290, 296, 305, 311, 318, 323, 332, 337, 342, 348, 352, 358, 367, 374, 380, 387
cervical cancer association,
III: 332;
IV: 323
chemistry of,
II: 38
childhood cancer association,
II: 299–300;
IV: 424–425
chloracne association,
II: 318–320;
III: 6, 7, 479–480;
IV: 466
chronic persistent peripheral neuropathy and,
II: 310–311
circulatory disorders association,
II: 335–337;
III: 3, 514–518;
IV: 510
cognitive/neuropsychiatric disorders and,
II: 307–309;
III: 468–469;
IV: 443;
V: 449–451
congressional hearings,
II: 27–28;
III: 25
congressional legislation on,
II: 28–29;
III: 26–27
Department of Veterans Affairs activities,
II: 29–31;
III: 27–28;
IV: 151, 157–158
developmental toxicity,
I: 124;
IV: 403, 413, 416, 431, 434
diabetes mellitus association,
II: 330–331, 334–335;
III: 2, 11–12, 125, 494–503
disease outcomes of exposure,
III: 6–15, 33–35, 38–43, 44–47, 48, 50, 71–105
early concerns about,
I: 17–19, 29–32, 35–36;
II: 26;
III: 25
environmental exposure studies,
I: 140–149, 184, 186, 189, 190, 193, 200–201, 221, 222, 234, 236, 241, 243, 287–288, 306, 312–313;
II: 271–272, 275, 277, 279–281;
III: 197–205, 218, 232–236, 283, 285, 287–288, 290, 291, 297–298, 301, 303, 305, 309, 316, 323, 328, 333, 336, 338, 342, 344, 345, 349, 350–351, 353, 354, 358, 361, 365, 369, 373, 375, 380, 382, 388–389, 392, 437, 454, 455, 456, 459, 467, 497, 520;
IV: 249, 254–255, 258, 261, 263, 266, 269, 271, 274, 276, 278, 280, 282, 286, 289, 291, 293, 297, 302, 305–306, 309, 312, 314–316, 319, 321, 323, 325–326, 328–329, 334, 336, 338, 341, 344, 347, 349, 351, 354, 356–357, 361, 366, 369, 372, 375, 379, 382–383
Environmental Protection Agency research activities,
II: 32;
III: 29–30
evidence insufficient for determining association in health outcomes,
I: 13–14, 19, 247, 457, 460, 473–474, 512, 521, 571, 577–578, 605, 618, 624, 627, 630, 634, 657, 666, 691, 699, 708, 713, 727;
II: 7, 11–12, 20–21, 22, 97, 181–187, 189, 205, 210–211, 213, 217, 225, 228, 247, 282, 284, 285–286, 298, 300, 308–309, 310, 311, 314, 325, 329, 334–335, 337;
III: 7–8, 10–12, 21, 132, 133, 286, 292, 304, 316, 322, 327, 332, 334, 346, 349, 351, 355, 390, 393, 444, 449, 453, 458, 473–474, 486, 491, 503, 507, 513, 518, 522;
IV: 268, 270, 274, 275, 279, 288, 289, 302, 305, 308, 311, 314, 318, 321, 323, 329, 336, 337, 342, 348, 374, 380, 384, 400, 403, 406, 407, 410–414, 416, 418, 424, 425, 426, 430–432, 441–443, 448, 454–457, 475, 480, 495, 500, 505, 506, 510, 512, 514
evidence limited/suggestive of association in health outcomes,
I: 10–12, 19, 247, 472, 519–521, 563, 574–576, 727;
II: 6, 8–10, 20, 22, 97, 203, 223, 244, 298, 300, 314, 323;
III: 7, 8–10, 20–21, 133, 295, 299, 340, 342, 383, 393, 444, 458, 474, 482, 519;
IV: 7
evidence of no association in health outcomes,
I: 12–13, 224, 247, 447–451, 503, 521, 525, 576–577;
II: 7, 12–13, 21, 22, 97, 181, 227, 230;
III: 8, 12, 21–22, 133, 268, 273, 282, 359, 393–394, 522;
IV: 251, 256, 340, 351, 352, 385, 514
evidence sufficient of association in health outcomes,
I: 8–10, 246–247, 500, 548, 556–557, 572–574, 678, 682;
II: 5, 6, 8, 19, 20, 21, 97, 208, 234, 236, 320;
III: 6, 7, 8, 20, 132–133, 311, 366, 373, 374, 390, 392, 480, 519;
IV: 6
exposure assessment issues,
II: 4–5, 99–109;
III: 5–6, 135–162
federal government response to concerns over military use of in Vietnam,
II: 27–32;
III: 25–30
female reproductive cancers association,
II: 211–213;
III: 7, 10, 330–334
gastrointestinal tract cancers association,
II: 177–181;
III: 8, 12, 268–282;
IV: 256
gastrointestinal ulcers association,
II: 334–335;
III: 510–514
hepatobiliary cancer and,
II: 2, 176, 181–187;
III: 7, 10, 282–288;
IV: 270;
V: 259–264
Hodgkin’s disease association,
II: 235–236;
III: 6, 7, 372–376;
IV: 367;
V: 355–361
immune system disorders and,
II: 327–329;
III: 3, 488–491;
IV: 480
immunotoxicity,
I: 122–123
infertility association,
II: 280–282;
III: 445–451;
IV: 407
International Agency for Research on Cancer research activities,
III: 30;
IV: 17, 133, 137–139, 252
laryngeal cancer and,
II: 202–203;
III: 292–295;
IV: 279
latency and cancer risk,
II: 13–14, 175, 260–276;
III: 3, 12–14, 265, 407–431
leukemia association,
II: 245–246;
III: 7, 10, 385–390, 391–392;
IV: 380;
V: 366–372
lipid abnormalities association,
II: 333–335;
III: 504–508, 520–521;
IV: 495
liver toxicity association,
II: 332–333, 334–335;
III: 510–514;
IV: 505
low birthweight and,
III: 456–458, 459;
IV: 416
lung cancer and,
III: 296–302, 421, 422, 423, 424;
IV: 284;
V: 272–278
mechanism of action,
II: 36;
III: 33, 38, 44, 47–48, 49–50, 53–71
mechanisms of toxicity,
II: 37
melanoma association,
III: 313–317;
IV: 306;
V: 287–295
metabolic and digestive disorders association,
II: 330–335;
III: 3
military research and development,
I: 25–26
military (US) use ban,
I: 32, 45;
VI: 182–186
motor/coordination dysfunction and,
II: 309–310;
III: 469–470
multiple myeloma assocation,
II: 237–244;
III: 7, 8, 9, 377–383;
IV: 512;
V: 361–366
nasal/nasopharyngeal cancer and,
II: 2, 176, 187–189;
III: 7, 10, 290–292;
IV: 275;
V: 264–268
neural tube defects associated with herbicides, numbers,
II: 297
neurobehavioral disorders and,
II: 305, 306, 314;
III: 3, 467, 468, 473–476;
IV: 457
non-Hodgkin’s lymphoma association,
II: 231–234;
III: 6, 7, 362–371, 428–430;
IV: 358;
V: 343–355
occupational exposure settings,
I: 36–38;
III: 150–156
occupational exposure studies,
II: 113–140, 182–184, 186, 188–189, 190, 191–200, 214–216, 219–220, 222, 232–234, 235–236, 237–243, 286–287, 306, 312;
III: 170–196, 218, 219–232, 268–271, 274–281, 282–283, 284, 287, 290, 291, 293–294, 296–297, 300–301, 303, 305, 308–309, 312, 316, 317, 321, 323, 324–326, 328, 332–333, 335–336, 337, 338, 341, 344, 345, 348, 350, 353, 354, 357–358, 360, 363–365, 367–369, 372–373, 374–375, 378–380, 381–382, 386–388, 391–392, 437, 450, 454, 455, 456, 459, 467, 483–485, 489, 491, 496, 510–512, 515–516, 520;
IV: 114, 249, 251, 253, 255–257, 259, 262, 265, 268, 270–271, 273–274, 276–282, 285, 288–290, 292, 296, 300–303, 305–307, 309, 312, 315, 317–318, 321, 324–325, 327–329, 331–333, 336, 338, 340–342, 346–348, 351, 353, 356, 358–361, 364–365, 368–369, 371–374, 377, 379, 381, 383
Operation Ranch Hand volume use, data by herbicide type,
III: 136
ovarian cancer association,
III: 333
perinatal death association,
II: 285–286;
III: 451–454, 455, 456;
IV: 413;
V: 421–422
porphyria cutanea tarda association,
II: 321–323;
III: 7, 8, 481–482;
IV: 468
preterm birth and,
III: 456–458, 459
prostate cancer association,
II: 2, 176, 217–223, 273–275;
III: 7, 8, 9, 335–343, 426–428;
IV, 10;
V: 316–324
renal cancer association,
II: 224–225;
III: 7, 10, 352–356;
IV: 348
reproductive toxicity,
I: 124;
II: 278–301;
III: 434–435
research recommendations,
II: 23–24;
III: 23;
IV: 13
respiratory cancers and,
II: 189–203, 268–273;
III: 7, 8, 9, 418, 420–426
respiratory disorders association,
II: 335–337;
III: 3, 483–486
skin cancers association,
II: 209–211;
III: 8, 10, 312;
IV: 305
soft-tissue sarcomas association,
II: 205–208;
III: 6, 7, 306–311;
IV: 384;
V: 282–287
spontaneous abortions association,
II: 283–284;
IV: 411;
V: 409–421
statistical association with diseases,
II: 88, 90–91;
III: 1–2, 6, 124, 126–127;
V: 22–23
TCDD contamination of,
I: 2, 3, 27, 91–92, 114, 126–127;
II: 2, 3, 26;
III: 3, 4, 5, 140–142
testicular cancer association,
II: 227–228;
III: 7, 10, 343–347;
IV: 337;
V: 324–328
time-related factors and cancer risk,
II: 263–264, 270, 271, 273, 274;
III: 411–412, 421, 422, 423, 424, 426, 427, 429
toxicity profiles update,
II: 45–77;
III: 43–108
toxicokinetics,
II: 35, 36, 38–39;
III: 32–33, 36–37, 43–44, 47, 48, 50–53
toxicology,
III: 3–5, 32–110
types of,
I: 88
uterine cancer association,
III: 333
Vietnam use by US military,
I: 1, 3, 24, 27, 74, 84–96, 98–107, 286;
II: 1, 2, 26–27;
III: 135–142
Vietnam veterans’ cancer risk and latency,
II: 276;
III: 12–13, 430–431
Vietnam veterans’ disease increased risk,
II: 14, 22–23, 88, 91, 298, 300–301, 321, 323;
III: 12–13, 14–15, 22–23, 124, 127–128, 329, 334, 343, 430–431, 444, 462, 475–476, 491, 503, 507–508, 525;
IV: 2, 9, 12, 20, 103, 105–106, 124
Vietnam veterans’ exposure concerns,
II: 26–32
Vietnam veterans’ exposure studies,
II: 149–161, 185, 187, 189, 190, 201–202, 204, 205, 208, 209, 211, 212, 213, 216–217, 218, 221, 223, 224, 225, 226, 227, 228, 229, 230, 231, 234, 235, 236, 244, 245, 246, 278, 280, 283, 285, 286, 288–296, 306, 308, 309, 310, 311, 313, 314, 318–320, 321–323, 324–326, 327–329, 330–337;
III: 206–217, 236–245, 272–273, 275, 277–278, 279, 281, 282–283, 287–288, 290, 291, 294–295, 298, 301, 303, 305, 309–310, 312, 316, 317, 323, 326, 328, 333, 336, 338, 339, 340, 342, 343–344, 345–346, 349, 351, 353, 355, 358–359, 361, 363, 365, 370–371, 372, 373, 376, 380, 382, 385, 386, 389, 392, 435, 436, 437–438, 445, 446, 450, 454, 455, 456, 457, 459, 467, 468, 469, 470, 473, 475, 479, 480, 481, 482, 485–486, 489, 491, 495, 497, 498, 500, 502, 505–506, 512–513, 516–518, 521;
IV: 249–250, 255–256, 259, 262, 264, 266–267, 269–270, 272, 275–276, 278–281, 283–284, 287, 289–292, 294, 296, 298–299, 301, 303–311, 313–314, 316–320, 322–327, 329–332, 334–336, 338–340, 342–343, 345, 347–348, 350, 352–353, 355–359, 362–364, 366–367, 370–371, 373–374, 376–378, 380–381, 383, 387–388;
VI: 182–191
See also 2,4-Dichlorophenoxyacetic acid (2,4-D);
2,3,7,8–Tetrachlorodibenzo-p-dioxin (TCCD);
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T);
Aerial spraying;
Agent Orange;
Agricultural herbicides;
Chemicals and chemical industry;
Defoliants;
Desiccant herbicides;
Domestic herbicide use;
Environmental herbicide exposure;
Ground/perimeter spraying;
Herbicide application methods;
Herbicide exposure assessment;
Herbicide exposure reconstruction model;
Occupational herbicide exposure;
Phenoxy herbicides;
Professional herbicide/pesticide applicators;
Selective herbicides
HERBS tapes,
I: 20, 97–98, 602, 725;
II: 108–109;
IV: 123, 125;
VI: 190
contents,
I: 96–97, 273
deficiencies,
I: 97, 104–105
exposure assessment use,
I: 273–279, 287, 291;
III: 146, 148
source of,
I: 62, 85, 96
Hercules Inc.,
I: 35
1,2,3,6,7,8-Hexachloro-dibenzo-p-dioxin (HxCDD),
II: 64, 65, 67
2,2',4,4,'5,5'–Hexachlorobiphenyl (HxCB),
II: 64, 65
Hexachlorophene,
I: 40;
II: 128;
III: 218, 219, 234;
IV: 133–135, 138, 148;
V: 104
HI. See Humoral immunity
High-density lipoprotein (HDLP) receptors,
II: 333, 334;
III: 501, 503, 520–521
Highway workers,
I: 326
Historic exposure reconstruction,
I: 17–18, 19–20, 254, 255–256, 725–726, 728;
III: 143;
IV: 126–127
HIV-I. See AIDS/HIV
Ho Chi Minh City, Vietnam,
II: 108;
IV: 228
Hodgkin’s disease (HD)
agricultural/forestry workers and,
I: 328, 329, 331, 335–336, 341, 550–553;
II: 138
biologic plausibility,
I: 557;
III: 377;
IV: 367;
V: 361;
VI: 319
chemical industry workers and,
I: 549–550
epidemiologic studies,
II: 138, 235–236;
III: 372–376;
IV: 199, 211, 212;
V: 357–360;
VI: 313–319
epidemiology,
I: 526, 527–528;
II: 231;
III: 371–372
herbicide association in,
I: 8, 9–10, 556–557, 574;
II: 5, 6, 20, 138, 235–236, 247;
III: 6, 7, 20, 24, 372–376;
IV: 17;
V: 14, 355–361
herbicide environmental exposure studies,
I: 384;
II: 236;
III: 373, 375;
IV: 366;
V: 358–359;
herbicide occupational exposure studies,
II: 235–236;
III: 372–373, 374–375;
IV: 365;
V: 357–358;
VI: 318
histopathology,
I: 526–527
incidence, data by race/gender, for selected age groups,
III: 372;
IV: 365;
V: 355;
VI: 313
research recommendations,
I: 19, 727
scientific literature update,
II: 235–236;
III: 372–373;
IV: 365;
V: 356
Vietnam veterans and,
I: 258, 526, 554–556;
II: 231, 236;
III: 372, 373, 376;
IV: 366;
V: 359–360, 361;
VI: 318
Vietnam veterans’ compensation,
II: 24, 30, 31
Vietnam veterans’ risk,
VI: 319
See also Malignant lymphomas
Hoffman-Taff,
I: 40
Honolulu Heart Program, 461
Hormonal effects
Biologic plausibility,
VI: 394
Hormonal system
estrogen-mediated responses,
I: 145, 154
TCDD carcinogenesis and,
I: 116, 145
TCDD in,
I: 156–159;
IV: 71
TCDD-induced wasting syndrome and,
I: 165
Hormones. See Follicle-stimulating hormone (FSH);
Hormonal system;
Luteinizing hormone (LH);
Testosterone
Hourglass spray system,
I: 25
House Committee on Veterans Affairs,
II: 27;
III: 25
HR. See Halsted Reitan neuropsychologic test battery
H.R. 1565,
II: 28
HSP90. See Heat shock protein
Human health studies,
Human immunodeficiency virus (HIV-I). See AIDS/HIV
Human milk. See Breast milk
Humoral immunity (HI)
TCDD and,
II: 69–70
HxCB. See 2,2',4,4,'5,5'-Hexachlorobiphenyl (HxCB)
HxCDD. See 1,2,3,6,7,8-Hexachloro-dibenzo-p-dioxin
Hydatidiform mole,
I: 30, 600–601
See also Reproductive disorders
Hydrocephalus,
I: 609, 611
See also Reproductive disorders
Hydrocortisone (HC),
II: 73
Hypercholesterolemia,
I: 690
See also Lipid and lipoprotein disorders
Hyperlipidemia,
I: 152–153, 688, 692
See also Lipid and lipoprotein disorders
Hypertension,
I: 705, 706, 707, 708;
IV: 135;
See also Circulatory disorders
Hyperthyroidism
TCDD-induced,
I: 168
See also Metabolic and digestive disorders;
Thyroid homeostasis
Hypoglycemia
TCDD-induced,
I: 166–168
See also Metabolic and digestive disorders
Hypospadias,
I: 609, 611
See also Reproductive disorders
I
IARC. See International Agency for Research on Cancer
ICD. See International Classification of Diseases
Iceland,
III: 228, 319, 338, 339, 344, 353;
IV: 142, 312, 333, 338
Association of Vegetable Farmers,
III: 228
Cancer Registry,
III: 228, 338
Committee on Toxic Substances,
III: 228
Farmers’ Association of Iceland,
III: 228
Horticultural College,
III: 228
Horticulturist’s Association,
III: 228
Market Gardeners Association Pension Fund,
III: 228
National Registry,
III: 228
Register of Deaths,
III: 228
I Corps,
I: 52, 96, 98, 394, 493–494, 542, 543, 546;
II: 201;
III: 139, 140, 241
mortality study,
I: 233;
IV: 121
II Corps,
I: 542
III Corps,
I: 59, 104, 276, 281–282, 542, 543;
II: 228;
III: 148, 344;
IV: 125–126
IV Corps,
I: 81, 98, 542
IL. See Interleukin-1;
Interleukin-4
ILO. See International Labor Organization
Immune system disorders
2,4-D toxicity,
I: 181;
II: 41;
III: 46, 524;
IV: 197;
V: 37
biologic plausibility,
VI: 447–448
cell-mediated immunity,
II: 69–70
cellular immunity,
I: 147
endocrine system and,
I: 150–151
epidemiologic studies,
II: 327–329;
III: 488–491;
IV: 79, 195;
V: 484–485;
VI: 443–448
epidemiology,
II: 326–327;
III: 487
herbicide toxicity,
I: 122–123;
II: 7, 11, 21, 327–329;
III: 3, 488–491;
V: 483–485;
VI: 445–446
humoral immunity,
I: 147–148;
II: 69–70
immune modulation in,
I: 692–696, 698–699;
macrophage function,
I: 148
picloram toxicity,
I: 192;
II: 41;
IV: 5
research methodology,
I: 692
scientific literature update,
II: 328–329;
III: 489–491;
V: 484;
VI: 445–446
suppression in,
I: 693;
II: 326, 329
TCDD toxicity,
I: 119–122, 146–151, 338;
II: 3, 40–41, 68–71, 328–329;
III: 85–92, 488, 489, 490, 491;
IV: 26, 31–32, 77–81;
V: 61, 74–75, 484, 517–518;
VI: 73–76
Vietnam veterans’ risk,
VI: 448
See also Allergies;
Autoimmune disease;
Autoimmunity;
Systemic autoimmune disease;
Systemic lupus erythematosus;
Viral infection
Immunoglobulin antibodies,
I: 693, 696, 697
2,4-D and,
IV: 31
Incineration
of Agent Orange,
I: 93–94;
IV: 116
of municipal waste,
V: 6
Incoordination. See Motor/coordination dysfunction
Indiana,
III: 47
Industrial accidents,
I: 316–317;
III: 224, 232–233
BASF,
I: 312–313, 444, 530, 550, 558;
III: 153, 221;
IV: 188–189
Nitro, West Virginia,
I: 38–39, 305–307, 597, 607, 686, 700;
III: 152–153, 220;
IV: 136
Industrial exposure,
VI: 177–181
Industrie Chimiche Meda Societa Anonima,
I: 43
Infant death. See Perinatal death
Infertility,
I: 631–634;
II: 7, 11;
V: 405–409
biologic plausibility,
II: 282;
III: 451;
V: 409;
VI: 372
epidemiologic studies,
II: 280;
III: 445–449, 450;
V: 409;
VI: 365–372
epidemiology,
II: 279;
III: 444–445
herbicide association in,
II: 278, 280–282;
III: 445–451;
IV: 405–409;
V: 405–409;
VI: 366–371
new studies summary,
II: 280–281;
III: 446–449, 450
scientific literature update,
V: 406–408;
VI: 366–371
Vietnam veterans and,
III: 445, 446, 450;
V: 408;
VI: 371–372
See also Reproductive disorders
Influenza,
I: 713
See also Respiratory disorders
Insecticides,
I: 87–88, 91
Insomnia. See Sleep disorders
Institute of Medicine (IOM),
I: 2, 20, 57, 62–64, 742, 743–744;
II: 1, 2, 17, 24, 25, 27;
III: 1, 2, 5–6, 17, 23, 24, 25, 125, 150;
IV: 1, 15, 126;
V: 1, 12–13;
Interactions,
Interagency Working Group on the Long-Term Health Effects of Phenoxyherbicides and Contaminants,
I: 46
Interleukin-1,
I: 148;
II: 59
Interleukin-4,
II: 70–71
Internal Revenue Service (IRS),
II: 152, 153
Social Security database,
II: 151;
III: 238;
IV: 151;
VI: 136
International Agency for Research on Cancer (IARC),
I: 8, 12–13, 246, 264–265, 270, 313–314, 478, 479, 499, 565, 573, 577, 731;
II: 101, 107, 131–135, 178–179, 196, 206, 212, 215, 220, 226, 232, 269;
III: 20, 151, 175–177, 218, 222–223, 268, 269, 284, 290, 293, 296, 303, 306, 307, 308, 310, 311, 314, 319, 325, 326, 331, 337, 344, 348, 353, 357, 364, 378, 379, 386, 422–423, 424, 425, 429, 484, 511, 516;
IV: 17;
V: 14, 108–109, 136–140, 219–221;
herbicide exposure assessment in occupational studies,
III: 151–152, 154;
IV: 111, 137–139, 189–194, 252, 257, 259–260, 262–263, 265, 271, 276, 280, 290, 293, 296–297, 300, 306, 312, 318–319, 324–325, 333, 338, 341, 343, 348–349, 353, 359–360, 368, 374–375, 381;
VI: 171–172
Vietnam military use of herbicides, response,
III: 30
International Classification of Diseases (ICD),
II: 325;
III: 265;
IV: 248, 249;
V: 242, 531–533;
ICD-9 cancer codes, SEER program site groupings for,
III: 537–539;
IV: 524–526;
VI: 572–574
International Labor Organization (ILO),
II: 324
International Register of Workers Exposed to Phenoxy Herbicides and Their Contaminants,
I: 313–314;
II: 131–135, 220, 232, 235, 238, 245;
III: 175–177, 218, 222–223
International Society of Exposure Analysis,
II: 25
Intracellular communication
TCDD and,
II: 3, 67–68
Intrahepatic bile duct cancers,
VI: 222
Intrauterine growth retardation (IUGR),
I: 625, 626;
III: 455, 457;
IV: 413–414;
V: 422
See also Reproductive disorders
Involuntary movements. See Motor/coordination dysfunction
IOM. See Institute of Medicine
Iowa,
I: 11, 37, 60, 318–319, 332, 333, 334–335, 374, 400, 447, 495, 534, 550, 560, 567, 603, 660, 677;
II: 8, 138–139, 219, 239, 248, 292;
III: 224, 229, 234, 243, 335;
IV: 140, 142, 143, 144, 149, 158, 210, 258, 261, 266, 290, 300, 334, 344, 349, 354, 361, 369, 375, 382;
V: 6, 117;
Iowa Health Registry,
II: 138–139
See also Agricultural Health Study (AHS)
Ireland, Republic of,
II: 136, 230, 233, 242, 246;
III: 224–225, 363;
IV: 198
Agricultural Institute,
II: 136
Central Statistics Office of Ireland,
II: 136
IRS. See Internal Revenue Service
Irvine, California,
III: 533
Ischemic heart disease,
VI: 7
Israel. See Jerusalem, Israel
Italy,
I: 320–321, 338–341, 384, 486–487, 492, 523, 537, 552, 553, 561, 566, 632;
II: 183, 229;
III: 9, 224, 230, 232, 234, 235, 271, 284–285, 294, 297, 299, 337, 358, 364, 373, 379–380, 387, 388, 516;
IV: 133, 140, 144, 147–148, 149, 208, 212, 214, 230, 278, 282, 315, 325, 336, 341, 347, 351, 354, 357, 360, 368, 372, 375, 379, 381, 425, 430, 445, 464, 472, 501, 507;
V: 5, 117;
VI: 124–125, 181, 246, 476–477
Forli Province,
III: 230
National Statistics Institute,
II: 141
Novara Province,
III: 225;
IV: 197;
VI: 124
Piedmont area,
III: 224, 232;
See also Lombardy, Italy;
Mantua, Italy;
Milan, Italy;
Palermo, Italy;
Seveso, Italy
IUGR. See Intrauterine growth retardation
J
Japan,
II: 237;
IV: 414;
V: 6, 436;
Jerusalem, Israel,
V: 508–509
Job exposure matrix,
I: 256
Johnston Island,
I: 93
Joint cancer. See Bone/joint cancer
Judgment, role of,
VI: 31
K
Kansas,
I: 9, 37, 335–336, 487, 490, 550;
II: 231;
III: 363;
IV: 215, 260, 297, 361, 369, 446
Kaposi’s sarcoma,
I: 338, 487, 695;
IV: 144, 214
See also Soft-tissue sarcoma (STS)
Khe Sanh-Thonh Son Lam area,
I: 96;
III: 140;
IV: 121
Kidney cancer
biologic plausibility,
III: 356;
IV: 348;
V: 338;
VI: 293
children and,
I: 628;
IV: 417, 420, 428
epidemiologic studies,
I: 515;
II: 224–225;
III: 352–355;
IV: 346–348;
V: 335–338;
VI: 292–296
epidemiology,
I: 513, 514;
II: 223;
III: 351–352;
IV: 345–346
herbicide association in,
I: 13, 521, 577;
II: 7, 11, 20, 139–140, 224–225, 249–250;
III: 7, 10, 352–356;
IV: 342, 346–348, 385;
V: 333–338
herbicide environmental exposure and,
III: 353, 354;
IV: 347;
V: 336, 337
herbicide occupational exposure and,
III: 353, 354;
IV: 346;
V: 334, 335, 337
histopathology,
I: 513
incidence, data by race/gender, for selected age groups,
III: 352;
IV: 334, 345–346;
VI: 292
risk factors,
I: 514;
IV: 342, 345;
V: 338
scientific literature update,
II: 224–225;
III: 353, 355;
IV: 346–347;
V: 334, 337;
VI: 293
Vietnam veterans’ risk,
I: 522;
II: 223, 224, 225;
III: 353, 355;
IV: 348;
V: 338;
VI: 296
See also Genitourinary cancers;
Wilm’s tumor
Kidneys
2,4-D toxicity in,
I: 125, 179–180;
II: 42;
IV: 28, 37, 42, 43, 66, 68, 73, 76;
V: 518
arsenic toxicity in,
IV: 39
cacolydic acid toxity in,
II: 42;
IV: 387
Korean War,
II: 150;
III: 237;
IV: 150;
VI: 135
See also South Koreans
L
Laos,
I: 106
Large-cell lymphoma,
V: 430
Laryngeal cancer,
I: 461, 470–471;
II: 202–203;
IV: 277–280;
V: 268–272;
VI: 230–234
biologic plausibility,
III: 295;
IV: 279;
V: 271–272;
VI: 234
epidemiologic studies,
III: 293–295;
IV: 277–278, 280–281;
V: 270–271;
VI: 232–233
epidemiology,
III: 292;
IV: 277
herbicide environmental exposure studies,
V: 270;
VI: 233
herbicide exposure and,
III: 293–295;
IV: 9, 277–278;
V: 268–272
herbicide occupational exposure studies,
III: 293–294;
IV: 277–278;
V: 270;
VI: 231–233
incidence, data by race/gender, for selected age groups,
III: 292;
IV: 277;
VI: 231
larynx,
IV: 6, 8, 9
scientific literature update,
III: 293–294, 295;
IV: 277–278;
V: 269;
VI: 231–234
TCDD association with,
V: 5
Vietnam veterans studies,
III: 294–295;
IV: 278;
V: 269;
VI: 233–234
See also Respiratory cancers
Latency effects in cancer studies,
I: 231–232, 434, 435, 436–438, 494, 495, 727;
II: 2, 13–14, 175;
III: 3, 12–14, 266, 407–408
aging effects control,
II: 261–262;
III: 409
arsenic and,
II: 268;
III: 420
asbestos and,
II: 268;
III: 420
data limitations,
III: 413, 414, 415, 416
data requirements,
II: 264, 265, 266;
III: 412, 414, 415, 416;
IV: 283
epidemiological studies, analysis of,
II: 261–266;
III: 408–412
epidemiological studies, new,
III: 419;
IV: 148, 254, 256, 269, 293, 329, 473, 483, 484, 506
gamma rays and,
II: 268;
III: 418
literature review results,
II: 266–267;
III: 416–418, 420–424, 426–427, 429;
IV: 257, 260, 263, 265, 271, 280, 297, 333, 343, 353, 368, 375
measurement errors,
II: 263–264;
III: 411–412
mortality and incidence studies for examining,
II: 263;
III: 410–411, 421, 422, 423, 424, 426, 427, 429
nickel and,
II: 269;
III: 420
non-Hodgkin’s lymphoma,
III: 428–430
potential problems with,
II: 264, 265, 266;
III: 413, 414, 415, 416
prostate cancer,
II: 273–275;
III: 426–428
radon daughters and,
II: 268;
III: 418
random misclassification and,
II: 263–264;
III: 411–412
relative risks,
II: 264, 265, 266, 271, 275, 351;
III: 412, 413, 414, 415, 418, 420, 422, 426–427, 428, 430–431
respiratory cancer,
II: 268–273;
III: 418, 420–426;
IV: 284, 285;
VI: 2
smoking and,
II: 268;
III: 418;
IV: 250, 273
time-related factors,
II: 262, 263–264;
III: 411–412, 421, 422, 423, 424, 426, 427, 429;
IV: 464, 465
Vietnam veterans, relevancy for,
II: 276, 351;
III: 12–13, 430–431;
IV: 466
See also Cancer
Lawn care,
I: 119, 177–178;
IV: 274
LDL. See Low-density lipoprotein receptors
Leather tanners,
I: 486, 514
Legal issues
Agent Orange manufacturers’ liability,
I: 34–35
federal government liability,
I: 34
South Korean Vietnam veterans,
I: 62
Times Beach, Missouri,
I: 41;
IV: 133
Legislation
epidemiologic studies on Agent Orange,
II: 28;
III: 26
federal,
I: 45–60;
III: 26–27
health care associated with Agent Orange,
II: 28
Public Law 91-441,
I: 47, 62
Public Law 96-151,
I: 50, 52, 57;
II: 28;
III: 26, 240
Public Law 97-72,
I: 50;
II: 28;
III: 26
Public Law 98-181,
I: 51
Public Law 98-542,
I: 50–51;
II: 28–29;
III: 26–27
Public Law 99-272,
I: 50;
II: 28;
III: 26
Public Law 100-687,
I: 51
Public Law 101-239,
I: 51
Public Law 102-4,
I: 2, 7, 20, 21, 51, 572, 721, 728–730;
II: 1, 5, 17, 19, 29, 97, 247;
III: 1, 6, 14, 17, 20, 124, 132, 390, 397, 462, 475, 519, 525;
IV: 1, 2, 6, 15, 103, 132, 388;
Public Law 102-585,
II: 28;
III: 26
Public Law 103-452,
II: 28;
III: 26
Public Law 104-110,
III: 26
Public Law 104-204,
III: 24, 26
Public Law 104-262,
III: 26
Public Law 105-114,
III: 25
Public Law 107-103,
VI: 1
Veterans’ Education and Benefits Expansion Act of 2001,
VI: 1
Veterans’ Health Programs Extension and Improvement Act of 1979,
III: 240
Vietnam veterans’ compensation,
I: 47, 50–51, 55–56;
II: 28–29;
III: 26–27
Leiomyosarcomas,
I: 475
See also Soft-tissue sarcoma (STS)
Lethality. See Deaths
Leukemia
acute lymphocytic leukemia,
III: 383, 384;
IV: 377;
V: 366
acute myelogenous leukemia,
IV: 417–429, 432;
V: 16, 366
acute myeloid leukemia,
III: 383–384;
IV: 9, 377;
V: 366
agricultural workers and,
I: 13, 332–333, 334–335, 566–568;
II: 136;
III: 387–388;
IV: 140, 143–144, 216
biologic plausibility
I: 571;
III: 390;
IV: 380–381;
V: 372, 376;
categories of herbicide association in,
V: 7
children and,
I: 628;
IV: 18, 417–424
chronic lymphocytic leukemia,
III: 384–385;
IV: 208, 211, 377, 417, 422;
V: 7, 366–367, 372–376;
chronic myeloid leukemia,
III: 384, 385;
IV: 377–378, 417;
V: 367
epidemiologic studies,
I: 564–572;
II: 136, 245–247;
III: 385–390, 391–392;
IV: 149, 198;
IV: 379–380, 381–383, 418–422, 427–429;
V: 369–372;
VI: 325–337
epidemiology,
I: 564;
II: 245;
III: 383–385;
IV: 377–378
herbicide association in,
I: 13, 571, 577–578;
II: 7, 11, 20, 245–247, 249–250;
III: 7, 10, 385–390, 391–392;
IV: 379–380, 385, 418–422;
V: 366–372
herbicide environmental exposure and,
III: 388–389, 392;
IV: 379, 419–420;
V: 368, 370–371;
VI: 332
herbicide occupational exposure and,
III: 386–388, 391–392;
IV: 379, 418–419;
V: 368, 369–370;
VI: 331–332
incidence, data by type/race/gender, for selected age groups,
III: 384;
IV: 377–378;
V: 367;
VI: 326
production workers and,
I: 564–566;
III: 386–387;
IV: 379
pulp/paper workers and,
I: 568;
IV: 379
risk factors,
I: 564;
V: 372
scientific literature update,
II: 245–246;
III: 386–389;
IV: 379–380, 418–422;
V: 368, 371;
Seveso, Italy, studies,
I: 13, 568–570, 571, 577;
III: 385, 386, 388–389, 390;
IV: 379
TCDD biologic plausibility in,
I: 571;
III: 390;
IV: 380–381, 426
Vietnam veterans’ risk,
I: 564, 570, 571–572;
II: 245, 246;
IV: 381, 426;
V: 372;
Vietnam veterans’ studies,
III: 385, 386, 389, 392;
IV: 373, 380, 420–422;
V: 371;
VI: 332–333
Lewy bodies,
V: 464;
VI: 410
Leydig cells,
II: 71, 279;
III: 445;
IV: 405;
V: 405
LH. See Luteinizing hormone
Li-Fraumeni syndrome,
V: 283;
VI: 246
Lindane,
I: 91
Lipid and lipoprotein disorders,
I: 688–690, 692;
IV: 492–497
biologic plausibility,
III: 507;
IV: 495;
V: 498;
VI: 459–463
epidemiologic studies,
I: 45;
II: 333, 334;
III: 504–506, 520–521;
IV: 479, 493–494, 496–497;
V: 494, 498;
VI: 457–463
epidemiology,
II: 333;
III: 503–504;
IV: 492–493
herbicide environmental exposure and,
III: 520;
IV: 493–494;
V: 496;
VI: 458
herbicide exposure association with,
II: 7, 21, 333–334;
III: 504–508, 520–521;
IV: 493–494
herbicide occupational exposure and,
III: 520;
IV: 493–494;
V: 495–496;
VI: 458–459
scientific literature update,
II: 334;
III: 504–506, 520, 521;
IV: 493–494;
V: 494;
VI: 458–459
TCDD in,
I: 152–153, 259–260;
II: 333, 334;
III: 505, 506, 507;
IV: 471, 474, 493–495;
V: 498
Vietnam veterans and,
II: 333;
III: 505–506, 521;
IV: 494;
V: 496–498;
VI: 463
See also Hypercholesterolemia;
Hyperlipidemia;
Liver disorders;
Metabolic and digestive disorders
Liposarcoma. See Soft-tissue sarcoma (STS)
Listeria
TCDD exposure and,
II: 68
Literature, identifying,
VI: 20–22
See also Data sources;
Scientific literature update;
specific topics
Liver cancer
background,
IV: 267
biologic plausibility,
IV: 270
children and,
I: 628
epidemiologic studies,
I: 453–455;
IV: 268–270
herbicide association in,
I: 13, 457, 577;
IV: 143, 157, 385
incidence,
VI: 222
picloram in,
I: 190
research recommendations,
I: 19, 727
risk factors,
I: 453
Seveso, Italy, studies,
I: 454–455;
IV: 269
TCDD in,
I: 116, 138–139, 142, 143;
IV: 267, 386–387, 515
Vietnam veterans and,
I: 391, 393, 455, 457;
IV: 269
See also Hepatobiliary cancers
Liver disorders
2,4-D in,
I: 179;
III: 524;
IV: 505
2,4,5-T in,
II: 42;
III: 524;
IV: 500, 505
arsenic and,
IV: 39–41
biologic plausibility,
III: 513–514, 524;
IV: 505;
V: 502
enzyme activity,
I: 155–156, 685–687, 691–692
epidemiologic studies,
I: 45;
II: 332–333;
III: 510–513;
IV: 500–504;
V: 502;
VI: 463–466
epidemiology,
II: 331–332;
III: 509–510;
IV: 498–500
herbicide occupational exposure and,
III: 510–512;
IV: 500–501
herbicides in,
I: 125;
II: 332–333;
III: 510–514;
IV: 135, 139, 141, 500–505
picloram chronic toxicity,
I: 191–192;
II: 42;
III: 524
scientific literature update,
II: 332–333;
III: 510–513;
IV: 500–504;
V: 500–501;
VI: 465–466
Seveso, Italy, studies,
I: 367;
IV: 501–502
TCDD in,
I: 115, 124, 129–130, 151–156, 165–166;
II: 42, 331–333;
III: 509;
IV: 25–30, 34, 37, 41–44, 56–60, 66–73, 77, 83, 498–505;
V: 499–500, 516–517
Vietnam veterans and,
II: 332;
III: 512–513;
IV: 502–504;
V: 501
See also Hepatomegaly;
Lipid and lipoprotein disorders;
Metabolic and digestive disorders
Lombardy, Italy,
II: 147, 299;
IV: 329
Low birthweight
biologic plausibility,
III: 458;
IV: 416–417;
V: 425;
VI: 382–383
definition,
I: 625;
IV: 413–414;
V: 422
epidemiologic studies,
III: 456–457, 459;
IV: 414–416;
V: 425;
VI: 379–383
epidemiology,
I: 625–626;
III: 454, 455, 456;
IV: 413–414
herbicide association in,
I: 14, 627–628;
II: 7, 11, 20;
III: 456–458, 459;
IV: 413–417;
V: 422–425
herbicide environmental exposure and,
III: 459;
IV: 414–416;
V: 423;
VI: 381–382
herbicide occupational exposure and,
III: 459;
IV: 414–416;
V: 423;
VI: 380–381
risk factors,
I: 625–626;
IV: 412;
V: 425
scientific literature update,
III: 457, 459;
IV: 414–416;
V: 423–424;
VI: 380–382
Vietnam veterans exposure studies,
III: 457, 459;
IV: 417;
V: 423–424, 425;
VI: 382, 383
See also Preterm delivery (PTD);
Reproductive disorders
Low-density lipoprotein (LDL) receptors,
I: 154–155;
II: 333, 334;
III: 503;
IV: 489, 492
Ludwigshafen, Germany,
III: 153, 154, 269, 297, 484, 511
Lumber industry
lumberjacks pesticide exposure,
V: 5
sawmill workers herbicide exposure,
III: 10, 156, 227–228, 338, 439–440, 447–448, 449, 452, 453, 457;
IV: 114, 142, 290, 296, 306, 307, 312, 333, 338, 343, 368, 404, 408, 418, 419, 422, 427;
V: 225;
VI: 177
See also Forests
Lung cancer
2,4-D in,
I: 177
agricultural/forestry workers and,
I: 466;
IV: 142
biologic plausibility,
III: 302;
IV: 284;
V: 278;
VI: 241
cacodylic acid and,
I: 187;
IV: 24;
V: 21
environmental exposure studies,
III: 297–298, 301;
IV: 282–283;
V: 275–276;
VI: 240
epidemiological studies,
II: 139;
III: 296–298, 300–301;
IV: 157, 210, 278, 282–284, 285–287, 473;
V: 274–277;
VI: 234–241
epidemiology,
III: 295–296;
IV: 281
herbicide association in,
I: 472;
II: 6;
III: 296–302;
IV: 282–284;
V: 21
herbicide/pesticide applicators and,
I: 326, 466–468;
II: 139;
IV: 142
incidence, data by gender/race, for selected age groups,
III: 296;
IV: 281;
VI: 235
latency and,
III: 421, 422, 423, 424
occupational exposure studies,
III: 296–297, 300–301, 421, 423;
IV: 142, 144, 282;
V: 274–275;
VI: 235–239
paper/pulp mill workers and,
I: 364, 468
production workers and,
I: 461–466;
III: 421, 423;
IV: 282
Ranch Hands,
IV: 9, 283
scientific literature update,
III: 296–298;
IV: 282–284;
V: 273, 277;
VI: 235–240
Seveso, Italy, studies,
I: 469;
III: 296, 297–298, 299, 422;
IV: 278, 282–283
TCDD and,
V: 277
TCDD association with,
V: 5
Vietnam veterans and,
I: 469–470, 472;
III: 298, 301, 424;
IV: 283, 284;
V: 278;
VI: 240–241
See also Respiratory cancers
Luteinizing hormone (LH),
II: 182, 279, 280, 281;
III: 41, 72–73, 444–445;
IV: 34, 399, 405;
V: 405
Lymphocytic leukemia. See Leukemia
Lymphopoietic cancers,
V: 5
M
Maine,
I: 60, 400, 603;
II: 292;
III: 243;
IV: 158
Malathion,
I: 87, 88, 91
Male reproductive function. See Infertility
Malignant lymphomas
2,4-D exposure and,
I: 119, 177–178
epidemiology,
II: 231;
IV: 137, 140, 143
See also Hodgkin’s disease (HD);
Multiple myeloma (MM);
Non-Hodgkin’s lymphoma (NHL)
Malignant neoplasms of heart. See Soft-tissue sarcoma (STS)
Mammary gland effects,
VI: 81
See also Breast cancer
Mangrove forests,
I: 31, 62, 90, 104
See also Forests
Manitoba, Canada,
II: 135–136, 232, 242, 246;
IV: 198
Mantua, Italy,
V: 229, 283
March of Dimes,
II: 286;
III: 435;
IV: 400;
V: 393;
VI: 355
Marine Corps. See US Marine Corps
Maryland. See Baltimore, Maryland;
Fort Detrick, Maryland
Massachusetts,
I: 60, 400–401, 405–406, 445, 470, 496, 602–603, 613, 620, 621, 622;
II: 202, 291;
III: 243, 244, 303, 310, 315, 339, 346, 349, 353;
IV: 158, 291, 298, 299, 308, 334, 339, 345, 350, 363
Cancer Registry,
III: 244
Mast cells,
I: 693
Maternal toxicity,
VI: 396
no-observed-adverse-effect level (NOAEL),
V: 35
MC-1 spray system,
I: 25
MCMI. See Millon Clinical Multiaxial Inventory
MCPA. See 4-Chloro-2-methylphenoxyacetic acid;
2-Methyl-4-chlorophenoxyacetic acid
MCPP. See 2-[4-Chloro-2-methylphenoxy]-propanoic acid
Medical Literature Analysis and Retrieval System,
I: 735
Mekong Delta,
II: 104
Melanomas
biologic plausibility,
III: 317;
IV: 305;
V: 295;
VI: 260
epidemiologic studies,
III: 313–317;
IV: 299–302, 306–308;
V: 288–294;
VI: 251–261
herbicide association with,
III: 313–317;
IV: 302–308;
V: 287–295
herbicide environmental exposure and,
III: 316;
IV: 302, 303;
V: 291–292;
VI: 256
herbicide occupational exposure and,
III: 316, 317;
IV: 302;
V: 288, 289, 290, 291, 292;
VI: 254–256
incidence of,
III: 313, 315;
IV: 299–300;
VI: 252
morbidity studies,
VI: 257–258
mortality studies,
III: 314–315, 316;
IV: 306–307;
V: 291–292;
VI: 255–256
scientific literature update,
III: 314–315;
IV: 302–304;
V: 290, 292;
VI: 254–259
Vietnam veterans studies,
III: 316, 317;
IV: 303–306;
V: 288, 289, 292, 293–294;
See also Basal/squamous cell skin cancer;
Skin cancer
Melatonin, TCDD-induced wasting syndrome and,
I: 165
Meta-analysis,
I: 243, 244;
VI: 25
Meta risk ratio (MRR),
IV: 253, 265, 267n
Metabolic and digestive disorders
biological plausibility,
II: 335;
III: 513–514;
IV: 505;
V: 502
epidemiological studies,
II: 330–331, 332–335;
III: 510–513;
IV: 500–504;
V: 502;
VI: 463–466
epidemiology,
III: 508;
IV: 498–500
herbicides association in,
II: 7, 11, 21, 330–331, 332–335;
III: 3, 510–514;
IV: 500–505
herbicides occupational exposure and,
III: 510–512;
IV: 500–501;
V: 500–501
scientific literature update,
III: 510–513;
IV: 500–504;
V: 500–501
Vietnam veterans and,
III: 510, 512–513;
IV: 502–504;
V: 502
See also Diabetes mellitus;
Hyperthyroidism;
Hypoglycemia;
Lipid and lipoprotein disorders;
Ulcers, gastrointestinal
Metabolism
energy of,
VI: 40
and half-life studies,
VI: 51–54
Methodological bias
biological stored samples, analysis,
I: 20–21, 729–730
cancer studies,
I: 436
controlling for,
I: 33, 226–227, 234–235, 242–246;
IV: 105, 108–109
healthy worker effect,
I: 230
herbicide exposure assessment,
I: 17, 257–259, 286–287, 291, 724
latency studies,
II: 263–264;
III: 408–412
proportionate mortality studies,
I: 233
recall bias,
I: 256, 601
reproductive outcome studies,
I: 591–592, 601
self-reports,
I: 270–271;
II: 109, 150
See also Methodology
Methodology
Agent Orange Study,
I: 58–59, 63–64;
II: 2
Agent Orange Working Group,
I: 19, 728
Alsea, Oregon, investigation,
I: 372–373, 598
American Legion Agent Orange study,
I: 602
assessment of strength of evidence,
I: 238–241;
II: 88–97;
III: 124–133
BASF study,
I: 312–313
biologic plausibility,
II: 88, 92;
III: 124, 128
burden of proof approach,
I: 226–227, 245
cancer expected incidence,
I: 439–440
cancer studies,
I: 435–440, 442–443, 445;
II: 175, 176;
III: 265–266
case-control studies,
I: 234–235, 256–257, 326–341;
II: 94–95;
III: 130;
VI: 9
case reports,
I: 235–236
Centers for Disease Control Birth Defects Study,
I: 611–612
Centers for Disease Control epidemiologic studies,
I: 19, 387–393, 498, 728
circulatory disease studies,
I: 699–700, 705–706, 707;
II: 335;
IV: 11, 463, 502, 506
cohort studies,
I: 229–232, 254–256, 318–323;
IV: 8–13, 28, 43, 46, 111, 114, 123–161 passim, 182–247 passim, 251–253, 256–388 passim, 402, 409, 418–422, 425–431, 473–474, 478–479, 483, 486–492, 500–509
confidence intervals,
I: 244;
IV: 19, 43, 251, 278, 342, 385, 419, 445, 472, 483, 515
consistency in,
VI: 26
controlled observational studies,
I: 228
Department of Veterans Affairs studies,
I: 393–399, 494–495;
IV: 1, 15, 133, 151, 157–158, 255, 284, 399, 421
disease latency effects,
I: 231–232, 434, 436–438, 494, 495, 727;
II: 351–357
dose-response relationship,
I: 239–230, 252;
II: 89;
IV: 40
Dow studies,
I: 307–312
epidemiologic studies evaluation,
I: 300–301;
II: 93–94;
III: 129–130;
IV: 103–109, 132–161, 182–247
evidence categories,
I: 227–237;
III: 132;
IV: 103–109 passim
experimental studies evaluation,
II: 92–93
health outcome categories for herbicide association,
I: 5–8, 223–225, 246–247;
II: 97;
III: 132;
IV: 6–12
herbicide environmental exposure assessment,
I: 262–263, 269–270;
III: 156–157
herbicide exposure, statistical association with diseases,
II: 88, 90–91;
III: 1–2, 6, 126–127;
IV: 103;
V: 22–23
herbicide exposure assessment strategies,
I: 251–259, 270–287;
III: 144–145
herbicide exposure reconstruction model evaluation,
I: 18, 289–290, 726;
II: 25
herbicide occupational exposure assessment,
I: 262–264, 269–270;
III: 150–156
immune system research,
I: 692
indirect adjustment,
I: 229
information management,
I: 735–738
judgment in,
I: 245–246;
II: 96;
III: 131–132
latency and cancer studies,
II: 261–266, 351;
III: 407–416
meta-analysis,
I: 225, 237–238, 242–243
neurological assessment,
I: 14, 641–642, 649
neuropsychiatric studies,
I: 657
new evidence integration,
II: 96;
III: 132
NIOSH studies,
I: 303–305;
II: 350–351, 356, 357;
IV: 111, 136
Nitro, West Virginia, industrial accident studies,
I: 305–307
NRC Commission on Life Sciences,
I: 63
odds ratio determination,
I: 234, 239;
II: 90;
III: 126–127;
IV: 105
Office of Technology Assessment,
I: 19, 728
paper/pulp mill worker studies,
I: 341, 364
publication bias,
II: 95–96;
III: 131;
IV: 108;
V: 27–28
Ranch Hand study,
I: 230–231, 385–386, 498, 757–762
random misclassification and latency,
II: 263–264;
III: 411–412
relative risk assessment,
I: 229, 239, 258;
II: 90, 351, 356;
III: 126, 127;
IV: 105
reproductive outcome studies,
I: 591–592
respiratory disease studies,
I: 708–709, 712–713;
II: 324
risk assessment,
I: 225–226;
II: 89;
III: 127–128
sample size and disease frequency,
I: 231, 242–243, 440, 499
Selected Cancers Study,
I: 234–235, 498
self-reports,
I: 270–271;
II: 109;
IV: 9, 113, 122, 125–126, 135, 141, 154–157, 159, 255, 262, 287, 297, 299, 304, 308, 310, 313, 320, 324, 325, 326, 335, 336–337, 339, 364, 380, 383, 402, 406, 418–419, 421–425, 484, 487, 492, 503–504, 507–509
soft-tissue sarcoma studies,
I: 482–490, 497–500
standardized mortality ratio,
I: 229–230
statistical significance/power,
I: 226–227, 243;
V: 23
TCDD biomarkers,
I: 259–262
Times Beach studies,
I: 368–370
toxicologic studies evaluation,
III: 128–129
type I error,
I: 243
type II error,
I: 243
Vietnam veterans disease risk estimation and latency,
II: 349–357
Vietnam veterans serum TCDD mean maximum estimation,
II: 349–350
See also Data sources;
Methodological bias;
Research needs;
Risk assessment methodology
2-Methyl-4-chlorophenoxyacetic acid (MCPA),
I: 700;
V: 104
6-Methyl-1,3,8-trichlorodibenzofuran,
I: 153
Michigan,
I: 374, 375, 383;
II: 113, 153, 161, 202, 308;
III: 159, 160, 218, 221, 234, 235, 243, 270, 357–358, 363, 373, 387, 388, 484, 511, 516;
IV: 133, 136, 149, 158, 231, 266, 335, 350, 355, 363, 368, 370, 381, 383, 414;
V: 117;
VI: 133
Department of Management and Budget’s Vietnam-era Bonus List,
II: 153, 161, 202, 208, 221, 225, 230, 234, 236, 246;
III: 308, 336, 353, 489
Department of Public Health,
II: 161
See also Detroit, Michigan;
Midland, Michigan;
Tecumseh, Michigan
Midland, Michigan,
III: 152, 221, 234;
IV: 149;
V: 117
Midwest Research Institute,
I: 29–30
Milan, Italy,
II: 243;
III: 232;
IV: 144
Military health care
Agent Orange legislation,
II: 28;
III: 26, 27
Department of Veterans Affairs activities,
II: 29;
III: 27
Military occupation specialty code (MOS),
II: 153;
III: 242
Military operations
Agent Orange surplus disposal,
I: 93–94
herbicide early research,
I: 25–26;
II: 27–32;
III: 25–30
herbicide (strategic) use ban,
I: 32, 45
herbicide use precautions,
I: 95
South Vietnam tactical zones,
I: 98
Vietnam distribution of personnel,
I: 81, 82
Vietnam herbicide applications,
I: 1, 3, 24, 27, 74, 84–96, 98–107, 286;
II: 26–27;
III: 135–142;
V: 229–232;
VI: 182–186
Vietnam herbicides aerial spraying,
I: 27, 85–91;
II: 26;
III: 135, 137, 138;
VI: 185
Vietnam herbicides ground spraying,
I: 94–96;
II: 26;
III: 138–140;
VI: 185
Vietnam herbicides use early objections,
I: 29, 31–32;
II: 26–27
Vietnam troop movements,
I: 52–53, 96, 273–279, 287
Vietnam US involvement,
I: 75–76, 84
See also Military records;
Operation Ranch Hand
Military personnel. See Demographic data, Vietnam veterans;
Foreign veterans;
Military health care;
Military occupation specialty code (MOS);
Military operations;
Military records;
Operation Ranch Hand;
US Air Force;
US Army;
US Army Chemical Corps (ACC);
US Coast Guard;
US Marine Corps;
US Navy;
US Special Forces;
Vietnam veterans;
Women veterans
Military records,
I: 742–743
herbicide exposure assessment use,
I: 271–280, 287–288;
II: 101;
III: 138, 140;
IV: 125
herbicide spray missions records,
I: 27, 62, 84–85, 104–106
HERBS tapes,
I: 62, 96–98;
III: 146, 148;
IV: 123–125
research recommendations,
I: 17, 724–725
Vietnam casualties,
I: 82–83
Vietnam herbicide ground spraying,
I: 94, 95;
IV: 110–111, 113–114
Vietnam service identification in,
II: 24–25, 175
Vietnam veterans in,
I: 75–80, 106;
II: 150–153
Millon Clinical Multiaxial Inventory (MCMI),
V: 449;
Milk. See Breast milk
Minnesota,
I: 37, 326, 332, 333, 468;
II: 47, 137–138, 178, 199, 325;
III: 226–227, 229, 440–441;
IV: 144, 210, 286, 306, 344, 349, 354, 362, 369, 375, 382;
Department of Agriculture,
II: 137;
III: 226, 440;
IV: 149
Minnesota Multiphasic Personality Inventory,
I: 641;
Miscarriages. See Spontaneous abortion
Missouri,
I: 621, 626, 664–665, 681;
II: 280;
III: 500;
IV: 133, 135, 148, 227, 272, 404, 484, 487, 493
See also Times Beach, Missouri;
Verona, Missouri
Mitochondrial function,
VI: 40
Mixed-function oxidase activity,
I: 131, 155, 156
MM. See Multiple myeloma
MMA. See Pentavalent monomethylarsonic acid;
Trivalent monomethylarsonous acid
Mobility factor analysis,
VI: 183
Models and modeling. See Herbicide exposure reconstruction model;
Quantitative structure-activity relationship (QSAR) models
Monsanto Company,
I: 34, 35, 38, 305–307, 444, 674, 700;
II: 114–115, 179, 182, 193, 204, 207, 220, 236;
III: 152, 171–172, 220, 348;
IV: 136, 185–186, 257, 260, 271, 290, 301, 333, 343;
V: 106–107, 131–132;
VI: 122
Montagnards,
I: 31, 371, 599
Montana,
II: 268;
III: 420;
IV: 149, 344, 349, 354, 362, 369, 375, 382
Mortality. See Child mortality studies;
Deaths;
Mortality studies;
Perinatal death
Mortality of Vietnam Veterans: The Veteran Cohort Study,
III: 273, 285–286
Mortality studies,
II: 130;
IV: 140, 141, 144, 146, 149, 156, 157, 159, 184–194, 252, 253
basal/squamous cell skin cancer,
III: 319, 321;
V: 296
cancer,
I: 442–445;
II: 133, 134, 136, 137, 185;
IV: 137, 140, 142, 143, 150, 199–200–206
circulatory disorders,
II: 335;
V: 504
death certificate data,
I: 236–237;
II: 136, 137–138
female reproductive cancers statistics,
II: 211
Finland respiratory cancer mortality and latency,
II: 271;
III: 422
Germany, in,
IV: 137, 138
latency results,
II: 263;
III: 410–411, 421, 422, 423
melanoma,
III: 314–315, 316;
V: 291–292
methodology,
I: 229–233, 435
National Institute for Occupational Safety and Health (NIOSH) conducted by,
IV: 105, 136, 251
non-Hodgkin’s lymphoma and latency,
III: 429
prostate cancer and latency,
II: 273, 274, 275, 276;
III: 426, 427;
V: 319–321
Ranch Hand baseline mortality studies,
II: 151;
IV: 151–153
respiratory cancer mortality and latency,
II: 270, 271;
III: 421, 422, 423, 424
Seveso, Italy, children study,
II: 147;
IV: 148
Seveso, Italy, males cancer mortality and latency,
II: 271, 275;
III: 422, 427;
IV: 148
standardized mortality ratio,
I: 229–230
women veterans,
II: 152–153, 201
See also Child mortality studies;
Deaths;
Perinatal death
MOS. See Military occupation specialty code
Motor/coordination dysfunction
epidemiological studies,
II: 309–310;
III: 469–470;
IV: 445–447;
VI: 410–422
herbicide association in,
I: 661–662;
II: 4, 7, 11, 21, 309–310;
III: 469–470;
IV: 443–447;
V: 452–465
herbicide environmental exposure studies,
I: 658–659;
IV: 445–447
herbicide occupational exposure studies,
I: 658;
IV: 445–447
scientific literature update,
II: 309–310;
III: 470;
IV: 445–447
Vietnam veterans’ risk,
I: 662;
II: 309, 310
See also Ataxia;
Dystonia;
Neurobehavioral toxicity;
Neurologic disorders;
Parkinsonism;
Stroke
Motor neuron disease,
V: 461
Motor/sensory/coordination problems,
I: 14, 658–662
Movement disorders. See Motor/coordination dysfunction
MPTP,
I: 661;
IV: 445, 448
MRR. See Meta risk ratio
Multiple myeloma (MM),
I: 331, 334, 335, 336, 341;
IV: 6, 8, 10, 144, 149
agricultural/forestry workers and,
I: 558–561;
II: 138–139, 238–239, 241–243;
III: 379–380;
IV: 140
biologic plausibility,
I: 563;
III: 383;
IV: 374;
V: 366;
VI: 325
epidemiologic studies,
I: 331, 334, 335, 336, 341, 557–563;
II: 138–139, 237–244;
III: 377–383;
IV: 199, 209, 211, 212, 215, 372–373, 374–376;
V: 363–366;
VI: 319–325
epidemiology,
I: 526, 528;
II: 236–237;
III: 377;
IV: 371–372
herbicide association in,
I: 10, 11–12, 563, 574, 576;
II: 6, 8, 20, 89, 236–244, 247;
III: 7, 8, 9, 20, 24, 377–383;
IV: 18, 143;
V: 14, 361–366;
VI: 15
herbicide environmental exposure and,
II: 241, 243;
III: 380, 382;
IV: 372–373;
V: 364–365;
VI: 324
herbicide occupational exposure and,
II: 237–243;
III: 378–380, 381–382;
IV: 372;
V: 363–364;
VI: 320
histopathology,
I: 527
incidence, data by race/gender, for selected age groups,
III: 377;
IV: 371–372;
V: 361;
VI: 320
paper/pulp workers and,
II: 143
production workers and,
II: 237–238;
III: 378–379;
IV: 373
risk estimates,
II: 240–241;
V: 366
scientific literature update,
III: 378–380;
IV: 372–373;
V: 362;
VI: 320–324
Vietnam veterans’ compensation,
II: 24, 30, 31
Vietnam veterans’ risk,
I: 563;
II: 231, 244;
IV: 374;
V: 366
Vietnam veterans’ studies,
III: 380, 382;
IV: 373;
V: 365;
VI: 324
See also Malignant lymphomas
Myelogenous leukemia,
Myeloid leukemia. See Leukemia
Myocardial fibrosis,
V: 505
Myocardial infarction,
I: 708;
IV: 135, 507–510
See also Cardiovascular system disorders;
Circulatory disorders
N
NAS. See National Academy of Sciences
Nasal/nasopharyngeal cancer
biologic plausibility,
III: 292;
IV: 275;
V: 268;
VI: 230
clinical description,
I: 457–458
epidemiologic studies,
II: 6, 187–189;
III: 290–291;
IV: 143, 274–276;
V: 267;
VI: 226–230
epidemiology,
I: 458–459;
II: 187–188;
III: 288–289;
IV: 273
herbicide association in,
I: 13, 19, 460, 577;
II: 2, 6, 11, 12, 20, 89, 187–189, 249–250;
III: 7, 10, 290–292;
IV: 7, 11;
V: 264–268
herbicide environmental exposure and,
II: 189;
III: 290, 291;
IV: 274–275;
V: 266;
VI: 229
herbicide occupational exposure and,
II: 188–189;
III: 290, 291;
IV: 274;
V: 266;
VI: 227
incidence, data by race/gender, for selected age groups,
III: 289;
IV: 273;
VI: 227
scientific literature update,
III: 290;
IV: 274–275;
V: 265–267;
VI: 227–230
TCDD association with,
V: 5
treatment,
I: 458
Vietnam veterans’ risk,
I: 460;
IV: 275;
V: 268
Vietnam veterans’ studies,
II: 189;
III: 290, 291;
IV: 275;
V: 266–267;
VI: 229–230
Nasal olfactory mucosa,
I: 130
National Academy of Sciences (NAS),
I: 2, 28–29, 31, 43, 47, 51, 55, 57;
II: 1, 17, 25, 29, 30, 63;
III: 1, 23, 28, 146;
IV: 1, 15;
V: 1, 12;
National Cancer Institute (NCI),
I: 9, 30, 37, 439;
II: 231;
III: 218, 363;
VI: 120
National Center for Health Statistics (NCHS),
III: 266;
IV: 249
ICD-9 cancer codes, SEER program site groupings for,
III: 537–539;
IV: 524–526;
V: 243, 531–533;
VI: 572–574
National Death Index,
II: 130, 152, 153
National Diabetes Data Group (NDDG),
III: 492, 493
National Health and Nutrition Evaluation Survey III (NHANES III),
III: 498
National Health Interview Survey (NHIS),
III: 499;
IV: 411
National Institute for Occupational Safety and Health (NIOSH),
I: 8, 12, 36–37, 260, 264, 270, 285, 303–305, 443, 478, 479, 499, 564, 573, 577, 650–651, 686, 731;
II: 13, 95, 101, 103, 105, 114–115, 128–129, 132, 178, 196, 206, 221, 229, 269, 270, 272, 273, 274, 275, 280, 309, 322, 350–351, 356, 357;
III: 11, 12, 131, 144, 162, 170–171, 218, 219–220, 306, 310, 420, 421, 424, 425, 426, 428, 445, 449, 469, 481, 500, 502;
IV: 10, 111, 133–134, 136, 182–184, 251, 257, 260, 263, 265, 268, 270–271, 277, 280, 282–283, 288, 290, 292, 295, 297, 300, 327, 331, 333, 341, 343, 346, 349, 351, 353, 356, 358, 366, 368, 372, 375, 379;
V: 10, 104–106, 128–131, 218–219, 410, 419, 487;
VI: 53, 120–122, 167, 169–171, 282, 493
National Institute of Environmental Health Sciences (NIEHS),
V: 526
National Institutes of Health (NIH),
I: 92
National Library of Medicine,
I: 735
National Medical Expenditures Survey (NMES),
III: 243;
IV: 238
National Occupational Mortality Surveillance System,
III: 231, 470
National Personnel Records Center,
I: 17, 77, 385, 724;
II: 150, 152;
III: 237, 242
National Research Council,
I: 20, 62–64
National Survey of the Vietnam Generation,
IV: 411
National Technical Information Service,
III: 29
National Toxicology Program (NTP),
I: 139–141;
IV: 284;
National Veterans Legal Services Project,
I: 60
National Vietnam Veterans Birth Defects/Learning Disabilities Registry and Data Base,
I: 741–742;
II: 292–293
National Vietnam Veterans Readjustment Study,
I: 79, 83, 655
Natural killer (NK) cells,
VI: 443
Nature,
IV: 511
Navy. See US Navy
NCHS. See National Center for Health Statistics
NCI. See National Cancer Institute
NDDG. See National Diabetes Data Group
Nebraska,
I: 9, 37, 332, 333–334, 535;
II: 139, 231, 233–234, 241;
III: 229, 363;
IV: 143–144, 211, 216, 360, 375, 382;
VI: 127–128
Nebraska Lymphoma Study,
II: 139
Neonatal death. See Perinatal death
Nerve conduction studies,
V: 466;
VI: 423
Netherlands,
I: 316–317, 323, 325–326, 443, 464, 468, 477, 558;
II: 132–133, 179, 196, 199, 220, 226, 232, 238, 243, 269;
III: 10, 223, 226, 230, 236, 348, 441–442, 490;
IV: 252–253, 256–257, 259–260, 262, 265, 293, 295–296, 302, 306, 333, 340, 343, 346, 348, 351, 353, 356, 358–360, 365, 368, 372, 374–375, 379, 381, 404–405;
V: 5;
V: 117;
VI: 127, 133, 181, 239, 242, 254, 259, 293, 331, 447, 468
Central Bureau of Statistics,
II: 133
herbicide exposure assessment,
III: 150–151
National Institute of Public Health and Environmental Protection,
II: 132–133
See also Amsterdam, Netherlands;
Rotterdam, Netherlands
Neural tube defects,
II: 297;
III: 437–438;
IV: 18, 400–405;
V: 16, 399–400;
VI: 15
See also Birth defects;
Reproductive disorders;
Spina bifida
Neurasthenia,
I: 649;
IV: 440;
V: 447
See also Cognitive/neuropsychiatric disorders
Neurobehavioral toxicity
2,4-D,
I: 180;
II: 305;
III: 473, 474
biological plausibility,
II: 314;
III: 474–475;
VI: 409
definition,
II: 304
epidemiological studies,
II: 306, 307–308, 309–310, 311, 312–313, 314;
III: 467–473;
VI: 406–410
epidemiology,
II: 304–305, 307;
III: 466, 468
evidence in epidemiological studies,
II: 314;
III: 473–474
herbicide association,
II: 305–314;
III: 3, 467–475
herbicide environmental exposure studies,
II: 306;
III: 467
herbicide occupational exposure studies,
II: 306;
III: 467
TCDD,
II: 305, 307–308, 309, 310–311, 314;
III: 469, 470–471, 474, 475;
IV: 25–26;
V: 71–72
Vietnam veterans increased risk,
II: 305, 306, 314;
III: 475–476;
VI: 410
See also Ataxia;
Cognitive/neuropsychiatric disorders;
Depressive disorders;
Motor/coordination dysfunction;
Neurologic disorders;
Peripheral nervous system (PNS) disorders;
Posttraumatic stress disorder (PTSD);
Stroke
Neuroblastoma,
I: 594;
V: 5
children and,
I: 628;
IV: 422, 425;
V: 425–432
Neurofibromatosis,
V: 283;
VI: 246
Neurologic disorders
2,4-D in,
I: 179;
II: 48;
III: 45–46, 473, 474
assessment issues,
I: 14, 641–642;
IV: 440–441
biologic plausibility,
III: 474–475;
IV: 457–459;
VI: 429–430
childhood cancer,
I: 628
classification of,
I: 640;
II: 304–305;
V: 447–448
cognitive/neuropsychiatric effects,
I: 649–658;
III: 468–469;
IV: 441–443;
V: 448–452
epidemiologic studies,
I: 44–45, 643–648;
II: 141, 305, 307, 309;
III: 467–473;
IV: 441–459;
herbicide association in,
I: 14, 657, 661, 666;
III: 467–476;
IV: 441–459
herbicide occupational exposure studies and,
I: 649–651, 658, 662–663;
III: 467
motor/coordination dysfunction,
I: 14, 658–662;
III: 469–470;
IV: 443–448
neurotoxicity,
peripheral nervous system disorders,
I: 662–666;
III: 470–473;
IV: 454–459
Seveso, Italy, studies,
I: 365–366, 523;
II: 141;
IV: 227
TCDD in,
I: 160–166;
II: 3, 75;
III: 84–85, 469, 470–471, 474, 475;
IV: 441–443, 445;
V: 60–61
Vietnam veterans’ compensation,
I: 55
Vietnam veterans’ offspring and,
I: 609, 660
Vietnam veterans’ risk,
I: 658, 662, 666;
III: 475–476;
IV: 459;
VI: 430–431
See also Chronic persistent peripheral neuropathy;
Cognitive/neuropsychiatric disorders;
Motor/coordination dysfunction;
Neurobehavioral toxicity;
Peripheral nervous system (PNS) disorders
Neuropathies. See Peripheral nervous system (PNS) disorders
New Brunswick, Canada,
III: 234;
IV: 149
New Hampshire,
I: 341, 364;
III: 232;
IV: 146, 222
New Jersey,
I: 656, 695;
II: 280;
III: 243, 500;
IV: 158, 483, 487, 493
Agent Orange Commission,
I: 60, 280–281, 401–402, 741;
II: 292
See also Newark, New Jersey
New Mexico,
I: 60, 402;
III: 243;
IV: 159
New York,
II: 202;
IV: 149, 159, 230, 291, 298, 355, 364, 371;
V: 429;
VI: 60, 364–365, 402–403, 444, 470, 495, 626
See also Binghamton, New York;
Camp Drum, New York
New York City,
V: 5
New Zealand,
I: 329–331, 373, 486, 490, 535–536, 552, 560–561;
II: 132, 134, 242;
III: 226, 229;
IV: 113, 142, 143, 149, 206, 215, 216, 297, 361, 369, 375, 404;
See also Northland, New Zealand
Newark, New Jersey,
II: 128–129;
III: 219, 220;
IV: 134–135;
V: 105
NHANES III. See National Health and Nutrition Evaluation Survey III
NHIS. See National Health Interview Survey
NHL. See Non-Hodgkin’s lymphoma
Nickel, respiratory cancer and latency,
II: 269;
III: 420
NIEHS. See National Institute of Environmental Health Sciences
NIH. See National Institutes of Health
NIOSH. See National Institute for Occupational Safety and Health
Nitro, West Virginia
industrial accident,
I: 38–39, 305–307, 597, 607, 686, 700;
II: 287;
III: 152, 220, 318;
IV: 136
NK. See Natural killer cells
NMES. See National Medical Expenditures Survey
No-observed-adverse-effect level (NOAEL),
V: 35
Non-Hodgkin’s lymphoma (NHL)
2,4-D in,
I: 256–257
age of onset,
I: 436
agricultural/forestry workers and,
I: 530–540;
II: 135, 138, 139, 232–234;
III: 364–365;
IV: 140
biologic plausibility,
III: 366;
IV: 358–359;
V: 355;
VI: 312
cytogenetic studies,
III: 365–366
epidemiologic studies,
I: 328, 329, 330, 331, 333–334, 335–338, 383, 384, 391–393, 401, 528–540, 573–574;
II: 134–135, 138, 139, 231–234;
III: 362–371;
IV: 116, 137, 199, 211, 212, 213, 214, 215, 216, 294, 356–358, 359–364;
V: 5, 345–355;
VI: 303–312
epidemiology,
I: 526, 527;
II: 231;
III: 362;
IV: 355–356
herbicide association in,
I: 8–10, 548, 573–574;
II: 5, 6, 20, 102, 108, 231–234, 247;
III: 6, 7, 20, 24, 362–371;
IV: 6, 8, 17, 384, 422, 425;
V: 14, 343–355;
VI: 16
herbicide environmental exposure studies,
I: 540–541;
II: 234;
III: 365, 369;
IV: 149, 357;
V: 5, 347–348, 351–354, 430–431;
herbicide occupational exposure and,
II: 232–234;
III: 363–365, 367–369;
IV: 142, 143–144, 146, 356;
V: 344, 345–347, 350–351;
VI: 310
histopathology,
I: 526
incidence, data by race/gender, for selected age groups,
III: 362;
IV: 355–356;
V: 344;
VI: 303
latency issues,
III: 428–430
paper/pulp workers and,
I: 540
production workers and,
I: 9, 529–530, 548;
II: 232;
III: 363–364, 429
research recommendations,
I: 19, 727
scientific literature update,
II: 232–234;
III: 363–366;
IV: 356–358;
V: 344, 350–351;
VI: 310–312
Selected Cancers Study and,
I: 234–235
Vietnam veterans and,
I: 9, 401, 526, 541–548, 549;
II: 231, 234;
III: 363, 365, 370–371;
IV: 156–157, 357–358, 359;
V: 348–350, 354, 355
Vietnam veterans’ compensation,
I: 51, 55–56;
II: 24, 29, 30, 31
Vietnam veterans’ risk,
VI: 312
See also Malignant lymphomas
Nonmelanoma skin cancer. See Basal/squamous cell skin cancer;
Skin cancer
North America,
II: 197;
III: 510
North Carolina,
IV: 202;
V: 6;
See also Agricultural Health Study (AHS)
North Dakota,
IV: 149, 344, 349, 354, 362, 369, 375, 382
Northeast Pharmaceutical and Chemical Corporation,
I: 40
Northland, New Zealand,
III: 234;
IV: 149;
VI: 133
Norway,
III: 10, 225, 442–443;
IV: 197, 209, 404;
Central Population Register,
III: 225, 442
Medical Birth Registry,
III: 225, 442
Population Registry,
III: 236
See also Frierfjord, Norway
NTP. See National Toxicology Program
Null hypothesis,
I: 225
O
Occupational herbicide exposure,
I: 5, 303;
acute and subacute transient peripheral neuropathy and,
II: 312;
IV: 10
agricultural/forestry workers,
II: 183–184, 197–198, 232–234, 238–239, 241–243;
III: 178–195, 224–232, 284–285, 335, 364–365, 379–380, 387–388;
IV: 112–113, 140–142;
basal/squamous cell skin cancer and,
III: 321, 323;
IV: 309;
V: 296, 297, 298–299
birth defects and,
II: 286–287;
III: 437;
IV: 404;
V: 394–395;
VI: 362
bladder cancer and,
III: 348, 350;
IV: 341–342;
V: 329, 330
bone/joint cancer and,
III: 303, 305;
IV: 288–289;
V: 280
brain tumors and,
III: 357–358, 360;
IV: 351;
V: 340–341;
VI: 301
breast cancer and,
II: 214–216;
III: 324–326, 328;
IV: 317;
V: 301, 302, 304
breast cancer estimated risk,
II: 218;
V: 300–301
cancer mortality,
I: 443–444;
II: 133, 134, 136, 137
cancer risk factor,
I: 442;
II: 133–135
cervical cancer and,
III: 332
childhood cancer,
IV: 418–419, 427
circulatory disorders and,
III: 515–516;
IV: 506–507;
V: 503;
VI: 467–468
colon cancer and,
V: 250–251
diabetes mellitus and,
III: 496;
IV: 483–484;
V: 487–491;
VI: 450
epidemiologic studies,
I: 303–365;
II: 3, 6–7, 113–140;
III: 170–196, 218, 219–232, 268–271, 274–280, 282–283, 284, 287, 290, 291, 293–294, 296–297, 300–301, 303, 305, 308–309, 312, 316, 317, 321, 323, 324–326, 328, 332–333, 335–336, 337, 338, 341, 344, 345, 348, 350, 353, 354, 357–358, 360, 363–365, 367–369, 372–373, 374–375, 378–380, 381–382, 386–388, 391–392, 437, 450, 454, 455, 456, 459, 467, 483–485, 489, 491, 496, 510–512, 515–516, 520;
IV: 134–147, 251–254, 257–258, 259–260, 262–263, 265–266, 268–269, 276, 277–278, 280, 285–286, 290, 292–293, 306, 307, 312, 318–319, 324, 325, 333–334, 338, 343–344, 348–349, 353–354, 359–361, 368–369, 374–375, 381–382, 404, 408, 418–419, 427, 445, 446, 473–474, 483–484, 489–490, 500–501, 506–507;
V: 104–115;
exposure assessment strategies,
I: 253–256, 258–259, 262–267, 269–270;
II: 5, 99–101, 107–108;
III: 144–145, 150–156
exposure indices development,
II: 107–108;
III: 161–162
female reproductive system cancers and,
III: 332–333;
IV: 321;
V: 311, 312, 313
gastrointestinal/digestive disorders and,
III: 510–512;
IV: 500–501;
V: 245;
VI: 465–466
gastrointestinal tract tumors and,
II: 178–179;
III: 268–271, 274–280;
IV: 251–254;
V: 245;
VI: 219
hepatobiliary cancer and,
II: 182–184, 185, 186;
III: 282–283, 284, 287;
IV: 268–269;
V: 261
Hodgkin’s disease and,
II: 235–236;
III: 372–373, 374–375;
IV: 365–366;
V: 357–358;
VI: 318
immune system disorders and,
III: 489, 491;
VI: 445
infant death and,
III: 456
infertility and,
III: 450;
IV: 406–407;
VI: 366
laryngeal cancer and,
III: 293–294;
IV: 277–278;
V: 270;
VI: 231–233
leukemia and,
III: 386–388, 391–392;
IV: 198, 379;
V: 368, 369–370;
VI: 331–332
lipid abnormalities and,
III: 520;
IV: 114–115, 117, 493;
VI: 458–459
low birthweight and,
III: 459;
IV: 414–416;
V: 423;
VI: 380–381
lung cancer and,
III: 296–297, 300–301, 421, 422, 423, 424;
IV: 282;
V: 274–275;
VI: 235–239
melanoma and,
III: 316, 317;
IV: 302;
V: 288, 289, 290, 291, 292;
VI: 254–256
multiple myeloma and,
II: 237–243;
III: 378–380, 381–382;
IV: 372;
V: 363–364;
VI: 320
nasal/nasopharyngeal cancer and,
II: 188–189;
III: 290, 291;
IV: 274;
V: 266;
VI: 227
neonatal death and,
III: 455
neural tube defects numbers,
II: 297
neurobehavioral disorders association studies,
II: 306;
III: 467
non-Hodgkin’s disease and,
II: 232–234;
III: 363–365, 367–369, 429;
IV: 356;
V: 344, 345–347, 350–351;
VI: 310
ovarian cancer and,
III: 333
production workers,
II: 182–183, 191, 193–197, 206–207, 232, 237–238;
III: 170–178, 219–224, 284, 363–364, 378–379, 386–387, 420, 423, 426, 429;
IV: 111–112,
134–140, 251–254, 271, 282, 288–289, 296–297, 302, 321, 327–329, 336, 340–341, 346–347, 351, 356, 365–366, 372, 379;
professional herbicide/pesticide applicators,
II: 198–200;
III: 182–185, 226–228;
IV: 113–114, 142–143, 404
prostate cancer and,
II: 219–220, 222;
III: 335–336, 337, 338, 341, 426, 427;
IV: 327–329;
V: 319–320;
VI: 280
pulp/paper workers,
I: 37–38, 267, 341, 364, 443, 447, 454, 468, 516, 523, 540, 561–562, 568;
II: 126–127, 184, 200, 243;
III: 196, 232;
IV: 114, 134, 252, 268
renal cancers and,
III: 353, 354;
IV: 346–347
research recommendations,
I: 15–16, 731
respiratory cancers and,
II: 190, 191–200;
IV: 282
respiratory disorders and,
III: 483–485;
IV: 473–474
sawmill workers,
III: 10, 156, 227–228, 338, 439–440, 447–448, 449, 452, 453, 457;
IV: 114
skin cancer and,
III: 312;
IV: 300, 301;
VI: 254–256
soft-tissue sarcomas,
II: 206–207;
III: 308–309;
IV: 292–293;
V: 284–285;
VI: 246
stillbirths and,
III: 454
stomach cancer and,
V: 247–248
testicular cancer and,
III: 344, 345;
IV: 336;
V: 326
thyroid homeostasis and,
VI: 479–480
uterine cancer and,
III: 333
Vietnam veteran exposure vs.,
I: 4, 285, 290
See also Herbicide exposure assessment;
Herbicides
Occupations. See Agricultural/forestry workers;
Highway workers;
Leather tanners;
Paper/pulp industry workers;
Production workers;
Professional herbicide/pesticide applicators;
Railroad workers;
Tannery workers
Odds ratio,
I: 224, 234;
II: 90;
III: 126–127;
IV: 105;
V: 22;
Office of Technology Assessment,
I: 19, 50, 52, 57, 728;
II: 28;
III: 26
OGTT. See Oral glucose tolerance test
Ohio,
I: 336, 550
See also Hancock County, Ohio
Olshan, Andrew,
III: 25
Ontario, Canada,
II: 199;
V: 5, 305, 414, 435
Ontario Farm Family Health Study,
V: 414, 435
Operation Ranch Hand,
I: 3, 4, 15, 16–17, 24, 74;
II: 5, 14, 18, 23, 54, 251, 293;
III: 6, 11, 12, 22, 23, 37, 50, 135, 136, 137, 138, 139;
IV: 13, 18, 117–119, 150–156, 160–161;
V: 10, 18;
VI: 4–6, 17, 51, 120, 134–138, 182, 220, 233, 240, 258–259, 291, 301–302, 311–312, 318, 324, 332, 406, 450, 455, 480
application techniques,
I: 25, 85–86, 87–88;
IV: 120–122
Army Chemical Corps and,
IV: 123–124
birth defects in offspring of,
IV: 18, 403–404, 408, 430;
V: 16
categorization based on potential exposure,
V: 120
chloracne and,
IV: 8, 464–466
chronic persistent peripheral neuropathy,
V: 465–466
cognitive/neuropsychiatric disorders,
V: 449–451
continuation of,
IV: 21, 160–161
diabetes mellitus,
V: 491–492
epidemiological studies,
II: 31, 32, 150–152, 154–156;
III: 28–29, 237, 438–439, 498;
IV: 9, 10, 150–156, 255, 262, 269, 272, 275–276, 278, 280, 283–284, 287, 291, 295, 298–299, 301, 303–305, 308–310, 313, 327, 329, 331–332, 334–336, 339, 342–343, 345, 347, 350, 352, 355, 357, 359, 362–363, 366, 370, 373, 376, 380, 383, 430–431, 435, 474, 479, 480, 485–488, 494, 502–504, 508–510;
V: 118–123, 177–181;
exposure assessment,
V: 232–233
herbicide formulations,
I: 88–91;
V: 230
herbicide surplus disposal,
I: 93–94
herbicide volume used, data by type,
III: 136
neurological disorders in,
IV: 442, 454–455, 459
number of military personnel in,
I: 94, 273
objectives,
I: 85
operations data,
I: 86, 87, 92, 106–107
porphyria cutanea tarda (PCT),
IV: 466–467;
V: 480
questionnaires, self-administered,
II: 109, 151;
IV: 124
research recommendations,
V: 524
spontaneous abortion,
V: 418
start of,
I: 84, 85
suspension of,
I: 27, 31, 32, 92–93;
II: 109
targeting procedures,
I: 86
TCDD half-life in,
IV: 24, 28, 43;
VI: 90
thyroid homeostasis and,
V: 513
See also Air Force Health Study (AFHS)
Operational Report Lessons Learned,
IV: 125
Oral, nasal, and pharyngeal cancer. See Nasal/nasopharyngeal cancer
Oral glucose tolerance test (OGTT),
III: 498, 500
Oregon,
I: 336–337, 341;
II: 149;
III: 230, 232, 234;
IV: 149, 231;
V: 117;
VI: 129–133
See also Alsea, Oregon
Outreach activities
Vietnam Veterans and,
II: 31;
III: 28
Ovarian cancer,
I: 338–339, 506, 510–511;
III: 333;
V: 313;
VI: 79–80
herbicide association in,
I: 13, 512;
II: 6;
III: 333;
IV: 320–323, 326, 385;
VI: 224
See also Reproductive system cancers, women
P
P450,
I: 130, 144–145, 170, 709;
II: 56, 70, 72, 74, 76;
III: 220;
IV: 27, 41–42, 47–48, 50–52, 54–55, 58–60, 63, 65, 67–69, 72–76, 78;
V: 379
PACER HO,
I: 93
PAI-2. See Plasminogen activator inhibitor
Palermo, Italy,
V: 462
Pancreatic cancer,
See also Gastrointestinal (GI) tract cancers
Paper/pulp industry workers,
cancers in,
I: 443, 454, 468, 516, 523, 540, 568;
II: 200;
IV: 114, 134, 252, 268
chemical exposures in,
I: 37–38, 267;
III: 155–156;
IV: 134, 252
epidemiologic studies,
I: 38, 341, 364;
II: 126–127, 184, 200, 243;
III: 196, 232;
IV: 134, 221–223, 252, 268;
V: 114–115, 166–167, 225;
VI: 128–129
hepatobiliary cancer,
II: 184
multiple myeloma and,
II: 243
Parkinson’s Disease (PD). See Parkinsonism
Parkinsonism,
I: 661;
II: 140, 149, 309–310;
III: 469–470, 475;
IV: 144, 443–445, 448, 458;
V: 6, 453–461, 524;
V: 453–461;
VI: 6
biologic plausibility,
VI: 419–420
epidemiologic studies,
V: 454–459;
VI: 410–420
herbicide association in,
V: 453–460, 464
scientific literature update,
V: 460–461;
VI: 411–420
Vietnam veterans’ risk,
VI: 420
See also Motor/coordination dysfunction
Parma, Italy,
IV: 445
See also Italy
PBPK. See Physiologically based pharmacokinetic model
PCBs. See Polychlorinated biphenyls
PCDDs. See Polychlorinated dibenzodioxins
PCDFs. See Polychlorinated dibenzofurans
PCMR. See Proportionate cancer mortality ratio
PCP. See Pentachlorophenol
PCT. See Porphyria cutanea tarda
PD. See Parkinson’s Disease
Pennsylvania,
I: 60, 403, 562;
II: 244;
III: 243;
IV: 186
1,2,3,7,8-Pentachlorodibenzo-p-dioxin (PnCDD),
II: 64, 65
2,3,4,7,8-Pentachlorodibenzofuran (PnCDF),
II: 64, 65
Pentachlorophenol (PCP),
II: 320;
III: 221, 511, 516;
IV: 257, 260, 263, 265, 271, 280, 285, 290, 296, 338, 353, 359, 368, 381
Pentavalent dimethylarsinic acid (DMA),
V: 39
Pentavalent monomethylarsonic acid (MMA),
V: 39
Pentoxyresorufin-O-dealkylase (PROD)
TCDD and,
II: 64
PEPCK. See Hepatic phosphoenol pyruvate carboxy kinase
Peptic ulcer disease,
VI: 464
Perimeter spraying. See Ground/perimeter spraying
Perinatal death
biologic plausibility,
III: 453, 458;
IV: 413;
V: 422;
VI: 379
definitions,
I: 618–619;
II: 284;
III: 451;
IV: 412
descriptive epidemiology,
I: 619–620;
II: 284–285;
III: 451
epidemiological studies,
I: 620–624;
II: 285–286;
III: 451–453, 454, 455, 456;
V: 421–422;
VI: 378–379
herbicide association in,
I: 14, 624;
II: 7, 11, 20, 278, 285–286;
III: 451–454, 455, 456;
IV: 413;
V: 421–422
herbicide environmental exposure and,
III: 454, 455, 456
herbicide occupational exposure and,
III: 454, 455, 456
risk factors,
I: 619–620;
V: 422
scientific literature update,
II: 285;
III: 452–453, 454, 456;
V: 421–422;
VI: 379
TCDD biologic plausibility in,
I: 624;
V: 422
Vietnam veterans and,
II: 285;
III: 454, 455, 456;
IV: 413;
V: 422;
VI: 379
Peripheral nervous system (PNS) disorders,
I: 55, 662–666;
II: 304, 312;
IV: 440;
VI: 426–427
acute and subacute transient peripheral neuropathy,
II: 2, 6, 89, 311–314;
III: 7, 8, 473;
IV: 10, 18, 457–459;
V: 14, 16, 27
biologic plausibility,
V: 470–472;
VI: 428
chronic persistent peripheral neuropathy,
II: 89, 310–311;
III: 470–472;454–456;
VI: 6
diagnosing,
V: 467–468
epidemiological studies,
II: 310–311, 312–314;
III: 470–473;
IV: 135, 454–455, 457;
V: 465–470;
VI: 423–429
herbicide association with,
I: 666;
II: 2, 6, 10, 11, 21, 89, 310–314;
III: 7, 8, 21, 470–473;
V: 454–457, 465–469;
VI: 15
herbicide environmental exposure studies,
I: 663–665;
II: 312–313
herbicide occupational exposure studies,
I: 662–663;
II: 312
methodology,
II: 311–312
scientific literature update,
II: 310–311;
III: 471, 473;
IV: 454–455, 457;
V: 466–467, 469;
VI: 426–427
Seveso, Italy, residents and,
II: 312–313
Vietnam veterans’ risk,
I: 666;
II: 311, 313;
IV: 457, 459;
VI: 429
See also Chronic persistent peripheral neuropathy;
Neurobehavioral toxicity;
Neurologic disorders
Pesticide/herbicide applicators. See Professional herbicide/pesticide applicators
Pesticides. See Agricultural herbicides;
Desiccant herbicides;
Fungicides;
Herbicides;
Insecticides;
Phenoxy herbicides;
Selective herbicides
Pharmacokinetics
2,4-D,
I: 175
2,4,5-T,
I: 182
cacodylic acid,
I: 186–187
picloram,
I: 190
TCDD,
I: 127–133, 260–261, 284;
II: 53–54;
III: 161;
IV: 41, 42, 47
TCDD-induced wasting syndrome,
I: 162–166
See also Toxicokinetics
Phenoxy herbicides,
I: 8, 9, 10, 11, 27;
III: 150, 151, 154, 222, 223, 422, 423, 429;
V: 3, 5
action of,
I: 27;
IV: 16
IARC registry and,
IV: 137
See also Herbicides
Phenoxyacetic acid,
V: 415
Phenoxyenolpyruvate carboxykinase,
I: 172
Phenoxypropionic acids,
I: 327
Philadelphia chromosome,
V: 367
Physiologically based pharmacokinetic (PBPK) model,
V: 32
Phytar 560-G,
I: 89
Picloram,
I: 88, 90, 91;
II: 4;
III: 5, 19, 135, 136, 137, 218;
IV: 5, 117–119, 133;
V: 1, 3;
VI: 1, 3, 11, 20–21, 118–119, 201, 276, 436
acute toxicity,
I: 191
animal studies,
I: 189–192;
III: 50, 396, 460
biologic plausibility,
III: 460, 524;
IV: 426
carcinogenicity,
I: 118, 119, 190–191;
II: 40;
III: 396;
V: 40
chemical properties/structure,
I: 111, 114–115, 189;
II: 38;
III: 32
chronic exposure,
I: 191–192
developmental/reproductive toxicity,
I: 192;
II: 42;
III: 460;
IV: 416, 426, 431, 434–435
domestic use,
I: 189
genotoxicity,
I: 191
immunotoxicity,
I: 122–123, 192;
II: 41
liver toxicity,
I: 125;
II: 42;
III: 524
metabolism,
I: 115, 116
neurologic effects,
V: 40
pharmacokinetics,
I: 190;
IV: 27–28
toxicity profile update,
II: 51;
III: 50;
IV: 22–24, 31, 33–34, 40–41;
V: 40, 79;
volume used in Operation Ranch Hand, data,
III: 136;
IV: 117
PKC. See Protein kinase C
Plantation workers. See Agricultural/forestry workers
Plasminogen activator inhibitor (PAI-2),
II: 74
Plasmodium, TCDD exposure and,
II: 68
Plausibility. See Biologic plausibility
Pleurisy,
I: 711, 713
See also Respiratory disorders
PMR. See Proportionate mortality ratio
PnCDD. See 1,2,3,7,8-Pentachlorodibenzo-p-dioxin
PnCDF. See 2,3,4,7,8-Pentachlorodibenzo-furan
Pneumoconiosis,
I: 713
See also Respiratory disorders
Pneumonia,
I: 710, 713
See also Respiratory disorders
PNS. See Peripheral nervous system disorders
Pointman Project,
I: 60, 280, 401–402, 656
Poland,
VI: 380
Polychlorinated biphenyls (PCBs),
II: 64, 67, 68, 182, 329;
III: 236, 515;
IV: 138, 399;
V: 27, 305, 478
Polychlorinated dibenzodioxins (PCDDs),
I: 126, 327;
II: 53, 64, 133, 149, 320, 329;
III: 153, 154, 156, 160, 221, 223, 236, 511, 515, 516;
IV: 111–112, 114;
V: 487, 503;
Polychlorinated dibenzofurans (PCDFs),
II: 53, 64, 68, 149, 320, 329;
III: 153, 154, 160, 223, 236;
Polymorphonuclear neutrophils,
I: 148
Population characteristics. See Age and aging;
Deaths;
Demographic data, Vietnam veterans;
Gender;
Perinatal death;
Race/ethnicity
Porphyria,
I: 153–154
Porphyria cutanea tarda (PCT)
biological plausibility,
II: 323;
III: 482;
IV: 468;
V: 480;
VI: 440
clinical features,
I: 679;
IV: 466–467;
V: 479
epidemiologic studies,
I: 680–682;
II: 6, 129, 321–323;
III: 481–482;
IV: 194, 467–468;
V: 480;
VI: 439–440
epidemiology,
II: 321;
III: 480–481;
IV: 10, 466–467
herbicide association in,
I: 10, 682;
II: 5, 6, 10, 20, 129, 321–323;
III: 7, 8, 20, 24, 481–482;
IV: 17, 18, 135, 183, 467, 468;
V: 14;
scientific literature update,
II: 322–323;
III: 482;
IV: 467–468;
V: 480;
VI: 439–440
Vietnam veterans’ compensation,
I: 50, 55;
II: 24, 28–29, 30, 31
Vietnam veterans’ risk,
I: 682–683;
II: 321, 322, 323;
III: 481, 482;
IV: 468;
V: 480;
VI: 439–440
See also Skin sensitivity
Posttraumatic stress disorder (PTSD),
I: 397–398, 653–656, 658;
II: 304, 308;
IV: 440;
V: 447;
VI: 379–383
See also Cognitive/neuropsychiatric disorders
PR. See Prevalence ratio
Prague, Czech Republic,
III: 224
Preterm delivery (PTD),
III: 454, 455, 456–458, 459;
IV: 400, 413, 416, 432;
V: 422–425;
VI: 379–383
See also Low birthweight
Prevalence ratio (PR),
V: 460
PROD. See Pentoxyresorufin-O-dealkylase
Production workers
bladder cancer,
I: 513–517;
IV: 341–342
brain cancer,
I: 523;
IV: 351
cancer mortality,
I: 443–444;
II: 133, 134, 270, 273, 274;
III: 423, 426, 429;
IV: 251, 268
chemical industry production workers studies,
I: 303–318;
II: 114–118, 128–135, 171–175, 182–183, 191, 193–197, 206–207, 232, 237–238, 273–274, 275;
III: 170–178, 219–224, 363–364, 378–379, 386–387, 422, 423, 426, 429;
IV: 270, 292;
V: 3
chloracne,
I: 674–676
circulatory disorders,
I: 700–701;
IV: 506–507
diabetes mellitus,
I: 684;
IV: 483–484
epidemiologic studies,
I: 36–37, 303–318;
II: 113, 114–118, 128–135, 182–183, 191, 193–197, 232, 237–238;
III: 170–178, 219–224, 284, 363–364, 378–379, 386–387;
IV: 182–197, 300, 312;
V: 105–109, 128–142, 218–222;
female reproductive/breast cancer,
I: 508–510;
IV: 317, 321
gastrointestinal tract cancers,
I: 447;
IV: 251–254
gastrointestinal ulcers,
I: 691
German herbicide employees, exposure assessment,
II: 4–5, 105, 108;
III: 423, 429
hepatic enzyme dysfunction,
I: 686, 687
hepatobiliary cancers,
I: 453–454, 455;
II: 182–183;
III: 284;
IV: 268–269
herbicide exposure assessment,
I: 264–265;
II: 103, 105, 107–108;
III: 150–154
Hodgkin’s disease,
I: 9;
IV: 365–366
immune system disorders,
I: 697–698
international register of workers exposed to phenoxy herbicides,
II: 131–135;
III: 175–177, 222–223
latency and cancer,
II: 269, 270, 272, 273–274, 275;
III: 422, 423, 426, 429;
IV: 284, 293
leukemia,
I: 564–566, 570–571;
III: 386–387;
IV: 379
lipid abnormalities,
I: 688–689;
IV: 493
multiple myeloma,
I: 557–578;
II: 237–238;
III: 378–379;
IV: 372
nasal/nasopharyngeal cancers,
I: 458, 459;
IV: 274
neurologic/neuropsychiatric disorders,
I: 649, 650–651, 662–663
non-Hodgkin’s lymphoma,
I: 9, 529–530, 548;
II: 134, 135, 232;
III: 363–364, 429;
IV: 356
porphyria cutanea tarda,
I: 680;
II: 129
prostate cancer,
I: 518;
II: 273–274, 275;
III: 426, 427;
IV: 327–329
renal cancer,
I: 515;
IV: 346–347
reproductive outcomes,
I: 596–598, 607, 620, 621
respiratory cancer,
I: 10, 461–466, 471;
II: 191, 193–197, 269, 270, 272;
III: 423;
IV: 282
respiratory disorders,
I: 709–710;
IV: 273–274
skin cancer,
I: 502;
IV: 300, 301
soft-tissue sarcoma,
I: 8, 477–479, 499;
II: 132, 134–135, 206–207;
IV: 292–293
testicular cancer,
I: 519;
IV: 336
See also Industrial accidents
Professional herbicide/pesticide applicators
cancer in,
I: 320–321, 323, 325–326, 443, 447, 466–468, 488, 491;
II: 137–138, 198–200;
III: 422;
IV: 321, 327–328, 330, 336
cohort studies,
IV: 202–206;
V: 112–113;
VI: 125–127
epidemiologic studies,
I: 323–326, 447, 466–468;
II: 120–126, 137–140;
III: 182–185, 226–228;
IV: 142–143, 144–145;
V: 224–225;
VI: 119
Finland respiratory cancer mortality and latency,
II: 271;
III: 422
herbicide exposure assessment,
I: 266–267;
II: 107–108;
III: 155;
IV: 113–114
reproductive outcomes,
I: 324–325;
IV: 410
See also Herbicide application methods;
Herbicides
Prolactin,
I: 165
Proportionate cancer mortality ratio (PCMR),
II: 179, 183, 197–198, 203, 204–205, 207, 210, 212, 216, 219, 224, 226, 227, 229, 233, 235, 246
Proportionate mortality ratio (PMR),
I: 232–233;
II: 161, 180, 185, 208, 225, 230, 234, 236, 242, 246;
III: 417–418, 428;
IV: 253, 369
Prostate cancer
biologic plausibility,
III: 343;
IV: 332;
VI: 282–283
epidemiologic studies,
I: 518–519;
II: 6, 219–223;
III: 335–342;
IV: 202, 327–329, 330–331, 333–335;
V: 319–323;
VI: 275–283
epidemiology,
I: 513, 514–515;
II: 217, 219;
III: 334;
IV: 326–327
herbicide association in,
I: 10, 11, 519–521, 575–576;
II: 2, 6, 8–9, 20, 89, 217–223, 247;
III: 7, 8, 9, 20, 335–343;
IV: 6, 8, 10, 18;
V: 14, 316–324;
VI: 15
herbicide environmental exposure studies,
II: 221, 222;
III: 336, 338, 342;
IV: 329;
V: 320–321, 322;
VI: 281
herbicide occupational exposure studies,
II: 219–220, 222;
III: 335–336, 337, 338, 341;
IV: 202, 327–329;
V: 319–320;
VI: 280
histopathology,
I: 513
incidence, data by race, for selected age groups,
III: 334;
IV: 249, 326–327;
V: 317;
VI: 276
latency issues,
II: 13, 14;
III: 426–428
morbidity and mortality,
VI: 277–280
mortality and latency,
II: 273, 274, 275;
III: 426, 427;
V: 319–321
research recommendations,
I: 19, 727;
V: 524
risk, estimated,
II: 222–223;
V: 324
scientific literature update,
III: 336–339;
IV: 74, 327–331;
V: 318, 322;
VI: 280–281
Seveso, Italy, male mortality and latency,
II: 275;
III: 336, 338, 427;
IV: 329
TCDD association with,
V: 63–64;
VI: 79
Vietnam veterans’ risk,
I: 11, 518, 519, 522;
II: 221, 223;
III: 343, 431;
IV: 332;
V: 324;
VI: 283
Vietnam veterans’ studies,
III: 336, 338, 339, 340, 342;
IV: 329;
V: 321, 322;
VI: 281
See also Genitourinary cancers
Protein kinase C (PKC),
II: 4, 52, 59, 60, 61, 62;
III: 65–67, 105;
IV: 69–71, 72
Psychiatric disorders
assessment for,
I: 641
epidemiological studies,
I: 649–657
herbicide association in,
I: 14, 657;
IV: 135, 151
posttraumatic stress disorder,
I: 397–398, 653–656, 658;
IV: 440
PTD. See Preterm delivery
PTSD. See Posttraumatic stress disorder
Public concern,
I: 1, 2, 23–24, 29–32, 35–36, 39
federal government response to,
I: 45–60;
II: 27–32;
III: 25–30
Public Law 91-441,
I: 47, 62
Public Law 96-151,
I: 50, 52, 57;
II: 28;
III: 26, 240
Public Law 97-72,
I: 50;
II: 28;
III: 26, 240
Public Law 98-181,
I: 51
Public Law 98-542,
I: 50–51;
II: 28–29;
III: 26–27
Public Law 99-272,
I: 50;
II: 28;
III: 26
Public Law 100-687,
I: 51
Public Law 101-239,
I: 51
Public Law 102-4,
I: 2, 7, 20, 21, 51, 572, 721, 728–730;
II: 1, 5, 17, 19, 29, 97, 247;
III: 1, 6, 14, 17, 20, 124, 132, 390, 397, 462, 475, 519, 525;
IV: 1, 2, 6, 15, 103, 388;
V: 1–3, 12–13;
Public Law 102-585,
II: 28;
III: 26
Public Law 103-452,
II: 28;
III: 26
Public Law 104-110,
III: 26
Public Law 104-204,
III: 24, 26
Public Law 104-262,
III: 26
Public Law 105-114,
III: 25
Public Law 107-103,
VI: 1
Public meetings,
VI: 569–570
Publication bias,
VI: 30
Pulmonary system
TCDD absorption,
I: 129;
IV: 135, 156;
V: 71
toxicity in,
VI: 70
Vietnam veterans disorders,
I: 402
See also Chronic obstructive pulmonary disease (COPD);
Respiratory cancers;
Respiratory disorders
Pulp. See Paper/pulp industry workers
Q
QSAR. See Quantitative structure-activity relationship models
Quail Run mobile home park,
I: 268, 369–370, 455, 665, 681, 687, 694;
II: 144, 184;
III: 200–201, 234, 283;
IV: 115, 148;
V: 116, 171–172
Quantitative structure-activity relationship (QSAR) models,
III: 106;
V: 27;
VI: 84
Questionnaires,
II: 109, 136, 150, 292;
IV: 111, 124
R
RA. See Retinoic acid
Race/ethnicity
acute lymphocytic leukemia incidence, data by race,
III: 384;
IV: 378;
VI: 326
acute myeloid leukemia incidence, data by race,
III: 384;
IV: 378;
VI: 326
bladder cancer incidence, data by race,
III: 347;
IV: 340;
V: 328;
VI: 287
bone/joint cancer incidence, data by race,
III: 302;
IV: 288;
VI: 242
brain tumor incidence, data by race,
III: 356;
IV: 351;
V: 339;
VI: 297
breast cancer incidence, data by race,
III: 324;
IV: 314;
VI: 265
cancer studies and,
II: 179, 180, 181, 183, 214, 219, 227, 237;
IV: 249–250
cardiovascular disorders, adjusted by,
IV: 494, 507
chronic lymphocytic leukemia incidence, data by race,
III: 384;
IV: 378;
VI: 326
chronic myeloid leukemia incidence, data by race,
III: 384;
IV: 378;
VI: 326
diabetes prevalence, data by race,
III: 492;
IV: 484–486, 492
female reproductive system cancer incidence and other effects, data by race,
III: 330;
IV: 321, 414, 421, 423, 429;
VI: 271
gastrointestinal tract cancer incidence, data by race and cancer type,
III: 267;
IV: 250;
VI: 204
Hodgkin’s disease incidence, data by race,
III: 372;
IV: 365;
V: 355;
VI: 313
laryngeal cancer incidence, data by race,
III: 292;
IV: 273;
VI: 231
leukemia incidence, data by type and race,
III: 384;
IV: 378;
VI: 326
liver/intrahepatic bile duct cancer incidence, by race,
III: 282;
IV: 267, 502;
VI: 222
lung cancer incidence, data by race,
III: 296;
IV: 281;
VI: 235
melanoma incidence, data by race,
III: 313;
IV: 300;
VI: 252
motor dysfunction, adjusted by,
IV: 444
multiple myeloma incidence, data by race,
III: 377;
IV: 372;
V: 361;
VI: 320
nasal/nasopharyngeal cancer incidence, data by race,
III: 289;
IV: 273;
VI: 227
non-Hodgkin’s lymphoma incidence, data by race,
III: 362;
IV: 356;
V: 344;
VI: 303
prostate cancer incidence, data by race,
III: 334;
IV: 326–327;
VI: 276
renal cancers incidence, data by race,
III: 352;
IV: 346;
VI: 292
risk adjusted by,
IV: 135, 150–152, 154–156
soft-tissue sarcoma incidence, data by race,
III: 306;
IV: 292;
VI: 245
testicular cancer incidence, data by race,
III: 343;
IV: 335;
V: 324;
VI: 283
Vietnam veterans,
I: 81, 82, 83, 84;
II: 180
See also Alaskan natives;
Asian Americans;
Demographic data, Vietnam veterans
Radiation exposure,
I: 564, 595
Radon daughters
respiratory cancer and latency,
II: 268;
III: 418
Railroad workers,
I: 323–324, 467, 486, 649–650, 658;
IV: 206
Ranch Hand study. See Air Force Health Study (AFHS);
Operation Ranch Hand
RARb. See Retinoic acid receptor b
Ratio. See Odds ratio
Reagan, Ronald,
III: 26
Rectal cancer,
VI: 214–216
See also Gastrointestinal (GI) tract cancers
Registries. See Agent Orange Registry (AOR);
Dioxin Registry;
European registry;
National Vietnam Veterans Birth Defects/Learning Disabilities Registry and Data Base
Regression analysis,
II: 281
Relative risk,
I: 224, 229, 230, 239, 258;
II: 90, 178, 264, 265, 266, 271, 275, 297, 351, 356;
III: 126–127, 412, 413, 414, 415, 418, 420, 422, 426–427, 428, 430–431;
IV: 83, 105, 138, 142, 153, 254, 277, 278, 282, 284, 303, 310, 315, 321, 322, 329, 331, 332, 366, 373, 379, 424, 447, 472, 500;
Relevant literature, identifying,
VI: 20–22
Renal cancer. See Kidney cancer
Renal toxicity
cacodylic acid and,
II: 50–51
TCDD and,
II: 77;
III: 75–76;
IV: 76–77
Reproductive disorders,
2,4-D in,
I: 180–181;
II: 42, 280–282;
III: 46, 460, 461–462;
IV: 416
2,4,5-T in,
I: 185;
II: 42, 280–282, 287;
III: 462;
IV: 404;
IV: 416
animal studies,
I: 123–124;
III: 460–462;
IV: 426, 431–435
biologic plausibility,
II: 300;
III: 444, 451, 453, 458, 460–462;
IV: 416, 426
cacodylic acid in,
I: 189;
II: 42;
IV: 403, 407, 411, 413, 416, 431, 435
epidemiologic studies,
III: 436, 437–438, 443, 445–449, 450, 451–453, 454, 455, 456–457, 459;
IV: 135, 153, 209, 227, 228, 233, 431;
IV: 416, 426;
VI: 354–403
herbicide association in,
I: 13–14, 605, 634;
II: 6, 7, 278–279, 300–301;
III: 3, 434–435, 436–444, 445–454, 455, 456–458, 459;
IV: 135
male-mediated,
I: 593–595;
III: 444–451;
IV: 413
methodological approach to study of,
I: 591–592
occupational risk factors,
I: 594–595;
IV: 399–400, 402, 404, 408, 418–419
picloram in,
I: 192;
II: 42;
III: 462;
IV: 403, 413, 416, 431
Ranch Hand study,
I: 758–762;
II: 293–295;
III: 436, 438, 439, 446–447, 449, 452–453, 457–458;
IV: 233
research recommendations,
I: 727
TCDD in,
I: 123–124, 156–159;
II: 3, 41–42, 71–72, 282, 285–286;
III: 92–105, 446–449, 460–461, 462;
IV: 26, 81–82, 416;
V: 64–65, 72–73
Vietnam veterans’ increased disease risk,
II: 278, 298, 300–301;
III: 444, 462;
IV: 417, 426, 431;
VI: 398
See also Birth defects;
Cervical cancer;
Endometrial cancer;
Hypospadias;
Infertility;
Intrauterine growth retardation (IUGR);
Low birthweight;
Neural tube defects;
Ovarian cancer;
Perinatal death;
Preterm delivery (PTD);
Reproductive system cancers, women;
Sex ratio;
Sperm parameter disorders;
Spontaneous abortion
Reproductive system cancers, women,
I: 13, 14, 505–512, 577;
II: 6;
IV: 320–326;
V: 309–316;
VI: 79–81
biologic plausibility,
III: 334;
IV: 323;
V: 316;
VI: 275
epidemiologic studies,
I: 508–512;
II: 211–213;
III: 330–334;
IV: 321–326;
V: 311–316;
VI: 270–275
epidemiology,
I: 505, 506–508;
II: 211;
III: 329–330;
IV: 320–321
herbicide association in,
I: 13, 14, 512, 577;
II: 6, 11, 20, 211–213, 249–250;
III: 7, 10, 330–334;
IV: 7, 11, 323, 385;
V: 309–316
herbicide environmental exposure and,
III: 333;
IV: 321–322, 325, 326–329, 334;
V: 311, 312, 313, 314
herbicide occupational exposure and,
III: 332–333;
IV: 321;
V: 311, 312, 313
histopathology,
I: 506
incidence and mortality statistics,
II: 211;
III: 329–330;
IV: 321;
VI: 270–271
scientific literature update,
II: 212;
III: 331–332;
IV: 321–324;
V: 313–315;
VI: 271
Vietnam veterans’ risk,
I: 512;
II: 211, 213;
III: 334;
IV: 323–324;
V: 316;
VI: 275
Vietnam veterans’ studies,
III: 333;
IV: 322–323;
V: 311, 312, 313, 314–315
See also Breast cancer;
Cervical cancer;
Ovarian cancer;
Reproductive disorders;
Uterine cancer
Reproductive toxicity,
VI: 38–39
Request for Proposals (RFP),
II: 25, 26;
III: 6, 126, 150;
IV: 5, 126–127
Research
Department of Veterans Affairs efforts,
II: 29–30;
III: 27–28;
IV: 151, 157–58
experimental studies update,
II: 43–45
herbicide exposure and cancer latency, literature review,
II: 266–275;
III: 416–431
herbicide exposure assessment strategies, recent literature,
II: 104–109;
III: 157–162;
IV: 5
publication bias,
II: 95–96;
III: 131;
IV: 108;
V: 27–28
See also Research needs
Research needs
age and aging,
V: 10
biomarkers,
I: 17, 725;
II: 25
cost of,
I: 727
health outcome priorities,
I: 19, 726–727
herbicide exposure assessment,
I: 4, 15, 16–17, 287–290, 291, 721–722, 724–728
herbicide occupational exposure data,
I: 731
Hodgkin’s disease,
I: 19, 727
military records,
I: 17, 724–725;
II: 24–25
motor/coordination dysfunction,
I: 660–661
neurobehavioral functioning,
I: 657
recommendations for,
I: 15–21, 721–731;
II: 23–24;
III: 23;
IV: 13;
research management,
I: 16, 17–18, 723–724, 726
risk assessment,
I: 731
serum mandated testing,
I: 21, 730
Vietnamese population studies,
I: 731;
Respiratory cancers
agricultural/forestry workers and,
I: 466;
II: 197–198
arsenic and, latency,
II: 268;
III: 420
asbestos and, latency,
II: 268;
III: 420
epidemiologic studies,
I: 461–472;
II: 189–203;
IV: 274–275, 276, 277–278, 280, 285–287
epidemiology,
I: 460–461;
II: 189–191;
IV: 273–274, 277, 281
Finland male herbicide/pesticide applicators mortality and latency,
II: 271;
III: 422
gamma rays and, latency,
II: 268;
III: 418
herbicide association in,
I: 10–11, 19, 574–575;
II: 6, 8, 20, 89;
II: 189–203, 247, 269–273;
III: 7, 8, 9, 20, 24;
IV: 6, 8, 18, 275, 279, 284;
V: 14;
VI: 15
herbicide environmental exposure and,
II: 190, 193, 200–201;
IV: 274–275, 278, 282–283
herbicide occupational exposure and,
II: 190, 191–200;
IV: 274, 277, 282
latency issues,
II: 13–14, 268–273;
III: 418, 420–426;
VI: 2
literature review,
II: 269–272;
III: 420–424
nickel and, latency,
II: 269;
III: 420
paper/pulp workers and,
I: 468–469;
II: 200
production workers and,
I: 461–466;
II: 191, 193–197;
III: 420, 422, 423, 429;
IV: 277, 282
professional herbicide/pesticide applicators,
II: 198–199
radon daughters and, latency,
II: 268;
III: 418
relative mortality and latency,
II: 270;
III: 421, 422, 423, 424
risk estimates,
II: 190, 192–193
risk factors,
I: 461
Seveso, Italy, men lung cancer mortality,
II: 271;
III: 422, 424;
IV: 278
Seveso, Italy, outcomes,
I: 469;
IV: 275, 278, 282–283
smoking and, latency,
II: 268;
III: 418
Vietnam veterans’ compensation,
I: 55;
II: 24, 30, 31
Vietnam veterans’ risk,
I: 460–461, 469–470, 472;
II: 190, 201–202, 203;
III: 430–431;
IV: 275–276, 279, 283, 284
See also Laryngeal cancer;
Lung cancer;
Respiratory disorders
Respiratory disorders
biologic plausibility,
III: 486;
IV: 475;
V: 482;
VI: 443
cofounding factors,
V: 481
epidemiologic studies,
II: 324–326;
III: 483–486;
IV: 272–274;
V: 6;
VI: 440–443
epidemiology,
III: 482–483;
IV: 468–471
herbicide association in,
I: 14, 713;
II: 7, 11, 21, 324–336;
III: 3, 483–486;
IV: 275;
V: 482
herbicide occupational exposure and,
III: 483–485;
IV: 273–274
paper/pulp mill workers and,
I: 341, 364
production workers and,
I: 709–710;
IV: 273–274;
V: 6
research methodology,
I: 708–709, 712–713;
II: 324
scientific literature update,
II: 325;
III: 483–486;
IV: 272–274;
V: 482;
VI: 442
TCDD in,
I: 170, 472, 709–710, 712, 713–714;
III: 484;
IV: 468, 471–475;
V: 481
Vietnam veterans’ risk,
I: 713–714;
III: 485–486;
IV: 275;
V: 483;
VI: 443
See also Asthma;
Bronchitis;
Chronic obstructive pulmonary disease (COPD);
Emphysema;
Influenza;
Pleurisy;
Pneumoconiosis;
Pneumonia;
Respiratory cancers;
Tuberculosis
Retinoic acid (RA),
II: 73;
III: 53, 73, 98
Retinoic acid receptor b (RARb),
II: 73
RFP. See Request for Proposals
Rhabdomyosarcoma. See Soft-tissue sarcoma (STS)
Ribonucleic acid (RNA),
II: 55, 58, 59, 62, 74, 75;
III: 80, 82, 99, 101, 102, 103, 104
Richter’s syndrome,
VI: 334
Risk assessment, Vietnam veterans,
I: 5, 14–15, 221, 225–226, 246, 247–248, 578;
II: 14, 22–23, 91;
III: 14–15, 22–23, 127–128, 475–476, 525;
IV: 388, 517;
amyloidosis,
IV: 513;
V: 507
birth defects,
I: 618;
II: 298, 300–301;
V: 405
bone/joint cancer,
I: 474–475;
IV: 290;
V: 282
breast cancer risk,
II: 218;
III: 329;
IV: 318;
V: 309
cancer,
I: 440, 442–443, 578;
II: 251, 276;
III: 397, 430–431
cancer in offspring,
I: 630–631;
IV: 426
chloracne,
I: 678–679;
II: 321;
IV: 466;
V: 479
circulatory disorders,
I: 708;
IV: 510;
V: 506
diabetes mellitus,
I: 692;
III: 503;
IV: 489;
V: 492
disease risk methodology,
II: 349–357
female reproductive system cancers,
I: 512;
III: 334;
IV: 323;
V: 316
fetal/infant death,
I: 625;
IV: 413
gastrointestinal cancers,
I: 452;
IV: 356;
VI: 221
genitourinary tract cancers,
I: 522
hepatic enzyme disorders,
I: 692;
IV: 505
hepatobiliary cancers,
I: 457;
II: 187;
IV: 270
Hodgkin’s disease,
I: 557;
IV: 367;
V: 361
immune system disorders,
I: 699;
III: 491;
IV: 481;
V: 485
impossible to quantify,
VI: 17
leukemia,
I: 571–572;
IV: 381;
V: 372
linear extrapolation of exposure and risk,
II: 356
lipid abnormalities,
I: 692;
III: 507–508;
IV: 495
low birthweight outcomes,
I: 628;
IV: 417
motor/coordination dysfunction,
I: 662
multiple myeloma,
I: 563;
IV: 374;
V: 366
nasal/nasopharyngeal,
I: 460;
IV: 275
neuropsychiatric outcomes,
I: 658
non-Hodgkin’s lymphoma,
I: 549;
IV: 359;
V: 355
peripheral nervous system disorders,
I: 666;
II: 314;
IV: 459
porphyria cutanea tarda,
I: 682–683;
II: 323;
IV: 468;
V: 479
prostate cancer risk,
II: 223;
III: 343;
IV: 332;
V: 324
reproductive outcomes,
I: 634;
II: 300–301;
IV: 407, 431
respiratory cancer,
I: 472;
II: 190, 192–193;
IV: 279, 284
respiratory disorders,
I: 713–714;
IV: 475;
V: 483
skin cancer,
I: 505;
IV: 305–306, 311
soft-tissue sarcoma,
I: 500;
IV: 17, 296;
V: 287
spina bifida in offspring,
II: 298, 301;
IV: 403
spontaneous abortion,
I: 605;
IV: 411;
V: 417–418
TCDD concentrations with time after exposure,
II: 356–357
TCDD serum levels back-extrapolated to measure dose,
II: 357
TCDD serum levels linear extrapolation,
II: 356
TCDD serum levels use to estimate disease risk,
II: 350–357
See also Relative risk
Risk assessment methodology,
I: 5, 221, 246
EPA dioxin research,
I: 59–60
predisposing factors,
I: 731
relative risk determination,
I: 224, 229, 258;
II: 351, 356;
IV: 105;
V: 22–23
standardized mortality ratio in,
I: 229–230
strength of association in,
I: 239
terminology,
I: 224
Vietnam veterans’ disease risk estimation,
II: 349–357;
IV: 17
Vietnam veterans’ TCDD concentrations with time after exposure,
II: 356–357
Vietnam veterans’ TCDD serum levels back-extrapolated to measure dose,
II: 357
Vietnam veterans’ TCDD serum levels linear extrapolation,
II: 356
Vietnam veterans’ TCDD serum levels use to estimate disease risk,
II: 350–357;
IV: 182
RNA. See Ribonucleic acid
Ronnel®,
II: 128;
III: 219;
IV: 134;
V: 105
Rotterdam, Netherlands,
III: 236;
V: 512
Rung Sat Special Zone,
I: 100, 104, 105, 106
Russia,
II: 319
See also Chapaevsk, Russia;
USSR
S
Salmonella, TCDD exposure and,
II: 68
Samara region. See Chapaevsk, Russia
Saskatchewan, Canada,
II: 135–136, 200, 232, 242, 246, 325;
III: 232;
V: 6, 504
Sawmills. See Lumber industry
Schistosoma haematobium,
III: 347;
V: 328
Scientific literature update,
IV: 27–32, 104–105, 108, 248–388 passim, 399–435 passim;
V: 4–6
SCL-90-R. See Symptom Checklist-90-Revised
Scotland,
V: 462
Seasonal factors
herbicide distribution and,
I: 26, 87
SEER. See Surveillance, Epidemiology, and End Results program
Selected Cancers Study
exposure assessment use,
II: 101;
III: 146, 231, 240
goals,
I: 59, 387, 391;
VI: 139
hepatobiliary cancers,
II: 185;
III: 283
Hodgkin’s disease in,
I: 554–556
liver cancer in,
I: 455
methodology,
I: 57, 234–235, 243, 258, 391–393, 440, 527
nasal/nasopharyngeal cancer,
I: 459;
II: 189
non-Hodgkin’s lymphoma in,
I: 9, 541–543, 573;
II: 231;
IV: 17
soft-tissue sarcoma in,
I: 493, 498
Selective herbicides,
I: 24, 88
See also Herbicides
Self-Report Symptom Inventory,
I: 641
Senate Committee on Veterans Affairs,
II: 24, 27–28;
III: 23–24, 25
Sensory dysfunction. See Neurologic disorders
Serontonergic system,
I: 166
Sertoli cells,
V: 405
Serum levels, TCDD,
I: 4, 19, 21, 261, 281–285, 289, 290, 725, 728, 729, 742–743;
II: 4–5, 104–106;
III: 140–142, 146–147;
IV: 37, 46, 112, 114, 125–126, 252, 293, 331
back-extrapolated serum TCDD as measure of dose,
II: 357;
IV: 154
Centers for Disease Control validation study,
I: 281–284;
II: 103, 104
concentrations of TCDD with time after exposure,
II: 356–357;
III: 159–161
estimated mean maximum levels,
II: 252–255
latency results, linear extrapolation from long exposure,
II: 356
measurement technique,
I: 260;
II: 349–350
pharmocokinetics,
I: 259–261
recommendations,
I: 20–21
significance of,
I: 4, 19, 261, 284–285, 289, 290, 725, 742–743;
II: 4–5, 102–106, 108–109
testing, mandated,
I: 728, 729
Vietnam veterans disease risk estimation, use for,
II: 350–357
Services HERBS tapes. See HERBS tapes
Seveso, Italy,
III: 9;
IV: 8–9, 147–148;
VI: 7, 51, 53–54, 120, 445–446
accidental contamination in,
I: 43;
II: 140–141;
III: 232–233;
IV: 147
birth defects,
II: 287;
III: 436
bladder cancer,
I: 517;
II: 226–227;
III: 348, 349;
IV: 341
bone/joint cancer,
III: 303;
IV: 289
brain tumors,
I: 523;
II: 230;
III: 356, 358;
IV: 351–352
breast cancer,
II: 216;
III: 324–326, 327;
IV: 315
cancer incidence,
II: 141, 148
cancer mortality,
I: 444;
III: 422, 424
child mortality study,
II: 147
childhood cancer,
II: 299–300;
IV: 425
chloracne,
I: 267, 676–677;
IV: 464
circulatory disorders,
I: 701–702;
IV: 507–509
diabetes mellitus,
III: 495;
IV: 11, 484
epidemiologic studies,
I: 44–45, 63, 365–368;
II: 113, 141–143, 148;
III: 130, 197–200, 232–233, 283, 285, 290, 296, 297–298, 303, 307, 309, 314, 318, 325–326, 327, 330, 331, 332, 336, 338, 344, 348, 349, 352, 353, 356, 358, 363, 365, 372, 373, 380, 385, 386, 388–389, 390, 436, 449, 495, 505;
IV: 224, 225, 226, 227, 258–259, 261, 263–264, 266, 271–272, 276, 280, 286–287, 291, 297–298, 306–307, 313, 319, 325–326, 334, 338, 344, 349, 354–355, 361–362, 369–370, 375–376, 382–383, 428, 430–431, 491;
V: 115–116, 168–171;
exposure assessment,
I: 267–268, 285, 598–599;
II: 4–5, 103, 105–106;
III: 150, 156, 158, 160–161, 162;
IV: 111, 114–115, 126;
V: 226–227
female reproductive cancers,
I: 511;
II: 211–212, 213;
III: 330, 331, 332;
IV: 321–322
gastrointestinal tract tumors,
II: 177, 180;
III: 271, 273;
IV: 254
gastrointestinal ulcers,
I: 691;
IV: 501–502
hepatic enzyme disorders,
I: 686–687
hepatobiliary cancers,
II: 184;
III: 283, 285;
IV: 269
Hodgkin’s disease,
II: 236;
III: 372, 373
immune modulation,
I: 695;
VI: 7
infertility,
III: 449
latency and cancer risk,
II: 271, 272, 273, 274, 275;
III: 13, 408, 414, 420, 422, 424, 425, 426, 427, 428, 430
leukemia,
I: 13, 569–570, 571;
II: 245–246;
III: 385, 386, 388–389, 390;
IV: 379, 425
lipid abnormalities,
I: 689;
III: 505
liver cancer,
I: 454–455
liver disorders,
I: 367;
IV: 501–502
lung cancer,
I: 469;
II: 271;
III: 296, 297–298, 299, 422, 424;
IV: 282–283
mortality studies,
I: 652;
II: 141, 271, 272–273, 275;
III: 422, 424, 426, 427
multiple myeloma,
I: 562;
II: 243;
III: 380;
IV: 372–373
nasal/nasopharyngeal cancer,
II: 189;
III: 290;
IV: 275
neurological disorders,
II: 141
neuropsychiatric outcomes,
I: 651–652
non-Hodgkin’s lymphoma,
I: 540–541;
II: 234;
III: 363, 365;
IV: 357
peripheral nervous system disorders,
I: 663–664;
II: 10, 312–313
porphyria cutanea tarda,
I: 680–681
prostate cancer,
I: 11;
II: 9, 221, 248, 274, 275;
III: 336, 338, 426, 427;
IV: 329
renal cancer,
II: 225;
III: 352, 353;
IV: 347
reproductive outcomes/toxicity,
I: 598–599;
II: 72;
III: 436, 449;
IV: 400, 430–431;
VI: 6
respiratory cancer,
II: 200–201, 269, 272;
III: 422, 424;
IV: 278, 279, 282–283, 284
respiratory outcomes,
I: 710;
IV: 472–473, 474, 475
response to accident,
I: 43–44
sex ratio,
V: 434
skin cancer,
I: 503;
II: 12, 209, 210;
III: 314, 318;
IV: 302
soft-tissue sarcoma,
I: 491–492;
II: 206, 207, 208;
III: 307, 309;
IV: 293–294, 295
testicular cancer,
II: 228;
III: 344;
IV: 336
Seveso Women’s Health Study (SWHS),
Sex ratio,
V: 432–438;
VI: 389–394
biologic plausibility,
VI: 393–394
scientific literature update,
VI: 390
SFR. See Standardized fertility ratio
SGOT. See Aspartate aminotransferase (AST)
SGPT. See Alanine aminotransferase (ALT)
Shanghai, China,
II: 188
Silvex®,
I: 309, 324;
II: 128;
III: 219;
IV: 134;
V: 105
SIR. See Standardized incidence ratio
Skaraborg, Sweden,
III: 234;
IV: 149
Skin cancer
animal studies,
I: 141, 142–143;
IV: 5, 24, 31, 40
biologic plausibility for TCDD,
I: 503;
IV: 305, 311;
clinical features,
I: 501, 502
epidemiologic studies,
I: 502–503;
II: 209–211;
III: 312–313;
IV: 19, 149, 154, 232, 302–305, 306–308, 312–313;
V: 5;
VI: 251–265
epidemiology,
I: 501–502;
II: 209;
III: 312, 313;
IV: 299–300
herbicide association in,
I: 12, 576;
II: 7, 11–12, 21, 209–211, 249–250;
III: 8, 10, 21, 312;
IV: 7, 11;
V: 16–17, 21
herbicide occupational exposure and,
III: 312;
IV: 302
morbidity studies,
V: 289;
mortality studies,
TCDD association with,
I: 141, 142–143, 502–503;
II: 209–211;
III: 313–316, 317, 319, 320, 322;
IV: 19;
V: 5
Vietnam veterans and,
II: 209;
III: 312;
IV: 303–304, 305, 309–311;
See also Basal/squamous cell skin cancer;
Melanomas
Skin sensitivity
2,4-D and,
I: 181
picloram and,
I: 192
Ranch hands,
IV: 8
TCDD and,
I: 172–174
See also Chloracne;
Porphyria cutanea tarda (PCT)
Sleep disorders,
I: 650;
IV: 442;
V: 449
SMRs. See Standardized mortality ratios
Social Security Administration,
II: 130, 152, 153
Society for Epidemiologic Research,
II: 25
Soft-tissue sarcoma (STS),
I: 311, 314
age of onset,
I: 436
agricultural/forestry workers and,
I: 322, 326–328, 329–330, 335–336, 337, 339–340;
IV: 140, 149
biologic plausibility of TCDD in,
I: 500;
III: 311;
IV: 296;
V: 287;
VI: 251
case-control studies,
I: 481–491;
IV: 143–144
CDC Selected Cancers Study and,
IV: 157
children and,
I: 628
clinical features,
I: 475, 476
cohort studies,
I: 231, 243;
V: 5
epidemiologic studies,
I: 231, 476, 477–500;
II: 132, 134–135, 205–208;
III: 306–310, 311;
IV: 149, 187, 216, 292–295, 296–299;
V: 5;
VI: 245–251
epidemiology,
I: 475;
II: 205;
III: 304, 306;
IV: 116, 136–137, 140, 143–144, 149, 157;
V: 282–287
herbicide association in,
I: 8, 9–10, 500, 572–573;
II: 5, 6, 20, 205–208, 247;
III: 6, 7, 20, 24, 306–310, 311;
IV: 6, 8, 17;
V: 14
herbicide environmental exposure studies,
I: 375, 383, 384;
II: 207–208;
III: 309;
IV: 293–294;
V: 285–286;
herbicide occupational exposure studies,
III: 308–309;
IV: 292–293;
V: 284–285;
VI: 246
IARC registry and,
IV: 137, 293
incidence, data by race/gender, for selected age groups,
III: 306;
IV: 292;
VI: 245
Midland, Michigan cohort,
IV: 136
pesticide applicators and,
I: 491
production workers and,
I: 8, 477–479, 499;
II: 132, 134–135, 206–207;
IV: 136, 292–293
research recommendations,
I: 19, 727
risk factors,
I: 10, 477;
V: 287
scientific literature update,
II: 206–208;
III: 308–310;
V: 283, 292–295
Vietnam veterans and,
I: 395–396, 401, 475, 492–498, 500;
II: 205, 208;
III: 309–310;
IV: 157, 294–295;
V: 286–287;
VI: 25
Vietnam veterans compensation,
I: 51, 55, 56;
II: 24, 29, 30, 31
See also Kaposi’s sarcoma;
Leiomyosarcomas
Somatostatin,
I: 168, 169
South America,
III: 510
South Dakota,
IV: 149, 344, 349, 354, 362, 369, 375, 382
South Koreans,
I: 61–62;
II: 108–109;
III: 240;
IV: 156;
VI: 1, 6–7, 134, 141–142, 439–440
Southeast Asia,
II: 181, 188, 294, 295;
III: 29, 237, 239, 241, 243, 282, 289, 318, 321, 452;
IV: 267
Soviet Union. See Russia;
USSR
Spain,
IV: 144–145, 207, 401
Special Forces. See US Special Forces
Sperm parameter disorders
altered sperm parameters,
I: 631, 632, 633–634;
II: 7, 11, 20;
III: 444–451;
IV: 200, 405–406, 433
See also Reproductive disorders
Spina bifida,
I: 609, 611, 612;
II: 6, 295–296;
VI: 15
Vietnam veterans offspring,
II: 9–10, 296, 298, 309;
III: 7, 8, 9–10, 21, 24–25, 437–438;
IV: 7, 10, 18, 404–405
See also Birth defects;
Neural tube defects
Spontaneous abortion,
I: 592
agricultural/forestry workers and,
I: 336–337;
IV: 197, 410–411
Alsea, Oregon, case,
I: 42–43, 372–373, 598
biologic plausibility,
V: 420;
VI: 378
definition,
I: 595–596;
II: 282;
IV: 409;
V: 409
epidemiologic data, quality of,
I: 603–605
epidemiologic studies,
II: 283;
IV: 410–411;
V: 420;
VI: 372–378
epidemiology,
II: 282–283
farm families,
V: 5
herbicide association in,
I: 14, 605;
II: 7, 20, 278, 283–284;
V: 409–421, 411–412
herbicide environmental exposure and,
I: 598–599;
IV: 410–411;
V: 414–417
herbicide occupational exposure and,
I: 596–598;
IV: 410;
V: 410, 413–414
maternal risk factors,
I: 596
Ranch Hand participants,
II: 283–284
risk factors,
I: 594;
IV: 409;
V: 420
scientific literature update,
II: 283–284;
IV: 410–411;
V: 410–417;
VI: 373–377
TCDD and,
V: 410, 413
Vietnam veterans’ increased risk,
II: 283;
IV: 411;
V: 417–418;
VI: 378
Vietnam veterans’ wives and,
I: 405–406, 601–603
Vietnamese civilians and,
I: 599–601
women Vietnam veterans’ increased risk,
V: 417–418
See also Reproductive disorders
Sprayers. See Professional herbicide/pesticide applicators
Spraying. See Aerial spraying;
Ground/perimeter spraying
Squamous cell skin cancer. See Basal/squamous cell skin cancer
Standardized fertility ratio (SFR),
III: 448
Standardized incidence ratio (SIR),
IV: 252–253, 269, 289, 293–294, 328–329, 336, 357, 365–366, 379
Standardized mortality ratios (SMRs)
cancer studies,
II: 134, 136, 137, 178, 182, 183, 191, 193, 194, 195, 198, 199, 200, 201, 202, 204, 206, 269, 270, 271, 273, 274;
III: 420, 421, 422, 423, 424, 425, 426, 429;
IV: 138, 142, 153;
IV: 251–253, 268, 292, 302, 327, 332, 341, 346–347, 351–352, 365–366, 372, 379
role of,
I: 229–230;
V: 503
State governments,
I: 60
Vietnam veterans epidemiologic studies by,
I: 399–405, 495–496;
II: 153, 158–159, 161, 202, 292;
III: 213–215, 243–244;
V: 126, 188–191;
VI: 140–141
See also specific states
Statistical association,
Statistics Sweden,
IV: 145
Umea Department of Oncology,
II: 138;
III: 228
University Hospital, Linkoping,
II: 138;
III: 228, 229
University Hospital, Umea,
III: 228
See also Skaraborg, Sweden;
Umea, Sweden;
Uppsala, Sweden
Stellman model,
VI: 493
Stillbirth. See Perinatal death
Stomach cancer,
I: 446, 447;
II: 7, 12;
III: 274–275;
IV: 250–254, 256, 259n, 385;
V: 17, 247–249;
VI: 205–208
TCDD effects in,
I: 169
See also Gastrointestinal (GI) tract cancers
Streptococcus pneumoniae, TCDD exposure and,
II: 68
Stress responses,
VI: 40
Stroke
herbicide exposure risk,
I: 658, 659, 660
See also Motor/coordination dysfunction;
Neurobehavioral toxicity
STS. See Soft-tissue sarcoma
Subcommittee on Hospitals and Health Care,
III: 25
Substance abuse,
I: 655
Suicide,
I: 398, 650, 655–656;
IV: 440;
V: 447
Surrogate-animal models,
V: 24
Surveillance, Epidemiology, and End Results (SEER) program,
I: 336, 439–440, 506;
II: 205, 213;
III: 229, 266, 313;
IV: 215, 249;
ICD-9 cancer codes, site groupings for,
III: 537–539;
IV: 524–526;
V: 243, 531–533;
VI: 572–574
Sweden,
I: 8, 9, 13, 37, 322–323, 326–329, 344, 350, 356, 375, 443, 444, 447, 467, 479, 480, 481, 482–486, 490, 510, 528–529, 530–533, 539, 548, 551–553, 561, 572–573;
II: 138, 183–184, 185, 197, 198, 199, 209, 215, 231, 233, 235–236, 242–243;
III: 226, 228–229, 236, 271–272, 285, 297, 306, 308, 309, 310, 314, 315, 317, 319, 325, 338, 340, 349, 353, 358, 363, 372, 484, 515;
IV: 201, 202, 206, 207, 208, 209, 210, 212, 213, 214, 322, 328, 330, 367;
V: 117, 292, 298, 318, 339, 416;
Cancer Environment Register,
III: 224;
IV: 140
Cancer Registry,
III: 224, 228, 229;
IV: 142;
V: 362
Lund University Hospital,
III: 229
National Register of Causes of Death,
IV: 141
Orebro Medical Center Hospital,
III: 229
Regional Cancer Registry,
II: 138;
III: 228, 229
See also Skaraborg, Sweden;
Umea, Sweden;
Uppsala, Sweden
SWHS. See Seveso Women’s Health Study
Switzerland,
II: 134
Symptom Checklist-90-Revised (SCL-90-R),
V: 449
Synchotron infrared spectromicroscopy,
V: 59
Systemic autoimmune disease,
I: 697–699
See also Autoimmune disease;
Immune system disorders
Systemic lupus erythematosus,
I: 697
See also Autoimmune disease;
Immune system disorders
T
2,4,5-T. See 2,4,5-Trichlorophenoxyacetic acid
T cell function,
I: 147–148, 151;
II: 3;
IV: 62, 80
autoimmunity and,
I: 697
immune modulation and,
I: 694, 695
TCDD and,
II: 68–70;
IV: 61, 62, 78
Vietnam veterans and,
I: 698
T-H Agricultural & Nutrition Company,
I: 35
Taiwan,
III: 231, 470;
chloracne as a biomarker in,
IV: 464
Movement Disorders Clinic, National Taiwan University Hospital,
III: 231
Tannery workers,
I: 486, 514
Tasmania,
I: 418, 603;
II: 293;
III: 244;
IV: 246
TBG. See Thyroxine-binding globulin
TCDD. See Serum levels, TCDD;
TCDD biologic plausibility;
2,3,7,8-Tetrachlorodibenzo-p-dioxin
TCDD biologic plausibility,
IV: 2, 3, 11–12, 107, 110, 385–387, 432–435, 515–517;
VI: 339–341
Ah receptor in,
I: 133–138;
IV: 25–27, 29–30, 42, 47–58, 85–86, 458
animal carcinogenicity studies,
I: 138–146, 439;
III: 394, 396
brain tumors and,
I: 525;
IV: 352
cancer,
II: 176;
IV: 248–388 passim
carcinogenesis,
I: 116–118, 434, 439;
III: 394, 396;
IV: 279, 385
cardiovascular toxicity,
I: 171;
IV: 510
childhood cancer and,
I: 630;
IV: 426
chloracne and,
I: 172–174, 678;
II: 320–321;
III: 480;
IV: 8, 17–18, 135, 466;
V: 479
cognitive/neuropsychiatric disorders and,
II: 314
diabetes mellitus,
III: 502–503;
IV: 488;
V: 492
fetal/infant death and,
I: 624;
IV: 413
gastrointestinal toxicity,
I: 169–170, 451;
III: 513–514
genitourinary tract cancers and,
I: 521–522
hepatobiliary cancers and,
I: 457;
IV: 270
Hodgkin’s disease and,
I: 557;
IV: 8, 367
immune system disorders and,
I: 122, 146–151, 699;
III: 523–524;
IV: 481;
V: 484
lethality,
IV: 76, 137
leukemia and,
I: 571;
IV: 380
lipid abnormalities,
III: 507;
IV: 495
liver disease,
III: 522–524;
IV: 10, 505
motor/coordination dysfunction and,
I: 661;
II: 314
multiple myeloma and,
I: 563;
IV: 374
nasal/nasopharyngeal cancer and,
I: 460;
IV: 275
neurological disorders and,
I: 160–166;
III: 474, 475;
IV: 441–443, 445, 457–459
non-Hodgkin’s lymphoma and,
I: 549;
IV: 8, 116, 358
peripheral neuropathy and,
II: 314;
IV: 457–459
porphyria cutanea tarda and,
I: 682;
II: 323;
IV: 468
reproductive disorders and,
I: 123–124, 156–159, 605, 618, 634;
II: 282;
III: 460–461, 462;
IV: 323, 403, 407, 411, 431
respiratory toxicity, I: 170;
IV: 475
skin cancer and,
I: 503;
IV: 305–311
soft-tissue sarcoma and,
I: 500;
IV: 8, 116, 296
See also Ah receptor (AhR);
Biologic plausibility;
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
TCP. See 2,4,5-Trichlorophenol
TEC. See Toxic equivalent concentration
Tecumseh, Michigan,
III: 235, 388
TEFs. See Toxic equivalency factors
TEQ factors. See Dioxin toxic equivalent factors
Teratogenicity,
I: 57, 62, 606–607
2,4-D,
I: 180–181
2,4,5-T,
I: 185, 373–374;
II: 4
cacodylic acid,
I: 189;
V: 39
picloram,
I: 192
TCDD,
I: 28, 30, 123, 159–160, 185, 368, 370, 372;
III: 461;
IV: 29, 53
viral potential,
I: 607
See also Birth defects
Testicular cancer,
I: 405
biologic plausibility,
III: 347;
IV: 337;
V: 327;
VI: 284
epidemiologic studies,
I: 519;
II: 153, 227–228;
III: 343–346;
IV: 336–337, 338–339;
V: 325–327;
VI: 283–286
epidemiology,
I: 515;
II: 223–224;
III: 343;
IV: 335
herbicide association in,
I: 13, 521;
II: 7, 11, 20, 227–228, 249–250;
III: 7, 10, 343–347;
IV: 7, 11;
V: 324–328
herbicide environmental exposure and,
III: 344, 345;
IV: 336;
V: 327
herbicide occupational exposure and,
III: 344, 345;
IV: 336;
V: 326
histopathology,
I: 513
incidence, data by race, for selected age groups,
III: 343;
IV: 335;
V: 324;
VI: 283
scientific literature update,
II: 227–228;
III: 344, 346;
IV: 159, 336–337;
V: 325;
VI: 284
studies summary,
III: 343–344, 345–346;
IV: 336, 338–339
TCDD association with,
V: 63;
VI: 78–79
Vietnam veterans’ risk,
I: 519, 522;
II: 153, 223–224, 227, 228;
IV: 338;
V: 328;
VI: 284
Vietnam veterans’ studies,
III: 343–344, 345–346;
IV: 157, 159, 336–337;
V: 326–327
See also Genitourinary cancers
Testimony,
I: 739–756;
II: 343–348;
III: 533–536
Testosterone,
I: 123, 157–158;
II: 280, 281, 282;
IV: 183, 399–400, 405, 407–408, 429, 433
Tetrachlorobenzene,
I: 28
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD),
III: 5, 19;
IV: 16, 132;
V: 1–4, 12, 329, 516–518;
VI: 1, 3–5, 11–12, 21–22, 118–119, 165, 201, 276, 436
acute toxicity,
II: 75–76
adipose tissue effects,
VI: 67–68
Ah receptor interaction,
I: 3, 114, 118, 122, 123, 133–138, 150, 151, 152, 159–160, 439, 452–453, 457;
II: 3–4, 51–53, 54–56, 57–62, 176;
III: 33, 34, 35, 53, 54, 58–61, 62–69, 129;
IV: 25, 26, 30, 32, 47–53, 58, 60;
V: 52–54
animal studies,
I: 111–114, 138–142, 477;
II: 3–4, 12, 51–77;
III: 4–5, 33, 34–36, 37, 40–43, 54–58, 62–63, 67–69, 74–105, 128, 129, 130, 394, 396, 460–461, 474, 475, 482, 501, 522–523;
IV: 26, 53–57, 59, 270, 284, 305, 311, 416, 426, 432–435, 458–459, 512;
VI: 29–30
anti-estrogenicity and,
I: 512;
II: 62;
III: 67–69
apoptosis of,
II: 3, 67
autoimmunity and,
I: 697–699
bioavailability,
I: 128–129
biological consequences of activation,
II: 57;
III: 61–62
biomarkers,
I: 4, 17, 259–262, 725;
II: 101–104;
III: 146–147
birth defects and,
V: 439–441
bladder cancer association,
II: 225–227;
III: 347–348;
IV: 341–342
body burdens,
III: 107–108;
IV: 478
body temperature regulation and,
I: 169
bone development effects,
VI: 69–70
bone/joint cancer association,
II: 204–205;
III: 303;
IV: 289
brain distribution,
I: 160–161
brain tumors association,
II: 229, 230;
III: 357, 358;
IV: 351
breast cancer association,
II: 215–217;
III: 327, 329;
IV: 316–317;
V: 65–66, 306
carcinogenesis promoter capability,
I: 116, 142–143, 434, 439
carcinogenicity,
I: 28–29, 116–118, 138–146, 439, 451;
II: 3, 39–40, 65–68, 175, 176;
III: 265, 394, 396, 430–431;
IV: 60–66, 270, 279;
V: 61–63, 75–76;
VI: 76–78
cardiovascular toxicity,
I: 171;
II: 76;
III: 74–75;
V: 58, 70
cell proliferation capability of,
I: 145;
II: 3, 67;
IV: 60
cellular effects of,
V: 4, 56–57
chemical properties,
I: 28, 114, 127
chemical significant interactions,
II: 64–65;
III: 69–71
chemical structure,
I: 125–126;
II: 38
chloracne and,
I: 4, 10, 28, 172–173, 262;
II: 3, 5, 6, 317–321;
III: 479–480;
IV: 135, 464;
V: 56
chronic persistent peripheral neuropathy association,
V: 465–469
circulatory disorders and,
I: 701–708;
II: 336–337;
III: 514, 515–516, 518;
IV: 506–507;
V: 503
cognitive/neuropsychiatric disorders and,
II: 308;
V: 449–452
concerns about,
I: 1, 2, 23–24, 28–32, 35–36;
II: 2, 17, 18, 19, 26–27;
III: 3–5, 12, 13, 14
corticosteroids and,
I: 168, 171–172
cytochrome P4501A2 and,
I: 130, 144–145, 170, 709;
IV: 274, 386
dermal toxicity,
II: 76;
III: 73–74;
V: 56–57
developmental toxicity,
I: 123–124, 149, 156–157, 159–160, 185;
II: 3, 41–42, 71, 72–73;
III: 92–105;
V: 67–69, 72–73;
VI: 83–87
diabetes mellitus and,
I: 683;
II: 330–331;
III: 494, 495, 500–501, 502;
IV: 483, 489;
V: 492
dietary significant interactions,
II: 64
dioxin categorization,
I: 23n, 125
disease outcomes,
V: 69–76
DNA binding capability and transcription activation and,
II: 56–57;
III: 58–61
dose-response relationships,
I: 111–114, 122, 128–129, 130, 137–138, 445, 673, 696;
II: 318
endocrine effects,
III: 83–84;
V: 66–67, 73–74;
VI: 82–83
endometriosis and,
V: 508–509
environmental exposure assessment,
I: 262–263, 267–270;
II: 140–149, 179–180, 184, 186, 190, 193, 200–201, 221, 222, 234, 236, 243;
III: 156–157, 232–233, 234, 235–236, 297–298, 303;
IV: 114–116, 147–150, 254, 269, 274–275, 278, 293, 296, 336, 347, 351, 357, 379;
environmental persistence,
I: 288
enzyme induction of,
II: 3, 66–67
estrogen-mediation of carcinogenesis,
I: 144–145
excretion,
I: 132–133
exposure assessment issues,
II: 4–5, 104–106;
III: 140–142, 144, 157–158, 159–161;
IV: 122–127, 132;
exposure sources,
I: 127
fatty acid biosynthesis and,
I: 168–169
female reproductive system/breast cancers and,
I: 512;
II: 211–213;
III: 331, 332;
IV: 315, 316, 322;
V: 309
free radicals,
II: 59;
III: 64–65
gastrointestinal toxicity,
I: 169–170, 447–452, 690–692;
II: 177–181;
III: 268–272, 511;
IV: 251–254, 499–501
gastrointestinal ulcers and,
II: 334–335;
III: 510;
V: 501;
VI: 72
gene modulation,
VI: 61–65
genotoxicity,
I: 118, 143–144;
II: 3;
V: 48–51
growth factor and,
II: 59
half-life,
I: 129, 260–261;
II: 104–105;
III: 157–158;
IV: 24, 27;
V: 44–47;
VI: 52
hepatic enzyme disorders and,
I: 155–156, 685–688, 691–692
hepatobiliary cancers and,
I: 457;
II: 181–187;
III: 283–285;
V: 263
hepatotoxicity,
II: 3, 73–75;
III: 76–79;
V: 58–60, 71
herbicide contaminant capacity,
I: 2, 3, 27, 91–92, 114, 126–127;
II: 2, 3, 26;
III: 1, 3, 5, 6, 140–142
hexachlorophene manufacture and,
I: 40;
IV: 134–135, 138, 148
H4IIE-luc cells and,
III: 107
Hodgkin’s lymphoma and,
II: 5, 6, 235, 236;
III: 372–373;
IV: 366
hypoglycemia and,
I: 166–168
immune modulation and,
I: 694–696;
II: 328–329;
III: 488, 489, 490, 491;
IV: 26
immunotoxicity,
I: 119–122, 146–151, 338, 477;
II: 3, 40–41, 68–71;
III: 85–92;
IV: 478–480;
V: 61, 74–75;
VI: 73–76
infertility association,
II: 282
inflammatory responses and,
I: 148
interactions, significant,
III: 69–71
intracellular communication of,
II: 3, 67–68
latency issues,
II: 13–14, 269, 270, 272;
III: 420, 421, 423, 424, 425, 426, 429, 431
lethality,
III: 71–73;
V: 69–70;
VI: 67
leukemia association,
II: 246;
III: 386–388, 390;
IV: 379, 426
lipid abnormalities and,
I: 688–690;
II: 333–334;
III: 505, 506, 507
liver toxicity,
I: 115–116, 124, 138–139, 142, 143, 151–156, 165–166;
II: 42, 331–333;
III: 509;
IV: 27, 268, 269, 499
lung cancer and,
III: 297–298, 299, 421, 423;
IV: 282–283;
V: 277
mammary gland effects,
VI: 81
mechanism of action, animal studies,
II: 3, 54–65;
III: 54–58, 62–63, 67–69;
IV: 28–30;
V: 4
mechanisms of toxicity,
II: 65–77;
IV: 67–76, 426;
V: 47–69
metabolism,
I: 115–116, 131–133, 155
multiple myeloma association,
II: 237–238, 243, 244;
III: 378–380, 383;
IV: 372–373
myelogenous leukemia and,
VI: 15–16
nasal/nasopharyngeal cancer and,
I: 460;
IV: 274–275
neuropsychiatric outcomes and,
I: 649–650, 651–652, 656, 657–658;
II: 308
neurotoxicity,
I: 160–166, 642;
II: 3, 75;
III: 84–85, 469, 470–471;
IV: 31;
V: 71–72;
VI: 72–73
non-Ah-mediated toxicity,
I: 138
non-Hodgkin’s lymphoma and,
I: 8, 9, 528–529, 574;
II: 5, 6, 231–234;
III: 364, 429;
IV: 357
occupational exposure,
I: 36–39, 262–267, 269–270, 303;
II: 108–109, 113–140, 178–179, 190, 191–200, 219–220, 222, 232–234, 237–238;
III: 153, 154, 155, 219, 220, 221–222, 223, 224, 284–285, 293, 296–297, 303;
IV: 111–114, 134–147, 187–190, 195–196, 251, 257, 259–260, 262, 265, 268, 271, 277, 280, 282, 284, 289, 290, 292, 306, 312, 318, 341, 343, 346, 348, 353, 359, 374;
V: 6;
VI: 169–177
opioid antagonist capacity,
I: 164
oral administration,
I: 128
perinatal death association,
II: 285–286
peripheral neuropathy and,
II: 310–311, 314;
III: 470–471;
IV: 184
pharmacokinetics,
I: 127–133, 160, 259–261, 284
porphyria cutanea tarda and,
II: 5, 6, 321–323;
III: 481–482;
IV: 466–468;
V: 59
potential health risk estimating,
II: 63–65;
III: 105–108
production of,
I: 28, 114
prostate cancer association,
II: 220–223, 273, 274, 275;
III: 336–337, 425, 426;
IV: 327–328, 329–331;
V: 63–64;
VI: 79
protein kinases and,
II: 60–62;
III: 65–67
protein modulation,
V: 48–51;
VI: 61–65
pulmonary toxicity,
V: 58, 71
Qsar model approach,
III: 106
Ranch Hand study,
II: 109;
III: 50, 146–147;
IV: 18
relevance to human health,
VI: 93–94
renal cancer association,
II: 225;
III: 353;
IV: 346–347
renal toxicity,
II: 77;
III: 75–76
reproductive toxicity,
I: 123–124, 156–159, 368, 371–372, 597, 599, 605;
II: 3, 41–42, 71–72;
III: 92–105, 446, 449;
IV: 398–438 passim;
V: 64–65, 72–73;
VI: 78–81
respiratory cancers and,
II: 13–14, 189–203, 269, 270, 272;
IV: 282–283;
VI: 12
respiratory disorders and,
I: 170, 472, 709–710, 712–714;
III: 484;
IV: 471–474
sensitivity interspecies and interindividual differences,
II: 63–64;
III: 108
skin cancer and,
I: 141, 142–143, 502–503;
II: 209–211;
III: 313–316, 317, 319, 320, 322;
VI: 67–68
soft-tissue sarcoma and,
I: 477, 478, 490, 498–500;
II: 5, 6, 205–208;
III: 307, 308;
IV: 292–293;
V: 287
solubility,
I: 114, 115–116, 127
teratogenicity,
I: 28–29, 30, 31, 123, 159–160, 185, 368, 370, 372;
III: 461
testicular cancer association,
II: 228;
III: 346;
IV: 336;
V: 63;
VI: 78–79
tissue specificity,
II: 64
tooth development effects,
VI: 68–69
toxic end points,
V: 55–69
toxic equivalency factors approach,
II: 63;
III: 106, 158, 159;
V: 26
toxic equivalent concentration approach,
III: 107
toxicity, factors influencing,
II: 63–65;
III: 105–108;
IV: 83–84
toxicity profile,
III: 50–108;
toxicity update summary,
II: 51–53;
IV: 3–5, 22, 26, 44, 62, 64, 83–86;
V: 40–76, 79–81
toxicokinetics, animal studies,
II: 3, 53–54;
III: 4–5, 48;
IV: 41–46;
V: 41–42
toxicokinetics, human studies,
V: 43–44
uterine effects,
VI: 80–81
Vietnam amount used,
I: 27, 106;
II: 26;
IV: 122
Vietnam military exposure,
I: 17, 26, 149–161;
II: 21, 22, 181, 185, 187, 190, 201–202, 204, 205, 208, 209, 211, 212, 226, 276, 308;
III: 146, 147, 237, 239, 240, 430–431;
IV: 150–160;
V: 231–232
Vietnam veterans’ compensation,
II: 28–29;
III: 26–27
Vietnamese civilians exposure,
II: 108–109, 148;
III: 156–157;
IV: 116–117, 148–149
wasting syndrome,
I: 160–161, 162–166;
II: 76–77;
III: 80–83;
IV: 25, 31, 57;
V: 56;
VI: 67
See also Herbicides;
Serum levels, TCDD;
TCDD biologic plausibility
12-O-Tetradexanoylphorbol-13-acetate (TPA),
II: 76
Texas,
I: 60, 403–404, 696;
III: 243
TGF. See Transforming growth factor
Thailand,
I: 26, 90
Thompson Chemicals Corporation,
I: 35
Thyroid
TCDD effects,
I: 168–169;
IV: 135, 386–387
thyroiditis,
I: 697, 698
Thyroid homeostasis,
V: 510–514;
VI: 40
biological plausibility,
V: 514;
VI: 481
clinical features,
V: 512–513
epidemiologic studies,
V: 513–514;
VI: 478–481
herbicide association in,
V: 510–514;
VI: 479–480
scientific literature review,
V: 511–513;
VI: 479–480
Vietnam veterans and,
V: 514;
Thyroid-stimulating hormone (TSH),
V: 510–514;
VI: 478–479
Thyrotropin-releasing hormone (TRH),
V: 510
Thyroxine-binding globulin (TBG),
V: 511
Times Beach, Missouri,
I: 40–42, 268, 368–370, 693–694;
II: 113, 144, 184;
III: 200–201, 234, 283;
IV: 115–116, 133, 148;
V: 116, 171–172, 227;
Tissue distribution, TCDD,
I: 129–131, 259
TNF. See Tumor necrosis factor
Tobacco exposure and use,
I: 11, 223, 442, 461, 463;
II: 190–191, 197;
III: 299, 377;
V: 328
perinatal mortality and,
I: 619–620
respiratory cancer and latency,
II: 268;
III: 418
Tollerud, David,
III: 25
Tooth development effects,
VI: 68–69
Topography,
I: 25
Tordon 75D®,
V: 36
Tordon 101®,
IV: 117–118
See also 2,4-Dichlorophenoxyacetic acid (2,4-D);
Picloram
Toxic equivalency factors (TEFs),
II: 45, 52, 63;
III: 37, 105, 106, 108;
IV: 83–84;
V: 26;
VI: 168
See also Dioxin toxic equivalent factors (TEQ)
Toxic equivalent concentration (TEC),
III: 105, 107
Toxicity
2,4-D profile update,
II: 46–49;
III: 43–47;
IV: 33–37;
V: 76–77;
2,4,5-T profile update,
II: 49–50;
III: 47–48;
IV: 37–38;
V: 77–78;
cacodylic acid profile update,
II: 50–51;
III: 48–50;
IV: 38–40;
V: 78;
cardiovascular,
VI: 69–70
contributing factors,
III: 105–108
definition,
II: 35
health risk estimation,
III: 105–108
liver,
VI: 70–72
picloram profile update,
II: 51;
III: 50;
IV: 40–41;
V: 79;
pulmonary,
VI: 70
TCDD profile update,
II: 51–77;
III: 50–108;
IV: 41–81;
V: 79–81;
Toxicokinetics,
III: 32–36;
VI: 34–36
2,4-D,
II: 46–47;
III: 32–33, 43–44;
IV: 24, 33
2,4,5-T,
II: 49;
III: 47;
IV: 24, 37
cacodylic acid,
II: 50;
III: 32–33, 48;
IV: 24, 38–39;
VI: 41
definition,
II: 35
literature update,
II: 36;
III: 36–37
picloram,
IV: 24
previous reports summary,
II: 38–39
TCDD,
II: 53–54;
III: 33, 53, 161;
IV: 23–24, 27–28, 41–46, 85–86;
VI: 44–55
Toxicology,
2,4-D profile update,
II: 46–49;
III: 43–47
2,4,5-T profile update,
II: 49–50;
III: 47–48
cacodylic acid profile update,
II: 50–51;
III: 48–50
disease outcomes,
II: 37, 48–49, 50–51, 65–77;
III: 33–35, 38–43, 44–47, 48, 50, 71–105
earlier reports summary,
II: 37–42;
III: 36;
VI: 34
evaluation issues,
III: 108–110
human health relevance,
III: 35–36;
IV: 43
literature update,
II: 43–45;
III: 36–43
mechanisms of toxic action,
II: 36, 47–48, 50, 54–65;
III: 33, 38, 44, 47–48, 49–50, 53–71;
IV: 24
picloram profile update,
II: 51;
III: 50
studies evaluation,
III: 128–129
summary,
II: 35–37;
III: 3–5, 32–36;
IV: 24–25
TCDD profile update,
II: 51–77;
III: 50–108
toxicity profiles update,
II: 45–77;
III: 45–108;
V: 76–81
TPA. See 12-O-Tetradecanoylphorbol-13-acetate
Trail-Making Test,
II: 308
Transforming growth factor (TGF),
I: 145;
II: 59, 74
Tremors. See Motor/coordination dysfunction
TRH. See Thyrotropin-releasing hormone
2,4,5-Trichlorophenol (TCP),
I: 28;
II: 319;
III: 152, 153, 219, 220, 223, 515;
IV: 16, 134, 136, 138, 186, 251, 268, 292, 500;
V: 104
2,4,5-Trichlorophenoxyacetic acid (2,4,5-T),
II: 4, 18;
III: 5, 19, 218, 219, 220, 223, 224, 226, 234;
IV: 2, 22, 110, 251, 268, 292, 474, 478, 479;
V: 1, 3, 12;
VI: 1, 3, 11, 20, 118–119, 201, 276, 436
acute toxicity,
I: 184
Agent Orange and,
I: 27;
II: 26
animal studies,
I: 181–185;
II: 49–50;
III: 47–48, 396, 462;
IV: 34, 426, 434–435, 458, 459, 512, 517
birth defects and,
II: 287;
III: 462;
IV: 404, 405n;
V: 394
calcium homeostasis and,
II: 4
carcinogenicity,
I: 37, 118, 119, 182–184;
II: 40;
III: 396;
IV: 387
chemical properties,
I: 114, 182;
II: 38;
III: 32
chemical structure,
I: 111, 114
chloracne and,
I: 36;
IV: 135, 500
chronic exposure,
I: 184
circulatory disorders and,
I: 700–701
development of,
I: 24, 26, 35, 181;
III: 135, 136, 137, 138, 140
developmental toxicity,
I: 185;
II: 42, 49–50
disease outcomes,
III: 48
domestic use,
I: 181
environmental exposure events,
I: 42–43
genotoxicity,
I: 119, 184
half-life of,
II: 4
industrial exposure events,
V: 6
infertility and,
II: 280–282
liver toxicity,
I: 125;
II: 42;
III: 524
mechanisms of action,
III: 33, 38, 47–48
mechanisms of toxicity,
II: 49–50
metabolism,
I: 115, 116
military applications,
I: 26, 88;
II: 26
myelotoxicity,
IV: 5, 31
neurobehavioral toxicity,
III: 475
pharmacokinetics,
I: 182
porphyria cutanea tarda and,
II: 322
reproductive toxicity,
I: 185;
II: 42;
III: 462;
IV: 407, 413, 416, 426, 431, 434–435
respiratory disorders and,
I: 709
suspension of use,
I: 1, 39, 42–43, 92, 181–182
TCDD contamination of,
I: 2, 3, 27, 91, 114, 126, 182;
III: 140
teratogenicity,
I: 30, 92, 373–374
toxicity profile update summary,
II: 49;
IV: 22–24, 28–29, 31, 37–41;
V: 37–38, 77–78;
VI: 33–34
toxicokinetics,
II: 49;
III: 47
volume used in Operation Ranch Hand, data,
III: 136
See also Herbicides;
2,3,7,8-Tetrachloro-dibenzo-p-dioxin (TCDD)
Triglyceride levels,
I: 688–689;
III: 520–521
Trinoxol,
I: 91;
III: 137;
IV: 119
Trivalent monomethylarsonous acid (MMA),
V: 39
TSH. See Thyroid-stimulating hormone
Tuberculosis,
I: 711
See also Respiratory disorders
Tumor necrosis factor (TNF),
I: 148;
II: 59, 60;
III: 87, 88
Twin studies,
I: 398–399, 406, 703, 711
Type 2 Diabetes. See Veterans and Agent Orange: Herbicides/Dioxin Exposure and Type 2 Diabetes
U
UDP glucuronyl transferase (UGT1),
II: 74;
III: 37, 52
Uerdingen, Germany,
III: 154;
IV: 124
UGT1. See UDP glucuronyl transferase
Ulcers, gastrointestinal,
I: 690–692
epidemiologic studies,
II: 334;
III: 510–513;
IV: 500–504;
V: 502
epidemiology,
II: 334;
III: 508–509;
IV: 498–499
herbicide environmental exposure and,
V: 501
herbicide exposure association with,
II: 334;
III: 510–514;
IV: 505
herbicide occupational exposure and,
III: 510–512;
IV: 500–501;
V: 500–501
scientific literature update,
II: 334; III: 510–513;
IV: 500–504;
V: 500–501;
VI: 465–466
Vietnam veterans and,
III: 512–513;
IV: 502–505;
V: 502
See also Metabolic and digestive disorders;
Peptic ulcer disease
Ultraviolet (UV) radiation,
V: 290
Umea, Sweden,
III: 228, 229
Unified Parkinson’s Disease Rating Scale (UPDRS),
V: 460–461
Uniroyal Inc.,
I: 35
Unit Identification Code list,
VI: 182
United Kingdom,
I: 315–316, 340, 382, 444, 462–463, 464, 477, 479, 537, 565, 595, 689;
II: 194, 196, 269;
III: 223, 224, 420;
VI: 128, 133
England National Cancer Register,
III: 232;
IV: 144;
VI: 128
herbicide exposure assessment,
III: 151;
IV: 139
Parkinson’s Disease Society Brain Bank,
IV: 445
See also Scotland;
Yorkshire, England
United Nations,
I: 45
United Paperworkers International Union,
III: 232
Update 1996. See Veterans and Agent Orange: Update 1996
Update 1998. See Veterans and Agent Orange: Update 1998
Update 2000. See Veterans and Agent Orange: Update 2000
Update 2002. See Veterans and Agent Orange: Update 2002
UPDRS. See Unified Parkinson’s Disease Rating Scale
Uppsala, Sweden,
III: 228
Urinary bladder cancer. See Bladder cancer and disorders
UROD. See Uroporphyrinogen decarboxylase
Uroporphyrinogen decarboxylase (UROD),
II: 321;
III: 480, 481
Uroporphyrins, increases in,
VI: 7
US Air Force,
I: 81, 113;
III: 29, 138, 218, 237, 239, 339, 513, 517;
VI: 24
Armstrong Laboratory, Population Research Branch,
III: 29
Baseline Morbidity Report,
II: 32
Baseline Mortality Report, 1982,
II: 31
Follow-Up Examination Results, 1985, 1987, 1992,
II: 32
Human Resources Laboratory records,
II: 150, 152;
III: 237
Military Personnel Center records,
II: 151;
III: 238;
IV: 151;
VI: 136
Mortality Updates, 1984, 1985, 1986, 1989, 1991,
II: 32
Reproductive Outcomes,
II: 32
Serum Dioxin Level Follow-Up Examination Results,
II: 32
TCDD half-life investigations,
II: 104–105
Vietnam casualties,
I: 83
women veterans mortality studies,
II: 152–153
See also Air Force Health Study (AFHS);
Operation Ranch Hand;
Ranch Hand study
US Army,
I: 81, 280, 281, 702;
II: 140, 185;
IV: 121–122, 126
Army Chemical Corps Vietnam Veterans Health Study proposal,
II: 24
Army I Corps,
IV: 157
Environmental Support Group (ESG),
II: 152
Vietnam casualties,
I: 83
Vietnam veteran studies,
II: 201, 226, 244;
III: 240, 241, 283, 294, 298, 313, 315, 318, 338, 339, 344, 346, 348, 365, 373, 380, 485, 512, 517;
IV: 21
women veterans mortality studies,
II: 152–153, 201
See also US Army Chemical Corps (ACC);
US Special Forces
US Army Chemical Corps (ACC),
I: 13, 15, 16–17, 94–95, 272, 273, 286, 394, 470, 571, 703–704, 705, 711, 722–725;
II: 5, 23, 24, 101, 103, 104, 201–202, 245;
III: 6, 23, 138–139, 146–147, 241, 272, 298, 309, 314, 344, 358–359, 385, 389, 485, 512, 517;
IV: 120–124, 157, 287;
V: 10–11, 233–234, 525;
US Coast Guard,
I: 81
US Congress,
I: 2, 31, 46–52;
III: 25–28, 237, 240;
VI: 138
See also Congressional hearings;
Legislation
US Marine Corps,
I: 81, 96, 280, 545, 702, 710;
II: 185, 201, 226, 244;
III: 140;
IV: 121
non-Hodgkin’s lymphoma in,
I: 542, 545, 546–547
Vietnam casualties,
I: 83
Vietnam veterans studies,
III: 241, 242, 283, 294, 298, 309, 313, 315, 338, 339, 346, 348, 365, 373, 380, 485, 489, 512, 517;
IV: 287, 298, 339
women veterans mortality studies,
II: 152–153
US Military Assistance Command,
III: 138;
IV: 119;
VI: 183
US Navy,
I: 81, 280–281, 286;
II: 185, 228;
III: 339, 344
herbicide use in,
I: 95;
II: 104;
III: 135, 139, 140
non-Hodgkin’s lymphoma odds ratio in,
I: 542
Vietnam casualties,
I: 83
women veterans mortality studies,
II: 152–153
US Special Forces,
I: 286;
II: 103–104;
III: 138
USDA. See Department of Agriculture, US
USSR,
I: 317;
III: 224
See also Russia
Utah,
I: 560;
II: 241
Uterine cancer,
I: 506;
III: 329, 333;
V: 312;
VI: 80–81
herbicide association evidence,
I: 13;
II: 6, 211, 213;
III: 333;
IV: 323–324;
VI: 273
See also Reproductive system cancers, women
UV. See Ultraviolet radiation
V
Valcular heart disease,
VI: 7
VAO. See Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam
Verona, Missouri,
II: 128–129;
III: 219, 220;
IV: 135, 148;
V: 105
Very low density lipoprotein (VLDL) receptors,
II: 333;
III: 503
VES. See Vietnam Experience Study
Veterans. See Foreign veterans;
Vietnam veterans;
Women veterans
Veterans Administration. See Department of Veterans Affairs, US (DVA)
Veterans and Agent Orange: Health Effects of Herbicides Used in Vietnam (VAO),
II: 1, 2, 5, 8, 10, 11, 12, 35, 45, 63, 65, 71, 89, 90, 91, 96, 97, 99, 101, 102, 104, 107, 112, 132, 176, 179, 180, 181, 187, 190, 196, 207, 209, 210, 214, 218, 225, 228, 232, 236, 237, 246, 247, 249, 250, 266, 271, 278, 279, 286, 293, 296, 300, 305, 312, 323, 328, 357;
III: 1, 2, 3, 5, 12, 32, 43, 85, 124, 125, 126, 132, 150, 157, 169, 220, 221, 223, 286, 303, 311, 320, 359, 389, 390, 416, 434, 435, 519, 522;
IV: 5, 156–159;
V: 1–2, 12–14, 16–18, 20–21, 104;
VI: 2–3, 11, 20, 33–34, 119, 121–124, 126, 129, 133, 135
background,
II: 17–19;
III: 17–23;
IV: 15, 103–104, 110, 132, 137, 249, 268, 351
basal/squamous cell skin cancer studies summary,
III: 317–318, 321, 323;
IV: 308, 312–313;
V: 295–296
birth defects studies summary,
III: 436–439;
IV: 400–401, 404, 435;
V: 394
bladder cancer studies summary,
II: 225–226;
III: 347–348, 350–351;
IV: 340, 343–345;
V: 329
bone/joint cancer studies summary,
II: 204;
III: 302, 305;
IV: 288, 290–291;
V: 279
brain tumor studies summary,
II: 229;
III: 356–357, 360, 361;
IV: 351, 353–355;
V: 339
breast cancer studies summary,
III: 324–326, 328;
IV: 314–315, 319–320;
V: 301
childhood cancer studies summary,
II: 299;
IV: 418, 429
chloracne studies summary,
II: 318;
III: 479–480;
IV: 465;
V: 478
chronic persistent peripheral neuropathy studies summary,
II: 310;
IV: 454
circulatory disorders studies summary,
II: 335–336;
III: 514;
IV: 506;
V: 503
cognitive/neuropsychiatric disorders studies summary,
II: 307;
III: 468–469;
IV: 441–442;
V: 448–449
congressional hearings on Agent Orange,
II: 27–28;
III: 25
Department of Veterans Affairs Task Force,
II: 4–26;
III: 24–25
diabetes mellitus studies summary,
II: 330;
III: 496–497;
IV: 482, 487, 488, 490, 492;
V: 486
federal government response to concerns over military use of herbicides in Vietnam,
II: 27–32;
III: 25–30
female reproductive cancers studies summary,
II: 211–212;
III: 330–331, 332, 333;
IV: 321, 324–325
gastrointestinal tract tumors studies summary,
II: 177–178;
III: 268, 274–281;
IV: 251, 256;
V: 244–245
gastrointestinal ulcers studies summary,
II: 334;
III: 510;
IV: 500;
V: 500
health outcomes conclusions,
II: 19–23;
III: 19–20;
IV: 11, 18–19, 20, 21, 384, 385, 414, 465, 467, 471, 513, 514;
V: 6–9;
VI: 13–18
hepatobiliary cancers studies summary,
III: 282–283, 287–288;
IV: 268, 269;
V: 259–260
herbicide environmental exposure studies,
II: 142–143, 144, 145–146;
III: 197–202, 203–205, 275, 277, 279, 281, 283, 288, 291, 301, 316, 323, 328, 336, 342, 345, 350–351, 354, 369, 382, 392, 437, 454, 455, 456, 459, 479, 520;
IV: 147–149, 261, 264, 266–267, 271–272, 276, 286, 291
herbicide occupational exposure studies,
II: 114, 115–116, 117–118, 119–120, 121–126;
III: 170–174, 176–178, 180–182, 183–185, 188–196, 274–275, 276–277, 278–279, 280, 282–283, 286, 291, 294, 300–301, 305, 310, 312, 316, 317, 321, 323, 324–326, 328, 332, 333, 335–336, 345, 350, 354, 360, 367–369, 374–376, 381–382, 391–392, 454, 455, 456, 459, 496, 520;
IV: 137, 139, 140–142, 144–146, 257–261, 263, 265–266, 271, 276, 280, 285, 290
Hodgkin’s disease studies summary,
II: 235;
III: 372, 374–375, 376;
IV: 365, 368;
V: 356
immune system disorders, studies summary,
II: 327;
III: 488–489;
IV: 477;
V: 484
impact of report,
II: 24–26;
III: 23–25
infertility studies summary,
II: 280;
III: 445–446, 450;
IV: 406, 409
laryngeal cancer studies summary,
III: 293, 294;
IV: 277, 280;
V: 268–269
legislation on Agent Orange,
II: 28–29;
III: 26–27
leukemia studies summary,
II: 245;
III: 385–386, 391–392;
IV: 378–379, 381, 383;
V: 368
lipid abnormalities studies summary,
II: 333;
III: 504, 520, 521;
IV: 483
liver toxicity studies summary,
II: 332;
III: 510;
IV: 500
low birthweight studies summary,
III: 456–457, 459;
IV: 399, 400, 412;
V: 423
lung cancer studies summary,
III: 296, 300–301;
IV: 281, 285–286;
V: 273
melanoma studies summary,
III: 313–314, 316, 317;
IV: 302, 306;
V: 290
metabolic and digestive disorders, studies summary,
II: 330, 332, 333, 334;
IV: 500
motor/coordination dysfunction studies summary,
II: 309;
III: 469–470;
IV: 443–444
multiple myeloma studies summary,
III: 377–378, 381–382;
IV: 372, 375–376;
V: 362
nasal/nasopharyngeal cancer studies summary,
III: 290, 291;
IV: 274;
V: 265, 274
neuroblastoma,
V: 426
next edition of,
VI: 94
non-Hodgkin’s lymphoma studies summary,
II: 231–232;
III: 362–363, 367–369, 370–371;
IV: 356, 360–363;
V: 344
perinatal death studies summary,
II: 285;
III: 451, 454, 455, 456;
IV: 412
peripheral neuropathy studies summary,
III: 470–471, 473;
IV: 454
porphyria cutanea tarda studies summary,
II: 321–322;
III: 481–482;
IV: 467;
V: 479
prostate cancer studies summary,
III: 335–336, 341, 342;
IV: 327, 333–335;
V: 317–318
renal cancer studies summary,
II: 224;
III: 352–353, 354, 355;
IV: 346, 349–350
research recommendations,
II: 23–24;
III: 23;
IV: 21
respiratory disorders studies summary,
II: 324–325;
III: 483;
IV: 471;
V: 481
sex ratios of offspring,
IV: 429–430;
V: 433
skin cancer studies summary,
III: 312;
IV: 299–314
soft-tissue sarcomas studies summary,
II: 205–206;
III: 306–308;
IV: 292, 297–299;
V: 283
spontaneous abortion studies summary,
II: 283;
IV: 410;
V: 410
summary of,
II: 37–42
toxicology, overview,
III: 36;
IV: 22, 38, 41;
V: 30–31;
VI: 33
Veterans and Agent Orange: Herbicides/Dioxin Exposure and Acute Myelogenous Leukemia in the Children of Vietnam Veterans (Acute Myelogenous Leukemia),
V: 2, 13, 14, 16–17, 21;
Veterans and Agent Orange: Herbicides/Dioxin Exposure and Type 2 Diabetes (Type 2 Diabetes),
IV: 1, 10–11, 16, 104;
V: 2, 12–13, 16, 486–487;
Veterans and Agent Orange: Length of Presumptive Period for Association Between Exposure and Respiratory Cancer,
Veterans and Agent Orange: Update 1996 (Update 1996),
III: 1, 2, 3, 6, 8, 10, 32, 37, 43, 44, 50, 85, 106, 109, 125, 126, 132, 150, 157, 159, 169, 220, 221, 222, 223, 266, 286, 295, 298, 303, 309, 311, 319, 320, 339, 349, 359, 389, 390, 416, 417–418, 424, 426, 428, 434, 435, 444, 458, 519, 522, 533;
IV: 1;
V: 2, 12–14,
16–18;
VI: 2, 11, 33–34, 121–129, 133, 135
background,
III: 17–23;
IV: 15–21, 110, 132, 137, 247, 251
basal/squamous cell skin cancer studies summary,
III: 317–318, 321, 323;
IV: 308–314;
V: 295–296
birth defects studies summary,
III: 436–439;
IV: 400–401, 435;
V: 394
bladder cancer studies summary,
III: 347–348, 350;
IV: 330–345;
V: 329
bone/joint cancer studies summary,
III: 302, 305;
IV: 287–291;
V: 279
brain tumor studies summary,
III: 356–357, 360, 361;
IV: 350–355;
V: 339
breast cancer studies summary,
III: 324–326, 327, 328;
IV: 314–320;
V: 301
childhood cancers,
IV: 418
chloracne studies summary,
III: 479–480;
IV: 465;
V: 478
circulatory disorders studies summary,
III: 514;
IV: 506;
V: 503
cognitive/neuropsychiatric disorders studies summary,
III: 468–469;
IV: 441–442;
V: 448–449
congressional hearings on Agent Orange,
III: 25
Department of Veterans Affairs Task Force,
III: 24–25
diabetes mellitus studies summary,
III: 496;
IV: 482–483, 490;
V: 486
federal government response to concerns over military use of herbicides in Vietnam,
III: 25–30
female reproductive system cancers studies summary,
III: 330–331, 332, 333;
IV: 321–326;
V: 310
gastrointestinal tract tumors studies summary,
III: 268, 274–281;
IV: 257–264;
V: 244–245
gastrointestinal ulcers studies summary,
III: 510;
IV: 500;
V: 500
health outcomes conclusions,
III: 19–20;
VI: 13–18
hepatobiliary cancers studies summary,
III: 282–283, 287–288;
IV: 267–272;
V: 259–260
herbicide environmental exposure studies,
III: 197, 201, 203, 275, 277, 279, 283, 288, 323, 328, 336, 342, 345, 354, 369, 375, 382, 392;
IV: 147, 149
herbicide occupational exposure studies,
III: 170, 172, 174, 175–176, 179, 183, 186–187, 274, 276, 278, 280, 282–283, 286, 291, 294, 300, 305, 316, 317, 321, 324–326, 328, 332, 333, 335–336, 345, 350, 354, 360, 367, 374, 381, 391, 496;
IV: 135–137, 140–142, 144
Hodgkin’s disease studies summary,
III: 373, 374, 375, 376;
IV: 364–371;
V: 356
impact of report,
III: 23–25
infertility studies summary,
III: 445–446;
IV: 406–408
laryngeal cancer studies summary,
III: 293, 294;
IV: 277–281;
V: 268–269
legislation on Agent Orange,
III: 26–27
leukemia studies summary,
III: 385–386, 391, 392;
IV: 377–383;
V: 368
lipid abnormalities studies summary,
III: 504;
IV: 493
liver disorders studies summary,
III: 510;
IV: 500
low birthweight studies summary,
III: 456–457;
IV: 412;
V: 423
lung cancer studies summary,
III: 296, 298, 300;
IV: 281–287;
V: 273
melanoma studies summary,
III: 313–314, 316, 317;
IV: 302–308;
V: 290
motor/coordination dysfunction studies summary,
III: 469–470;
IV: 444
multiple myeloma studies summary,
III: 377–378, 381, 382;
IV: 371–377;
V: 362
nasal/nasopharyngeal cancer studies summary,
III: 290, 291;
IV: 273–276;
V: 265
non-Hodgkin’s lymphoma studies summary,
III: 362–363, 367, 369, 370;
IV: 355–364;
V: 344
pancreatic cancer,
IV: 264–267
perinatal death studies summary,
III: 451;
IV: 412
peripheral neuropathy studies summary,
III: 470–471, 473;
IV: 18
porphyria cutanea tarda studies summary,
III: 481–482;
IV: 467;
V: 479
prostate cancer studies summary,
III: 335–336, 341, 342;
IV: 326–335;
V: 317–318
renal cancers studies summary,
III: 352–353, 354, 355;
IV: 345–350
research recommendations,
III: 23
respiratory disorders studies summary,
III: 483;
IV: 471–472;
V: 481
sex ratios of offspring,
IV: 429–430;
V: 433
skin cancer,
IV: 299–301
soft-tissue sarcoma studies summary,
III: 306–308;
IV: 291–299;
V: 283
testicular cancer studies summary,
III: 343–344, 345;
IV: 335–339;
V: 325
toxicology, overview,
III: 36;
IV: 22;
V: 30–31;
VI: 33
Veterans and Agent Orange: Update 1998 (Update 1998),
V: 2, 12–14, 16–18;
VI: 2, 11, 33–34, 121–129, 133, 135
Australian Veterans,
IV: 159
background of,
IV: 1, 3, 8–10, 110, 132, 247, 251, 399–400
basal/squamous cell skin cancer studies summary,
IV: 308–314;
V: 295–296
birth defects studies summary,
IV: 400–401, 435;
V: 394
bladder cancer studies summary,
IV: 330–345;
V: 329
bone/joint cancer studies summary,
IV: 287–291;
V: 279
brain tumor studies summary,
IV: 350–355;
V: 339
breast cancer studies summary,
IV: 314–320;
V: 301
childhood cancers,
IV: 418, 426
cognitive/neuropsychiatric disorders studies
summary,
V: 448–449
Department of Veterans Affairs and,
IV: 157–158
environmental exposure,
IV: 148–149
epidemiology,
IV: 257
female reproductive system cancers studies summary,
IV: 321–326;
V: 310
gastrointestinal tract tumors studies summary,
IV: 257–264;
V: 244–245
health outcomes conclusions;
VI: 13–18
hepatobiliary cancers studies summary,
IV: 267–272;
V: 259–260
Hodgkin’s disease studies summary,
IV: 364–371;
V: 356
infertility studies summary,
IV: 406–408
laryngeal cancer studies summary,
IV: 277–281;
V: 268–269
leukemia studies summary,
IV: 377–383;
V: 368
low birthweight studies summary,
IV: 412;
V: 423
lung cancer studies summary,
IV: 281–287;
V: 273
melanoma studies summary,
IV: 302–308;
V: 290
mortality in,
IV: 254
multiple myeloma studies summary,
IV: 371–377;
V: 362
nasal/nasopharyngeal cancer studies summary,
IV: 273–276;
V: 265
non-Hodgkin’s lymphoma studies summary,
IV: 355–364;
V: 344
occupational exposure,
IV: 135–137, 139–142, 144
Operation Ranch Hand,
IV: 150, 152
pancreatic cancer,
IV: 264–267
prostate cancer studies summary,
IV: 326–335;
V: 317–318
quantitative structure-activity relationship (QSAR) models,
V: 27
renal cancers studies summary,
IV: 345–350
sex ratios of offspring,
IV: 429–430;
V: 433
skin cancer,
IV: 299–301
soft-tissue sarcoma studies summary,
IV: 291–299;
V: 283
spontaneous abortion,
IV: 408–412;
V: 410
testicular cancer studies summary,
IV: 335–339;
V: 325
toxicology overview,
IV: 22;
V: 30–31;
VI: 33
Veterans and Agent Orange: Update 2000 (Update 2000),
V: 2, 12–18, 21, 103;
VI: 2, 11, 21, 33–34, 58, 121–126, 129
basal/squamous cell skin cancer studies summary,
IV: 308–314;
V: 295–296
birth defects studies summary,
V: 394
bladder cancer studies summary,
V: 329
bone/joint cancer studies summary,
V: 279
brain tumor studies summary,
V: 339
breast cancer studies summary,
IV: 314–320;
V: 301
carcinogenicity,
V: 37
cell stress responses,
V: 34
cognitive/neuropsychiatric disorders studies summary,
V: 449–450
developmental toxicity,
V: 35–36
disease outcomes,
V: 34–37
energy metabolism,
V: 33–34
female reproductive system cancers studies summary,
V: 310
gastrointestinal tract tumors studies summary,
V: 244–245
genotoxic effects,
V: 33
health outcomes conclusions,
VI: 13–18
Hodgkin’s disease studies summary,
V: 356
immunotoxicity,
V: 37
laryngeal cancer studies summary,
V: 268–269
leukemia studies summary,
V: 368
lung cancer studies summary,
V: 273
mechanisms of toxic action,
V: 33–34
melanoma studies summary,
V: 290
mitochondrial function,
V: 33–34
multiple myeloma studies summary,
V: 362
nasal/nasopharyngeal cancer studies summary,
V: 265
neuroblastoma,
V: 426
neurotoxicity,
V: 35
non-Hodgkin’s lymphoma studies summary,
V: 344
parkinsonism,
V: 453, 460
prostate cancer studies summary,
IV: 326–335;
V: 317–318
reproductive toxicity,
V: 35–36
respiratory disorders studies summary,
V: 481
sex ratios of offspring,
V: 433
soft-tissue sarcoma studies summary,
V: 283
testicular cancer studies summary,
V: 325
thyroid hormones,
V: 34
toxicology overview,
V: 30–31
Veterans and Agent Orange: Update 2002 (Update 2002),
VI: 2, 5–7, 11, 33–37, 43, 51, 55, 58–60, 66–73, 83–84, 88–92, 118, 121–126, 129–130, 135
health outcomes conclusions,
VI: 11–18
toxicology overviews,
Veterans’ benefits. See Compensation, veterans
Veterans’ compensation. See Compensation, veterans
Veterans’ Dioxin and Radiation Exposure Compensation Standards Act of 1984. See Public Law 98-542
Veterans’ Education and Benefits Expansion Act of 2001,
VI: 1
Veterans’ Health Care, Training, and Small Business Loan Act of 1981. See Public Law 97-72
Veterans’ Health Care Eligibility Reform Act of 1996. See Public Law 104-262
Veterans’ Health Programs Extension and Improvement Act of 1979,
III: 240
Veterans’ service organizations,
VI: 20
Vibrotactile abnormalities,
V: 466, 468
Vietnam,
III: 533;
herbicide latency issues, methodology,
II: 13;
III: 12–14
herbicide targeting in,
I: 99–106;
IV: 116–117
herbicide use in, concerns about,
I: 29–32, 45;
II: 1, 2, 4, 11, 17, 18, 26;
III: 1, 2, 5, 12, 13, 17, 18, 25;
V: 3, 30–31, 229–232
research in,
I: 30–31
troop movements in,
I: 52–53, 96, 287
US casualties in,
I: 82–83
US involvement,
I: 75–76, 84
US military herbicide use in,
I: 1, 3, 24, 27, 84–85, 89–93, 94–96, 98–107, 286;
II: 17, 18, 26, 27–32;
III: 135–142;
V: 116–117;
VI: 120
See also Ca Mau peninsula;
Con Thieu province, Vietnam;
Hanoi, Vietnam;
Ho Chi Minh City, Vietnam;
Khe Sanh-Thonh Son Lam area;
Mekong Delta;
Rung Sat Special Zone;
Vietnamese
Vietnam Experience Study (VES),
III: 26, 240, 512;
birth defects in offspring,
II: 288, 289, 290;
III: 436, 438, 439, 445
cancer mortality in,
I: 444–445
childhood cancer in,
I: 629;
II: 300
chloracne in,
I: 677
circulatory disorders in,
I: 702
exposure assessment use,
II: 101;
III: 146
hepatobiliary cancers,
II: 185;
III: 283
Hodgkin’s disease in,
I: 556
immune system disorders in,
I: 696
infertility in,
II: 280
liver cancer in,
I: 455
low birthweight outcomes in,
I: 626
lung cancer in,
I: 469
methodology,
I: 57–58, 281, 284, 389–391
multiple myeloma,
II: 244
neonatal death in,
I: 622
neurologic/neuropsychiatric outcomes in,
I: 656
non-Hodgkin’s lymphoma in,
I: 542–543
origins,
I: 50
reproductive outcomes in,
I: 601, 609, 610–611, 626, 632
respiratory cancer in,
II: 201
respiratory disorders in,
I: 710–711
spina bifida in offspring,
II: 9;
IV: 8
Vietnam herbicides used by military,
II: 26–27;
VI: 182–186
Vietnam Veteran Agent Orange Health Study,
I: 741
Vietnam veterans,
I: 1;
II: 2;
V: 20–21;
acute and subacute transient peripheral neuropathy,
II: 313;
III: 473;
IV: 6, 459
advocacy groups,
I: 60–61
Air Force research activities,
II: 31–32;
III: 28–29;
IV: 13, 42–43, 150–156, 160–161
altered sperm parameters in,
I: 632, 634;
III: 445, 446, 450;
IV: 7
amyloidosis,
IV: 7;
V: 507;
VI: 473
amyotrophic lateral sclerosis,
VI: 422
Australian,
I: 61, 91, 406, 418, 444, 470, 496–497, 546, 614–615, 633, 702, 710;
II: 113, 149, 160, 202, 293;
III: 9, 216–217, 218, 237, 244–245, 273, 285–286, 290, 294, 295, 298, 299, 303, 310, 311, 314, 315, 327, 329, 349, 353, 355, 359, 365, 380, 389, 413, 424, 425, 469, 486, 489, 500, 506, 512–513, 517;
IV: 9, 10, 159–160, 322–333, 402, 421–422;
VI: 141
autoimmune disease in,
I: 698, 699
basal/squamous cell skin cancer in,
III: 323;
IV: 309–310;
V: 298, 300;
VI: 265
birth defects in children of,
I: 609–615, 618;
II: 288–296, 298, 300;
III: 435, 436, 437–438;
IV: 7, 402;
V: 402–403; 339, 340, 343, 346,
VI: 365
bladder cancer in,
I: 517;
II: 223–224;
III: 349, 351;
IV: 7, 342;
V: 332, 333;
VI: 292
bone/joint cancer in,
I: 473, 474–475;
II: 204;
III: 303, 305;
IV: 7, 289;
V: 281;
VI: 245
brain tumors in,
I: 522, 523, 525;
III: 358–359, 361;
IV: 7, 352;
V: 342, 343;
VI: 302
breast cancer in,
II: 213, 217, 218;
III: 326, 328, 329;
IV: 7, 316;
V: 304, 309;
VI: 270
cancer expected incidence,
I: 439–440, 442, 446, 452, 461, 501, 505, 513, 522, 526, 564;
II: 176–177;
III: 266–267, 430–431;
IV: 249–250
cancer in children of,
I: 629, 630–631;
II: 299;
IV: 7, 420–422;
V: 430–431
cancer mortality,
I: 444–445
cancer studies,
I: 391–393, 401, 402–403, 405, 436–438;
II: 176–177;
III: 266–267, 430–431
chloracne in,
I: 677–679;
II: 317, 318, 321;
III: 479–480;
IV: 6, 135, 485;
V: 479;
VI: 438
chronic persistent peripheral neuropathy in,
II: 311;
circulatory disorders in, I: 702–705;
II: 336;
IV: 7, 456
III: 516–518;
IV: 7, 508–509;
VI: 471
class action suit,
cognitive/neuropsychiatric disorders in,
II: I: 34–35 318;
III: 469;
IV: 7, 443;
V: 449–451
colon cancer in,
V: 252
compensation for,
I: 34–35, 47, 50–51, 55–56;
II: 28–29, 30–31;
III: 26–27, 28
congressional responses to concerns of,
I: 46–52;
II: 27–29;
III: 25–28
defining,
I: 78
demographics,
I: 79, 80–84
developmental toxicity,
II: 72
diabetes mellitus in,
I: 684, 685, 698;
II: 330;
III: 495, 497, 498, 500, 502;
IV: 6, 485–487;
V: 489–490, 491;
VI: 450–455
disabilities discharges,
I: 32
disease increased risk for,
I: 14–15, 221, 225–226, 247–248, 578;
II: 14, 22–23, 88, 89, 91, 218, 223, 251, 276, 298, 300–301, 314, 321, 323; 23, 124, 127–128, 329, 334, 343, 397,
III: 14–15, 22–430–431, 444, 462, 475–476, 491, 503, 507–508, 525;
IV: 12, 256, 270, 275, 279, 284, 290, 296, 323–324, 332, 338, 343, 348, 353, 359, 367, 374, 381, 403, 407, 411–412, 413, 305–306, 311, 318, 417, 426, 466, 468, 475, 489, 495, 505, 510, 513;
V: 246, 264, 268, 272, 278, 282, 287, 295, 300, 309, 316, 324, 328, 333, 338, 343, 355, 361, 366, 372, 376, 405, 409, 420–421, 422, 425, 432, 441, 472, 479, 480, 483, 485, 492, 498, 502, 506, 510, 518–519;
VI: 221, 226, 230, 234, 241, 245, 251, 261, 265, 270, 275, 283, 284, 292, 296, 302, 312, 319, 325, 333, 337, 341, 365, 372, 378, 379, 383, 398, 410, 420, 422, 429, 430–431, 438, 440, 443, 448, 456, 463, 466, 471, 473, 478, 481
distribution by branch of service,
I: 81
endometriosis in,
VI: 478
Environmental Protection Agency research activities,
II: 32;
III: 29–30
epidemiologic studies,
I: 50, 57–59, 62–63, 384–418;
II: 3, 6–7, 28, 113, 149–161;
III: 26, 206–217, 236–245, 272–273, 275, 277–278, 279, 281, 283, 285–286, 288, 290, 291, 294–295, 298, 301, 303, 305, 309–310, 312, 316, 317, 323, 326, 328, 333, 336, 338, 339, 340, 342, 343–344, 345–346, 349, 351, 353, 355, 358–359, 361, 363, 365, 370–371, 372, 373, 376, 380, 382, 385, 386, 389, 392, 435, 436, 437–438, 445, 446, 450, 454, 455, 456, 457, 459, 467, 468, 469, 470, 473, 479, 480, 481, 482, 485–486, 489, 491, 495, 497, 498, 500, 502, 505–506, 512–513, 516–518, 521;
IV: 150–160, 255, 269, 275, 278, 283, 294–295, 303–304, 309–310, 316, 322–323, 329, 336–337, 342, 347, 357–358, 366–367, 373, 380, 402, 411, 420–422, 474, 485–487, 494, 502–504, 508–509;
V: 177–193;
exposure assessment,
I: 234–235;
federal government activities/research on military use of herbicides,
II: 27–32;
III: 25–30
female reproductive system cancers in,
I: 505, 511–512, 577;
II: 211, 212;
III: 333;
IV: 7, 322–323;
V: 311, 312, 313, 314–315;
VI: 275
gastrointestinal disorders in,
I: 691, 692;
III: 512–513;
IV: 502–504;
V: 502;
VI: 466
gastrointestinal tract cancers in,
I: 446;
II: 177, 180–181;
IV: 7, 255;
V: 245–246;
VI: 220
genitourinary tract cancers in,
I: 513, 518, 522;
II: 223–224;
III: 272–273, 275, 277–278, 279, 281;
IV: 7, 342
health care of,
II: 28, 29;
III: 26, 27
health concerns of,
I: 1, 32–34, 46–47;
II: 17–24, 26–27;
III: 17–30
hepatic enzyme disorders in,
I: 687
hepatobiliary cancers in,
I: 455, 457;
II: 181, 185, 187;
III: 283, 285–286, 288;
IV: 7, 269;
V: 264;
VI: 226
herbicide exposure assessment issues,
II: 4–5, 14, 17–24, 26–27;
III: 2, 5–6, 142, 143, 146–150;
IV: 122–127;
V: 28
herbicide exposure assessment strategies for,
I: 270–284;
II: 99–109;
III: 144–145
Hodgkin’s disease in,
I: 526, 554–556, 557;
II: 235, 236;
III: 372, 373, 376;
IV: 6, 366–367;
V: 359–360, 361;
VI: 319
immune modulation in,
I: 695–696, 699;
III: 489, 491
immune system disorders,
VI: 448
individual exposures,
VI: 18
infertility,
I: 632, 633, 634;
II: 280;
III: 445, 446, 450;
IV: 7;
VI: 372
International Agency for Research on Cancer research activities,
III: 30
kidney cancer in,
VI: 286
laryngeal cancer in,
III: 294–295;
IV: 6, 9, 278;
V: 272;
VI: 234
latency relevance for assessing herbicides effect on cancer risk in,
II: 276;
III: 12–13, 430–431
legislation concerning herbicide exposure and health of,
II: 28–29;
III: 26–27
leukemia in,
I: 13, 564, 570, 571–572;
II: 245, 246;
III: 385, 386, 389, 392;
IV: 7, 380;
V: 371;
lipid abnormalities in,
I: 689, 692;
II: 333;
III: 505–506, 521;
IV: 7, 494;
VI: 463
liver toxicity in,
II: 332;
III: 512–513;
IV: 502–504
low birthweight outcomes for,
I: 626, 628;
III: 457, 459;
IV: 7;
V: 423–424, 425;
VI: 383
lung cancer in,
III: 298, 301;
IV: 6, 283;
V: 278;
VI: 240
melanoma in,
III: 316, 317;
IV: 303–304;
V: 288, 289, 292, 293–294;
VI: 256–259
military experiences,
I: 75, 82, 272, 286, 399
motor/coordination dysfunction in,
I: 659–660, 662;
II: 309, 310;
III: 469, 470;
IV: 7, 448
multiple myeloma in,
I: 526, 562, 563;
II: 244;
III: 380, 382;
IV: 6, 10, 373;
V: 365;
VI: 325
nasal/nasopharyngeal cancer in,
I: 459, 460;
II: 189;
III: 290, 291;
IV: 7, 275;
V: 268;
VI: 229–230
National Personnel Records Center listing,
I: 17
neural tube defects in offspring, numbers,
II: 297;
IV: 7, 18, 404–405;
V: 16
neurobehavioral disorders in,
II: 305, 308, 309, 310, 311, 313, 314;
III: 467, 468;
IV: 457–459;
V: 472;
VI: 410
neuropsychiatric outcomes,
I: 653–656, 658;
II: 308;
III: 469;
IV: 443;
VI: 430–431
non-Hodgkin’s lymphoma in,
I: 526, 541–548, 549;
II: 234;
III: 363, 365, 370–371;
IV: 6, 357–358;
V: 348–350, 354, 355;
VI: 312
number of,
I: 3, 4, 74, 75–80
outreach activities,
II: 31;
III: 28 (See also Air Force Health Study [AFHS]; Compensation, veterans; Demographic data, Vietnam veterans; Operation Ranch Hand; Risk assessment)
pancreatic cancer in,
V: 258–259
parkinsonism in,
II: 309–310;
VI: 420
perinatal deaths in offspring,
II: 285;
III: 454, 455, 456;
IV: 7;
VI: 379
peripheral nervous system disorders in,
I: 665, 666;
II: 311, 313;
III: 473, 475;
IV: 6, 7, 456;
VI: 429
porphyria cutanea tarda in,
I: 681, 682–683;
II: 321–322, 323;
III: 481, 482;
IV: 6, 8;
V: 480;
VI: 440
prostate cancer in,
I: 513, 518, 519, 522;
II: 9, 217–218, 221, 223;
III: 336, 338, 339, 340, 342;
IV: 6, 8, 10, 329;
V: 321, 322;
records-based exposure assessment,
I: 271–280;
IV: 121–126
records identification,
II: 24–25
rectal cancer in,
V: 256
renal cancers in,
III: 352, 353, 355;
IV: 7, 347;
VI: 296
reproductive outcomes,
I: 405–406, 418, 601–603, 609–615, 618, 620–622, 625;
II: 71, 278, 300–301;
III: 435, 436, 437–438, 445, 446, 450, 454, 455, 456, 457, 459;
IV: 7, 402;
VI: 398
research recommendations,
II: 23–25;
III: 23;
V: 523–525
respiratory cancers in,
I: 469–470, 472;
II: 190, 201–202, 203;
IV: 6, 283
respiratory disorders in,
I: 710–712, 713–714;
III: 485–486;
IV: 7, 474;
V: 483;
VI: 443
risk assessment for,
I: 14–15, 221, 225–226, 247–248, 578;
II: 14, 22–23, 89, 91, 251, 276, 298, 300–301, 314, 321, 323, 349–357;
III: 14–15, 22–23, 124, 127–128, 430–431;
IV: 20, 105–108;
V: 7, 9–10, 23;
serum testing,
I: 20–21
skin cancer in,
I: 501, 505;
II: 209;
III: 312;
IV: 7, 301;
soft-tissue sarcoma in,
I: 475, 492–498, 500;
II: 205, 208;
III: 309–310;
IV: 6, 294–295;
V: 286–287;
VI: 251
South Koreans,
I: 61–62;
spina bifida in offspring,
II: 9–10, 296, 298, 301;
III: 7, 8, 9–10, 21, 24–25, 437–438;
IV: 7, 10, 18, 402
spontaneous abortions in,
I: 601–603, 605;
II: 283;
IV: 7, 411;
V: 420–421;
VI: 378
state-sponsored studies of,
II: 152–153, 158–159, 161, 202, 292;
III: 213–215, 243–244;
IV: 158–159
stomach cancer in,
V: 249
suicide incidence,
I: 655–656
testicular cancer in,
II: 153;
III: 343–344, 345–346;
IV: 7, 336–337;
V: 326–327;
VI: 284
thyroid homeostasis,
VI: 481
twin studies,
I: 398–399, 406, 703, 711
Vietnamese veterans, Vietnamese studies of,
III: 245
women,
I: 50, 83–84;
II: 152–153, 180, 181, 190, 201, 204, 205, 209, 211, 212, 213, 216–217, 218, 223, 226, 228, 229, 231, 245, 278, 280;
III: 326–329, 333, 434–435;
IV: 316
Vietnam veterans’ exposure studies,
II: 154, 156–157, 158–159;
III: 206–209, 210–217, 275, 278, 279, 281, 283, 288, 291, 305, 310, 312, 316, 317, 323, 326, 328, 336, 342, 345–346, 351, 355, 370–371, 376, 382, 437–438, 450, 454, 455, 456, 459, 497, 521;
IV: 150, 156–158, 262, 264, 272–273, 276–277;
V: 118–127, 232–235;
Vietnam veterans’ increased disease risk,
II: 22–23;
III: 22–23
Vietnam Veterans of America,
I: 60
Vietnamese
birth defects and herbicide exposure,
II: 287–288;
V: 394, 400
cancer in,
II: 148;
III: 283
epidemiologic studies,
I: 599–601;
II: 113, 144–145, 148, 184, 287–288;
III: 202, 234, 283;
V: 172–173
herbicide environmental exposure,
II: 144–145, 148, 287–288;
III: 283
herbicide exposure assessment,
I: 269, 370–372;
II: 4–5, 108–109;
III: 156–157;
IV: 116–117;
V: 3, 229
herbicide exposure indices development,
II: 107–108
reproductive outcomes,
I: 599–601, 608–609;
IV: 148–149
research recommendations,
I: 731;
V: 11, 526;
scientists in, studies of Vietnamese veterans,
III: 245;
VI: 493
Vietnamese Veterans,
IV: 160
Viral infection
immune system response,
I: 692–693
TCDD-enhanced susceptibility,
I: 149
teratogenic potential,
I: 607
See also Immune system disorders
Vitamin A,
I: 174
VLDL. See Very low density lipoprotein receptors
W
WAIS. See Wechsler Adult Intelligence Scales
Wales. See United Kingdom
Walking abnormalities. See Motor/coordination dysfunction
War Research Service,
I: 25
Washington, D.C.,
II: 343;
III: 533;
V: 5, 400
Washington state,
I: 336–338, 341, 487–488, 535;
II: 149, 241;
III: 229, 230, 232, 234;
IV: 149, 215;
V: 117;
Waste incineration workers,
V: 6
Wasting syndrome, TCDD-induced,
I: 162–166;
II: 76–77;
III: 80–83;
IV: 25, 31, 57, 76;
V: 56;
VI: 67–68
Weakness. See Motor/coordination dysfunction
Wechsler Adult Intelligence Scales (WAIS),
I: 641;
V: 450–451
Wechsler Memory Scale (WMS),
V: 450–451
West Germany,
II: 328–329;
III: 223, 337, 379, 387, 483, 506, 511, 515
West Virginia,
I: 60, 404, 470, 496, 546, 621, 662–663, 686, 689, 700;
II: 202;
III: 243;
IV: 364, 371
See also Nitro, West Virginia
Western Europe,
II: 268;
III: 510
WHO. See World Health Organization
Wide Range Achievement Test (WRAT),
V: 450–452
Wilm’s tumor,
I: 594;
V: 334;
VI: 292
See also Children, cancer in;
Kidney cancer
Wisconsin,
I: 37, 60, 336, 404–405, 445, 455, 470, 496, 517, 523, 534, 546, 556, 560, 702, 710;
II: 185, 202, 226, 229, 239, 241;
III: 229, 243, 283, 313, 348;
IV: 259, 262, 264, 267, 272, 291, 299, 301, 335, 339, 345, 350, 355, 361, 363–364, 371, 375
WMS. See Wechsler Memory Scale
Women. See Breast cancer;
Cervical cancer;
Demographic data, Vietnam veterans;
Gender;
Ovarian cancer;
Reproductive disorders;
Reproductive system cancers, women;
Uterine cancer;
Women veterans
Women veterans,
I: 79;
II: 30
breast cancer estimated risk,
II: 218;
III: 329;
IV: 318;
V: 301
breast cancer expected incidence,
I: 440, 461, 501, 505, 513, 522, 526, 564;
II: 213;
IV: 314;
V: 301
breast cancer in,
II: 213, 216–217;
III: 322, 324–328, 329;
IV: 314–320;
V: 300–301
circulatory disease in,
I: 702
epidemiologic studies,
I: 50, 81;
II: 28, 152–153, 180, 181, 190, 201, 204, 205, 209, 211, 212, 213–217, 218, 219–223, 226, 228, 229, 231, 245, 278, 280;
III: 324–328, 333;
IV: 314–320
mortality studies,
I: 394–395, 470, 545;
II: 152–153, 180, 201
reproductive outcomes,
III: 434–435;
IV: 399–400;
V: 5
reproductive system cancers in,
II: 211, 212;
III: 333;
IV: 320–326;
V: 314–316
research recommendations,
I: 728
statistics,
I: 83–84
See also Reproductive system cancers, women
Women Veterans Health Programs Act of 1992. See Public Law 102-585
World Health Organization (WHO),
II: 282;
III: 30, 454, 492;
IV: 413, 415;
V: 372, 422;
TEF factors,
V: 26–27
World War II,
I: 25, 32, 82;
II: 150, 268;
III: 237, 420;
VI: 135
WRAT. See Wide Range Achievement Test
X
Xenobiotic responsive elements (XREs),
II: 56, 57, 58, 71;
III: 66, 67, 104
Y
Yorkshire, England,
III: 234;
IV: 149;
V: 117